WO2024107996A1 - Metap2 inhibitors for the treatment of prostate cancer - Google Patents
Metap2 inhibitors for the treatment of prostate cancer Download PDFInfo
- Publication number
- WO2024107996A1 WO2024107996A1 PCT/US2023/080080 US2023080080W WO2024107996A1 WO 2024107996 A1 WO2024107996 A1 WO 2024107996A1 US 2023080080 W US2023080080 W US 2023080080W WO 2024107996 A1 WO2024107996 A1 WO 2024107996A1
- Authority
- WO
- WIPO (PCT)
- Prior art keywords
- prostate cancer
- enzalutamide
- subject
- metap2 inhibitor
- treatment
- Prior art date
Links
- 238000011282 treatment Methods 0.000 title claims abstract description 251
- 239000003112 inhibitor Substances 0.000 title claims abstract description 200
- 206010060862 Prostate cancer Diseases 0.000 title claims abstract description 193
- 208000000236 Prostatic Neoplasms Diseases 0.000 title claims abstract description 193
- 101150032582 Metap2 gene Proteins 0.000 title 1
- WXCXUHSOUPDCQV-UHFFFAOYSA-N enzalutamide Chemical compound C1=C(F)C(C(=O)NC)=CC=C1N1C(C)(C)C(=O)N(C=2C=C(C(C#N)=CC=2)C(F)(F)F)C1=S WXCXUHSOUPDCQV-UHFFFAOYSA-N 0.000 claims description 167
- 229960004671 enzalutamide Drugs 0.000 claims description 166
- 150000003839 salts Chemical class 0.000 claims description 154
- 238000000034 method Methods 0.000 claims description 138
- 229940125904 compound 1 Drugs 0.000 claims description 84
- 229940123407 Androgen receptor antagonist Drugs 0.000 claims description 20
- 239000003936 androgen receptor antagonist Substances 0.000 claims description 20
- 230000003818 metabolic dysfunction Effects 0.000 claims description 20
- 238000009167 androgen deprivation therapy Methods 0.000 claims description 16
- NOESYZHRGYRDHS-UHFFFAOYSA-N insulin Chemical compound N1C(=O)C(NC(=O)C(CCC(N)=O)NC(=O)C(CCC(O)=O)NC(=O)C(C(C)C)NC(=O)C(NC(=O)CN)C(C)CC)CSSCC(C(NC(CO)C(=O)NC(CC(C)C)C(=O)NC(CC=2C=CC(O)=CC=2)C(=O)NC(CCC(N)=O)C(=O)NC(CC(C)C)C(=O)NC(CCC(O)=O)C(=O)NC(CC(N)=O)C(=O)NC(CC=2C=CC(O)=CC=2)C(=O)NC(CSSCC(NC(=O)C(C(C)C)NC(=O)C(CC(C)C)NC(=O)C(CC=2C=CC(O)=CC=2)NC(=O)C(CC(C)C)NC(=O)C(C)NC(=O)C(CCC(O)=O)NC(=O)C(C(C)C)NC(=O)C(CC(C)C)NC(=O)C(CC=2NC=NC=2)NC(=O)C(CO)NC(=O)CNC2=O)C(=O)NCC(=O)NC(CCC(O)=O)C(=O)NC(CCCNC(N)=N)C(=O)NCC(=O)NC(CC=3C=CC=CC=3)C(=O)NC(CC=3C=CC=CC=3)C(=O)NC(CC=3C=CC(O)=CC=3)C(=O)NC(C(C)O)C(=O)N3C(CCC3)C(=O)NC(CCCCN)C(=O)NC(C)C(O)=O)C(=O)NC(CC(N)=O)C(O)=O)=O)NC(=O)C(C(C)CC)NC(=O)C(CO)NC(=O)C(C(C)O)NC(=O)C1CSSCC2NC(=O)C(CC(C)C)NC(=O)C(NC(=O)C(CCC(N)=O)NC(=O)C(CC(N)=O)NC(=O)C(NC(=O)C(N)CC=1C=CC=CC=1)C(C)C)CC1=CN=CN1 NOESYZHRGYRDHS-UHFFFAOYSA-N 0.000 claims description 16
- 238000011474 orchiectomy Methods 0.000 claims description 16
- 230000009467 reduction Effects 0.000 claims description 11
- 229940124041 Luteinizing hormone releasing hormone (LHRH) antagonist Drugs 0.000 claims description 10
- 230000002950 deficient Effects 0.000 claims description 9
- 239000002474 gonadorelin antagonist Substances 0.000 claims description 9
- 102000004877 Insulin Human genes 0.000 claims description 8
- 108090001061 Insulin Proteins 0.000 claims description 8
- 229940125396 insulin Drugs 0.000 claims description 8
- 229940082819 Luteinizing hormone releasing hormone (LHRH) agonist Drugs 0.000 claims description 7
- 230000000955 neuroendocrine Effects 0.000 claims description 7
- 108010076365 Adiponectin Proteins 0.000 claims description 6
- 102000011690 Adiponectin Human genes 0.000 claims description 6
- LKJPYSCBVHEWIU-KRWDZBQOSA-N (R)-bicalutamide Chemical compound C([C@@](O)(C)C(=O)NC=1C=C(C(C#N)=CC=1)C(F)(F)F)S(=O)(=O)C1=CC=C(F)C=C1 LKJPYSCBVHEWIU-KRWDZBQOSA-N 0.000 claims description 5
- AOMXMOCNKJTRQP-UHFFFAOYSA-N 1-[4-[1-[(2,6-difluorophenyl)methyl]-5-[(dimethylamino)methyl]-3-(6-methoxypyridazin-3-yl)-2,4-dioxothieno[2,3-d]pyrimidin-6-yl]phenyl]-3-methoxyurea Chemical compound C1=CC(NC(=O)NOC)=CC=C1C1=C(CN(C)C)C(C(=O)N(C=2N=NC(OC)=CC=2)C(=O)N2CC=3C(=CC=CC=3F)F)=C2S1 AOMXMOCNKJTRQP-UHFFFAOYSA-N 0.000 claims description 5
- WQZGKKKJIJFFOK-GASJEMHNSA-N Glucose Natural products OC[C@H]1OC(O)[C@H](O)[C@@H](O)[C@@H]1O WQZGKKKJIJFFOK-GASJEMHNSA-N 0.000 claims description 5
- 108010069236 Goserelin Proteins 0.000 claims description 5
- BLCLNMBMMGCOAS-URPVMXJPSA-N Goserelin Chemical compound C([C@@H](C(=O)N[C@H](COC(C)(C)C)C(=O)N[C@@H](CC(C)C)C(=O)N[C@@H](CCCN=C(N)N)C(=O)N1[C@@H](CCC1)C(=O)NNC(N)=O)NC(=O)[C@H](CO)NC(=O)[C@H](CC=1C2=CC=CC=C2NC=1)NC(=O)[C@H](CC=1NC=NC=1)NC(=O)[C@H]1NC(=O)CC1)C1=CC=C(O)C=C1 BLCLNMBMMGCOAS-URPVMXJPSA-N 0.000 claims description 5
- 206010022489 Insulin Resistance Diseases 0.000 claims description 5
- 108010000817 Leuprolide Proteins 0.000 claims description 5
- 108010050144 Triptorelin Pamoate Proteins 0.000 claims description 5
- 108010052004 acetyl-2-naphthylalanyl-3-chlorophenylalanyl-1-oxohexadecyl-seryl-4-aminophenylalanyl(hydroorotyl)-4-aminophenylalanyl(carbamoyl)-leucyl-ILys-prolyl-alaninamide Proteins 0.000 claims description 5
- HJBWBFZLDZWPHF-UHFFFAOYSA-N apalutamide Chemical compound C1=C(F)C(C(=O)NC)=CC=C1N1C2(CCC2)C(=O)N(C=2C=C(C(C#N)=NC=2)C(F)(F)F)C1=S HJBWBFZLDZWPHF-UHFFFAOYSA-N 0.000 claims description 5
- 229950007511 apalutamide Drugs 0.000 claims description 5
- 229960000997 bicalutamide Drugs 0.000 claims description 5
- 229950001379 darolutamide Drugs 0.000 claims description 5
- 229960002272 degarelix Drugs 0.000 claims description 5
- MEUCPCLKGZSHTA-XYAYPHGZSA-N degarelix Chemical group C([C@H](C(=O)N[C@@H](CC(C)C)C(=O)N[C@@H](CCCCNC(C)C)C(=O)N1[C@@H](CCC1)C(=O)N[C@H](C)C(N)=O)NC(=O)[C@H](CC=1C=CC(NC(=O)[C@H]2NC(=O)NC(=O)C2)=CC=1)NC(=O)[C@H](CO)NC(=O)[C@@H](CC=1C=NC=CC=1)NC(=O)[C@@H](CC=1C=CC(Cl)=CC=1)NC(=O)[C@@H](CC=1C=C2C=CC=CC2=CC=1)NC(C)=O)C1=CC=C(NC(N)=O)C=C1 MEUCPCLKGZSHTA-XYAYPHGZSA-N 0.000 claims description 5
- MKXKFYHWDHIYRV-UHFFFAOYSA-N flutamide Chemical compound CC(C)C(=O)NC1=CC=C([N+]([O-])=O)C(C(F)(F)F)=C1 MKXKFYHWDHIYRV-UHFFFAOYSA-N 0.000 claims description 5
- 229960002074 flutamide Drugs 0.000 claims description 5
- 239000008103 glucose Substances 0.000 claims description 5
- 229960002913 goserelin Drugs 0.000 claims description 5
- 108700020746 histrelin Proteins 0.000 claims description 5
- HHXHVIJIIXKSOE-QILQGKCVSA-N histrelin Chemical compound CCNC(=O)[C@@H]1CCCN1C(=O)[C@H](CCCNC(N)=N)NC(=O)[C@H](CC(C)C)NC(=O)[C@H](NC(=O)[C@H](CC=1C=CC(O)=CC=1)NC(=O)[C@H](CO)NC(=O)[C@H](CC=1C2=CC=CC=C2NC=1)NC(=O)[C@H](CC=1N=CNC=1)NC(=O)[C@H]1NC(=O)CC1)CC(N=C1)=CN1CC1=CC=CC=C1 HHXHVIJIIXKSOE-QILQGKCVSA-N 0.000 claims description 5
- 229960002193 histrelin Drugs 0.000 claims description 5
- GFIJNRVAKGFPGQ-LIJARHBVSA-N leuprolide Chemical group CCNC(=O)[C@@H]1CCCN1C(=O)[C@H](CCCNC(N)=N)NC(=O)[C@H](CC(C)C)NC(=O)[C@@H](CC(C)C)NC(=O)[C@@H](NC(=O)[C@H](CO)NC(=O)[C@H](CC=1C2=CC=CC=C2NC=1)NC(=O)[C@H](CC=1N=CNC=1)NC(=O)[C@H]1NC(=O)CC1)CC1=CC=C(O)C=C1 GFIJNRVAKGFPGQ-LIJARHBVSA-N 0.000 claims description 5
- 229960004338 leuprorelin Drugs 0.000 claims description 5
- BLIJXOOIHRSQRB-PXYINDEMSA-N n-[(2s)-1-[3-(3-chloro-4-cyanophenyl)pyrazol-1-yl]propan-2-yl]-5-(1-hydroxyethyl)-1h-pyrazole-3-carboxamide Chemical compound C([C@H](C)NC(=O)C=1NN=C(C=1)C(C)O)N(N=1)C=CC=1C1=CC=C(C#N)C(Cl)=C1 BLIJXOOIHRSQRB-PXYINDEMSA-N 0.000 claims description 5
- XWXYUMMDTVBTOU-UHFFFAOYSA-N nilutamide Chemical compound O=C1C(C)(C)NC(=O)N1C1=CC=C([N+]([O-])=O)C(C(F)(F)F)=C1 XWXYUMMDTVBTOU-UHFFFAOYSA-N 0.000 claims description 5
- 229960002653 nilutamide Drugs 0.000 claims description 5
- 229950004238 relugolix Drugs 0.000 claims description 5
- 229960004824 triptorelin Drugs 0.000 claims description 5
- VXKHXGOKWPXYNA-PGBVPBMZSA-N triptorelin Chemical compound C([C@@H](C(=O)N[C@H](CC=1C2=CC=CC=C2NC=1)C(=O)N[C@@H](CC(C)C)C(=O)N[C@@H](CCCNC(N)=N)C(=O)N1[C@@H](CCC1)C(=O)NCC(N)=O)NC(=O)[C@H](CO)NC(=O)[C@H](CC=1C2=CC=CC=C2NC=1)NC(=O)[C@H](CC=1N=CNC=1)NC(=O)[C@H]1NC(=O)CC1)C1=CC=C(O)C=C1 VXKHXGOKWPXYNA-PGBVPBMZSA-N 0.000 claims description 5
- 208000001072 type 2 diabetes mellitus Diseases 0.000 claims description 5
- 208000032928 Dyslipidaemia Diseases 0.000 claims description 4
- 102000016267 Leptin Human genes 0.000 claims description 4
- 108010092277 Leptin Proteins 0.000 claims description 4
- 208000017170 Lipid metabolism disease Diseases 0.000 claims description 4
- 208000008589 Obesity Diseases 0.000 claims description 4
- 208000037976 chronic inflammation Diseases 0.000 claims description 4
- 230000006020 chronic inflammation Effects 0.000 claims description 4
- 230000000994 depressogenic effect Effects 0.000 claims description 4
- 229940011871 estrogen Drugs 0.000 claims description 4
- 239000000262 estrogen Substances 0.000 claims description 4
- 230000001747 exhibiting effect Effects 0.000 claims description 4
- 229940039781 leptin Drugs 0.000 claims description 4
- NRYBAZVQPHGZNS-ZSOCWYAHSA-N leptin Chemical compound O=C([C@H](CO)NC(=O)[C@H](CC(C)C)NC(=O)[C@H](CC(O)=O)NC(=O)[C@H](CC(C)C)NC(=O)[C@H](CCC(N)=O)NC(=O)[C@H](CC=1C2=CC=CC=C2NC=1)NC(=O)[C@H](CC(C)C)NC(=O)[C@@H](NC(=O)[C@H](CC(O)=O)NC(=O)[C@H](CCC(N)=O)NC(=O)[C@H](CC(C)C)NC(=O)[C@H](CO)NC(=O)CNC(=O)[C@H](CCC(N)=O)NC(=O)[C@@H](N)CC(C)C)CCSC)N1CCC[C@H]1C(=O)NCC(=O)N[C@@H](CS)C(O)=O NRYBAZVQPHGZNS-ZSOCWYAHSA-N 0.000 claims description 4
- 235000020824 obesity Nutrition 0.000 claims description 4
- 230000009278 visceral effect Effects 0.000 claims description 4
- 108700012941 GNRH1 Proteins 0.000 claims description 3
- 239000000579 Gonadotropin-Releasing Hormone Substances 0.000 claims description 3
- 239000000556 agonist Substances 0.000 claims description 3
- 108010011536 PTEN Phosphohydrolase Proteins 0.000 claims 1
- 102100032543 Phosphatidylinositol 3,4,5-trisphosphate 3-phosphatase and dual-specificity protein phosphatase PTEN Human genes 0.000 claims 1
- 206010028980 Neoplasm Diseases 0.000 description 118
- 241000699670 Mus sp. Species 0.000 description 83
- 239000003981 vehicle Substances 0.000 description 49
- 230000014509 gene expression Effects 0.000 description 45
- 150000001875 compounds Chemical class 0.000 description 38
- 108090000623 proteins and genes Proteins 0.000 description 34
- 239000003814 drug Substances 0.000 description 32
- 102100038358 Prostate-specific antigen Human genes 0.000 description 24
- 108010072866 Prostate-Specific Antigen Proteins 0.000 description 23
- 230000005907 cancer growth Effects 0.000 description 23
- 208000037265 diseases, disorders, signs and symptoms Diseases 0.000 description 23
- 230000037396 body weight Effects 0.000 description 22
- -1 GLS Proteins 0.000 description 21
- 229940124597 therapeutic agent Drugs 0.000 description 19
- 102100031573 Hematopoietic progenitor cell antigen CD34 Human genes 0.000 description 18
- 101000777663 Homo sapiens Hematopoietic progenitor cell antigen CD34 Proteins 0.000 description 18
- 201000010099 disease Diseases 0.000 description 17
- 210000004072 lung Anatomy 0.000 description 17
- 210000002216 heart Anatomy 0.000 description 16
- 210000003734 kidney Anatomy 0.000 description 16
- 210000004185 liver Anatomy 0.000 description 16
- 239000000203 mixture Substances 0.000 description 16
- 238000013388 immunohistochemistry analysis Methods 0.000 description 12
- 238000004519 manufacturing process Methods 0.000 description 12
- 239000012453 solvate Substances 0.000 description 12
- 210000005166 vasculature Anatomy 0.000 description 12
- XLYOFNOQVPJJNP-UHFFFAOYSA-N water Chemical compound O XLYOFNOQVPJJNP-UHFFFAOYSA-N 0.000 description 12
- 241000282414 Homo sapiens Species 0.000 description 11
- 239000013078 crystal Substances 0.000 description 11
- 150000002148 esters Chemical class 0.000 description 11
- 102100032187 Androgen receptor Human genes 0.000 description 10
- 108010080146 androgen receptors Proteins 0.000 description 10
- 125000004429 atom Chemical group 0.000 description 10
- 230000004083 survival effect Effects 0.000 description 10
- 230000000670 limiting effect Effects 0.000 description 9
- 239000008194 pharmaceutical composition Substances 0.000 description 9
- 230000002265 prevention Effects 0.000 description 9
- 125000002924 primary amino group Chemical group [H]N([H])* 0.000 description 9
- 239000002904 solvent Substances 0.000 description 8
- 230000002123 temporal effect Effects 0.000 description 8
- 230000004614 tumor growth Effects 0.000 description 8
- FBPFZTCFMRRESA-KVTDHHQDSA-N D-Mannitol Chemical compound OC[C@@H](O)[C@@H](O)[C@H](O)[C@H](O)CO FBPFZTCFMRRESA-KVTDHHQDSA-N 0.000 description 7
- 229930195725 Mannitol Natural products 0.000 description 7
- 230000008901 benefit Effects 0.000 description 7
- 230000002354 daily effect Effects 0.000 description 7
- 239000000594 mannitol Substances 0.000 description 7
- 235000010355 mannitol Nutrition 0.000 description 7
- 239000013642 negative control Substances 0.000 description 7
- 230000037361 pathway Effects 0.000 description 7
- 238000003419 tautomerization reaction Methods 0.000 description 7
- 210000004027 cell Anatomy 0.000 description 6
- 208000035475 disorder Diseases 0.000 description 6
- 230000003511 endothelial effect Effects 0.000 description 6
- 230000005764 inhibitory process Effects 0.000 description 6
- 239000003550 marker Substances 0.000 description 6
- 230000001225 therapeutic effect Effects 0.000 description 6
- JGLMVXWAHNTPRF-CMDGGOBGSA-N CCN1N=C(C)C=C1C(=O)NC1=NC2=CC(=CC(OC)=C2N1C\C=C\CN1C(NC(=O)C2=CC(C)=NN2CC)=NC2=CC(=CC(OCCCN3CCOCC3)=C12)C(N)=O)C(N)=O Chemical compound CCN1N=C(C)C=C1C(=O)NC1=NC2=CC(=CC(OC)=C2N1C\C=C\CN1C(NC(=O)C2=CC(C)=NN2CC)=NC2=CC(=CC(OCCCN3CCOCC3)=C12)C(N)=O)C(N)=O JGLMVXWAHNTPRF-CMDGGOBGSA-N 0.000 description 5
- 241000124008 Mammalia Species 0.000 description 5
- 239000003098 androgen Substances 0.000 description 5
- 230000015572 biosynthetic process Effects 0.000 description 5
- 238000002648 combination therapy Methods 0.000 description 5
- 125000000524 functional group Chemical group 0.000 description 5
- 238000003305 oral gavage Methods 0.000 description 5
- 208000024891 symptom Diseases 0.000 description 5
- 102100041003 Glutamate carboxypeptidase 2 Human genes 0.000 description 4
- 102100030595 HLA class II histocompatibility antigen gamma chain Human genes 0.000 description 4
- 101001082627 Homo sapiens HLA class II histocompatibility antigen gamma chain Proteins 0.000 description 4
- 238000004458 analytical method Methods 0.000 description 4
- 229910052799 carbon Inorganic materials 0.000 description 4
- HVYWMOMLDIMFJA-DPAQBDIFSA-N cholesterol Chemical compound C1C=C2C[C@@H](O)CC[C@]2(C)[C@@H]2[C@@H]1[C@@H]1CC[C@H]([C@H](C)CCCC(C)C)[C@@]1(C)CC2 HVYWMOMLDIMFJA-DPAQBDIFSA-N 0.000 description 4
- 125000000031 ethylamino group Chemical group [H]C([H])([H])C([H])([H])N([H])[*] 0.000 description 4
- 230000008073 immune recognition Effects 0.000 description 4
- 239000000463 material Substances 0.000 description 4
- 238000010254 subcutaneous injection Methods 0.000 description 4
- 239000007929 subcutaneous injection Substances 0.000 description 4
- 125000001424 substituent group Chemical group 0.000 description 4
- 238000003786 synthesis reaction Methods 0.000 description 4
- 238000011269 treatment regimen Methods 0.000 description 4
- CSCPPACGZOOCGX-UHFFFAOYSA-N Acetone Chemical compound CC(C)=O CSCPPACGZOOCGX-UHFFFAOYSA-N 0.000 description 3
- 102100031650 C-X-C chemokine receptor type 4 Human genes 0.000 description 3
- LFQSCWFLJHTTHZ-UHFFFAOYSA-N Ethanol Chemical compound CCO LFQSCWFLJHTTHZ-UHFFFAOYSA-N 0.000 description 3
- 101000922348 Homo sapiens C-X-C chemokine receptor type 4 Proteins 0.000 description 3
- 101000892862 Homo sapiens Glutamate carboxypeptidase 2 Proteins 0.000 description 3
- 206010021143 Hypoxia Diseases 0.000 description 3
- 108060004872 MIF Proteins 0.000 description 3
- 241001465754 Metazoa Species 0.000 description 3
- 102100032420 Protein S100-A9 Human genes 0.000 description 3
- 201000011510 cancer Diseases 0.000 description 3
- 239000003795 chemical substances by application Substances 0.000 description 3
- 238000011161 development Methods 0.000 description 3
- 230000018109 developmental process Effects 0.000 description 3
- 230000000694 effects Effects 0.000 description 3
- 125000001495 ethyl group Chemical group [H]C([H])([H])C([H])([H])* 0.000 description 3
- 230000006872 improvement Effects 0.000 description 3
- 230000003287 optical effect Effects 0.000 description 3
- AICOOMRHRUFYCM-ZRRPKQBOSA-N oxazine, 1 Chemical compound C([C@@H]1[C@H](C(C[C@]2(C)[C@@H]([C@H](C)N(C)C)[C@H](O)C[C@]21C)=O)CC1=CC2)C[C@H]1[C@@]1(C)[C@H]2N=C(C(C)C)OC1 AICOOMRHRUFYCM-ZRRPKQBOSA-N 0.000 description 3
- 239000000243 solution Substances 0.000 description 3
- 239000000126 substance Substances 0.000 description 3
- 210000001550 testis Anatomy 0.000 description 3
- 238000002560 therapeutic procedure Methods 0.000 description 3
- 210000001519 tissue Anatomy 0.000 description 3
- WVAKRQOMAINQPU-UHFFFAOYSA-N 2-[4-[2-[5-(2,2-dimethylbutyl)-1h-imidazol-2-yl]ethyl]phenyl]pyridine Chemical compound N1C(CC(C)(C)CC)=CN=C1CCC1=CC=C(C=2N=CC=CC=2)C=C1 WVAKRQOMAINQPU-UHFFFAOYSA-N 0.000 description 2
- 102100037152 BAG family molecular chaperone regulator 1 Human genes 0.000 description 2
- 102100032912 CD44 antigen Human genes 0.000 description 2
- 101001046554 Dictyostelium discoideum Thymidine kinase 1 Proteins 0.000 description 2
- 208000000059 Dyspnea Diseases 0.000 description 2
- 206010013975 Dyspnoeas Diseases 0.000 description 2
- 108010037362 Extracellular Matrix Proteins Proteins 0.000 description 2
- 102000010834 Extracellular Matrix Proteins Human genes 0.000 description 2
- 102100032340 G2/mitotic-specific cyclin-B1 Human genes 0.000 description 2
- PEDCQBHIVMGVHV-UHFFFAOYSA-N Glycerine Chemical compound OCC(O)CO PEDCQBHIVMGVHV-UHFFFAOYSA-N 0.000 description 2
- 239000004471 Glycine Substances 0.000 description 2
- 108010050568 HLA-DM antigens Proteins 0.000 description 2
- 101000740062 Homo sapiens BAG family molecular chaperone regulator 1 Proteins 0.000 description 2
- 101000868273 Homo sapiens CD44 antigen Proteins 0.000 description 2
- 101000868643 Homo sapiens G2/mitotic-specific cyclin-B1 Proteins 0.000 description 2
- 101001037132 Homo sapiens Gamma-interferon-inducible lysosomal thiol reductase Proteins 0.000 description 2
- 101000979001 Homo sapiens Methionine aminopeptidase 2 Proteins 0.000 description 2
- 101000575639 Homo sapiens Ribonucleoside-diphosphate reductase subunit M2 Proteins 0.000 description 2
- 101000945477 Homo sapiens Thymidine kinase, cytosolic Proteins 0.000 description 2
- 108700002010 MHC class II transactivator Proteins 0.000 description 2
- 102100023174 Methionine aminopeptidase 2 Human genes 0.000 description 2
- 241000699666 Mus <mouse, genus> Species 0.000 description 2
- 101100521345 Mus musculus Prop1 gene Proteins 0.000 description 2
- 238000011887 Necropsy Methods 0.000 description 2
- 108091000080 Phosphotransferase Proteins 0.000 description 2
- 108700017836 Prophet of Pit-1 Proteins 0.000 description 2
- 102100026006 Ribonucleoside-diphosphate reductase subunit M2 Human genes 0.000 description 2
- 108091006296 SLC2A1 Proteins 0.000 description 2
- 102100023536 Solute carrier family 2, facilitated glucose transporter member 1 Human genes 0.000 description 2
- 102100034838 Thymidine kinase, cytosolic Human genes 0.000 description 2
- GWEVSGVZZGPLCZ-UHFFFAOYSA-N Titan oxide Chemical compound O=[Ti]=O GWEVSGVZZGPLCZ-UHFFFAOYSA-N 0.000 description 2
- 108091023040 Transcription factor Proteins 0.000 description 2
- 239000002253 acid Substances 0.000 description 2
- 230000033115 angiogenesis Effects 0.000 description 2
- 230000009286 beneficial effect Effects 0.000 description 2
- 108700021031 cdc Genes Proteins 0.000 description 2
- 230000004640 cellular pathway Effects 0.000 description 2
- 235000012000 cholesterol Nutrition 0.000 description 2
- 229940125782 compound 2 Drugs 0.000 description 2
- 229940126214 compound 3 Drugs 0.000 description 2
- 238000002425 crystallisation Methods 0.000 description 2
- 230000008025 crystallization Effects 0.000 description 2
- 108010057085 cytokine receptors Proteins 0.000 description 2
- OPTASPLRGRRNAP-UHFFFAOYSA-N cytosine Chemical compound NC=1C=CNC(=O)N=1 OPTASPLRGRRNAP-UHFFFAOYSA-N 0.000 description 2
- 230000003247 decreasing effect Effects 0.000 description 2
- 230000009274 differential gene expression Effects 0.000 description 2
- 210000002744 extracellular matrix Anatomy 0.000 description 2
- 230000004136 fatty acid synthesis Effects 0.000 description 2
- 230000034659 glycolysis Effects 0.000 description 2
- UYTPUPDQBNUYGX-UHFFFAOYSA-N guanine Chemical compound O=C1NC(N)=NC2=C1N=CN2 UYTPUPDQBNUYGX-UHFFFAOYSA-N 0.000 description 2
- 229940088597 hormone Drugs 0.000 description 2
- 239000005556 hormone Substances 0.000 description 2
- 108091008039 hormone receptors Proteins 0.000 description 2
- 150000004677 hydrates Chemical class 0.000 description 2
- 125000004435 hydrogen atom Chemical group [H]* 0.000 description 2
- 230000007954 hypoxia Effects 0.000 description 2
- 230000002401 inhibitory effect Effects 0.000 description 2
- 238000002347 injection Methods 0.000 description 2
- 239000007924 injection Substances 0.000 description 2
- WTFXARWRTYJXII-UHFFFAOYSA-N iron(2+);iron(3+);oxygen(2-) Chemical compound [O-2].[O-2].[O-2].[O-2].[Fe+2].[Fe+3].[Fe+3] WTFXARWRTYJXII-UHFFFAOYSA-N 0.000 description 2
- 230000003902 lesion Effects 0.000 description 2
- 239000003446 ligand Substances 0.000 description 2
- 230000037356 lipid metabolism Effects 0.000 description 2
- 230000001394 metastastic effect Effects 0.000 description 2
- 206010061289 metastatic neoplasm Diseases 0.000 description 2
- 239000002773 nucleotide Substances 0.000 description 2
- 125000003729 nucleotide group Chemical group 0.000 description 2
- 230000003285 pharmacodynamic effect Effects 0.000 description 2
- 229920001481 poly(stearyl methacrylate) Polymers 0.000 description 2
- 230000001737 promoting effect Effects 0.000 description 2
- 208000013220 shortness of breath Diseases 0.000 description 2
- 239000007787 solid Substances 0.000 description 2
- 230000008685 targeting Effects 0.000 description 2
- RWQNBRDOKXIBIV-UHFFFAOYSA-N thymine Chemical compound CC1=CNC(=O)NC1=O RWQNBRDOKXIBIV-UHFFFAOYSA-N 0.000 description 2
- 208000016261 weight loss Diseases 0.000 description 2
- JNYAEWCLZODPBN-JGWLITMVSA-N (2r,3r,4s)-2-[(1r)-1,2-dihydroxyethyl]oxolane-3,4-diol Chemical compound OC[C@@H](O)[C@H]1OC[C@H](O)[C@H]1O JNYAEWCLZODPBN-JGWLITMVSA-N 0.000 description 1
- XUHRVZXFBWDCFB-QRTDKPMLSA-N (3R)-4-[[(3S,6S,9S,12R,15S,18R,21R,24R,27R,28R)-12-(3-amino-3-oxopropyl)-6-[(2S)-butan-2-yl]-3-(2-carboxyethyl)-18-(hydroxymethyl)-28-methyl-9,15,21,24-tetrakis(2-methylpropyl)-2,5,8,11,14,17,20,23,26-nonaoxo-1-oxa-4,7,10,13,16,19,22,25-octazacyclooctacos-27-yl]amino]-3-[[(2R)-2-[[(3S)-3-hydroxydecanoyl]amino]-4-methylpentanoyl]amino]-4-oxobutanoic acid Chemical compound CCCCCCC[C@H](O)CC(=O)N[C@H](CC(C)C)C(=O)N[C@H](CC(O)=O)C(=O)N[C@@H]1[C@@H](C)OC(=O)[C@H](CCC(O)=O)NC(=O)[C@@H](NC(=O)[C@H](CC(C)C)NC(=O)[C@@H](CCC(N)=O)NC(=O)[C@H](CC(C)C)NC(=O)[C@@H](CO)NC(=O)[C@@H](CC(C)C)NC(=O)[C@@H](CC(C)C)NC1=O)[C@@H](C)CC XUHRVZXFBWDCFB-QRTDKPMLSA-N 0.000 description 1
- DYLIWHYUXAJDOJ-OWOJBTEDSA-N (e)-4-(6-aminopurin-9-yl)but-2-en-1-ol Chemical compound NC1=NC=NC2=C1N=CN2C\C=C\CO DYLIWHYUXAJDOJ-OWOJBTEDSA-N 0.000 description 1
- KJUGUADJHNHALS-UHFFFAOYSA-N 1H-tetrazole Substances C=1N=NNN=1 KJUGUADJHNHALS-UHFFFAOYSA-N 0.000 description 1
- AQQSXKSWTNWXKR-UHFFFAOYSA-N 2-(2-phenylphenanthro[9,10-d]imidazol-3-yl)acetic acid Chemical compound C1(=CC=CC=C1)C1=NC2=C(N1CC(=O)O)C1=CC=CC=C1C=1C=CC=CC=12 AQQSXKSWTNWXKR-UHFFFAOYSA-N 0.000 description 1
- 102100029077 3-hydroxy-3-methylglutaryl-coenzyme A reductase Human genes 0.000 description 1
- HBAQYPYDRFILMT-UHFFFAOYSA-N 8-[3-(1-cyclopropylpyrazol-4-yl)-1H-pyrazolo[4,3-d]pyrimidin-5-yl]-3-methyl-3,8-diazabicyclo[3.2.1]octan-2-one Chemical class C1(CC1)N1N=CC(=C1)C1=NNC2=C1N=C(N=C2)N1C2C(N(CC1CC2)C)=O HBAQYPYDRFILMT-UHFFFAOYSA-N 0.000 description 1
- 102100035623 ATP-citrate synthase Human genes 0.000 description 1
- 102100039164 Acetyl-CoA carboxylase 1 Human genes 0.000 description 1
- 102100038910 Alpha-enolase Human genes 0.000 description 1
- 108010044434 Alpha-methylacyl-CoA racemase Proteins 0.000 description 1
- 102100038238 Aromatic-L-amino-acid decarboxylase Human genes 0.000 description 1
- 208000006820 Arthralgia Diseases 0.000 description 1
- 102000004000 Aurora Kinase A Human genes 0.000 description 1
- 108090000461 Aurora Kinase A Proteins 0.000 description 1
- 102100032306 Aurora kinase B Human genes 0.000 description 1
- 102100021663 Baculoviral IAP repeat-containing protein 5 Human genes 0.000 description 1
- 102100029648 Beta-arrestin-2 Human genes 0.000 description 1
- 241000283690 Bos taurus Species 0.000 description 1
- 239000004255 Butylated hydroxyanisole Substances 0.000 description 1
- 239000004322 Butylated hydroxytoluene Substances 0.000 description 1
- NLZUEZXRPGMBCV-UHFFFAOYSA-N Butylhydroxytoluene Chemical compound CC1=CC(C(C)(C)C)=C(O)C(C(C)(C)C)=C1 NLZUEZXRPGMBCV-UHFFFAOYSA-N 0.000 description 1
- 241000282836 Camelus dromedarius Species 0.000 description 1
- 241000283707 Capra Species 0.000 description 1
- OKTJSMMVPCPJKN-UHFFFAOYSA-N Carbon Chemical compound [C] OKTJSMMVPCPJKN-UHFFFAOYSA-N 0.000 description 1
- 206010009691 Clubbing Diseases 0.000 description 1
- 108010035532 Collagen Proteins 0.000 description 1
- 102100039551 Collagen triple helix repeat-containing protein 1 Human genes 0.000 description 1
- 206010011224 Cough Diseases 0.000 description 1
- 108010009356 Cyclin-Dependent Kinase Inhibitor p15 Proteins 0.000 description 1
- 102000009512 Cyclin-Dependent Kinase Inhibitor p15 Human genes 0.000 description 1
- 102100037579 D-3-phosphoglycerate dehydrogenase Human genes 0.000 description 1
- FBPFZTCFMRRESA-FSIIMWSLSA-N D-Glucitol Natural products OC[C@H](O)[C@H](O)[C@@H](O)[C@H](O)CO FBPFZTCFMRRESA-FSIIMWSLSA-N 0.000 description 1
- MYMOFIZGZYHOMD-UHFFFAOYSA-N Dioxygen Chemical compound O=O MYMOFIZGZYHOMD-UHFFFAOYSA-N 0.000 description 1
- 206010061818 Disease progression Diseases 0.000 description 1
- 102100023401 Dual specificity mitogen-activated protein kinase kinase 6 Human genes 0.000 description 1
- 102000004190 Enzymes Human genes 0.000 description 1
- 108090000790 Enzymes Proteins 0.000 description 1
- 241000283073 Equus caballus Species 0.000 description 1
- 241000282326 Felis catus Species 0.000 description 1
- 101001067614 Flaveria pringlei Serine hydroxymethyltransferase 2, mitochondrial Proteins 0.000 description 1
- 102100028466 Frizzled-8 Human genes 0.000 description 1
- 102100028461 Frizzled-9 Human genes 0.000 description 1
- 102100040225 Gamma-interferon-inducible lysosomal thiol reductase Human genes 0.000 description 1
- 108010010803 Gelatin Proteins 0.000 description 1
- 108090000369 Glutamate Carboxypeptidase II Proteins 0.000 description 1
- 102100031181 Glyceraldehyde-3-phosphate dehydrogenase Human genes 0.000 description 1
- 102100028970 HLA class I histocompatibility antigen, alpha chain E Human genes 0.000 description 1
- 102100033079 HLA class II histocompatibility antigen, DM alpha chain Human genes 0.000 description 1
- 102100031258 HLA class II histocompatibility antigen, DM beta chain Human genes 0.000 description 1
- 102100040505 HLA class II histocompatibility antigen, DR alpha chain Human genes 0.000 description 1
- 108010067802 HLA-DR alpha-Chains Proteins 0.000 description 1
- 108010027412 Histocompatibility Antigens Class II Proteins 0.000 description 1
- 102000018713 Histocompatibility Antigens Class II Human genes 0.000 description 1
- 102100038970 Histone-lysine N-methyltransferase EZH2 Human genes 0.000 description 1
- 101000988577 Homo sapiens 3-hydroxy-3-methylglutaryl-coenzyme A reductase Proteins 0.000 description 1
- 101000782969 Homo sapiens ATP-citrate synthase Proteins 0.000 description 1
- 101000963424 Homo sapiens Acetyl-CoA carboxylase 1 Proteins 0.000 description 1
- 101000882335 Homo sapiens Alpha-enolase Proteins 0.000 description 1
- 101000798306 Homo sapiens Aurora kinase B Proteins 0.000 description 1
- 101100382122 Homo sapiens CIITA gene Proteins 0.000 description 1
- 101000746121 Homo sapiens Collagen triple helix repeat-containing protein 1 Proteins 0.000 description 1
- 101000739890 Homo sapiens D-3-phosphoglycerate dehydrogenase Proteins 0.000 description 1
- 101000624426 Homo sapiens Dual specificity mitogen-activated protein kinase kinase 6 Proteins 0.000 description 1
- 101000819458 Homo sapiens Frizzled-3 Proteins 0.000 description 1
- 101001061408 Homo sapiens Frizzled-8 Proteins 0.000 description 1
- 101001061405 Homo sapiens Frizzled-9 Proteins 0.000 description 1
- 101000986085 Homo sapiens HLA class I histocompatibility antigen, alpha chain E Proteins 0.000 description 1
- 101000882127 Homo sapiens Histone-lysine N-methyltransferase EZH2 Proteins 0.000 description 1
- 101001081176 Homo sapiens Hyaluronan mediated motility receptor Proteins 0.000 description 1
- 101001090713 Homo sapiens L-lactate dehydrogenase A chain Proteins 0.000 description 1
- 101000981661 Homo sapiens Leucine-rich repeat and immunoglobulin-like domain-containing nogo receptor-interacting protein 4 Proteins 0.000 description 1
- 101000880402 Homo sapiens Metalloreductase STEAP4 Proteins 0.000 description 1
- 101000628949 Homo sapiens Mitogen-activated protein kinase 10 Proteins 0.000 description 1
- 101000628968 Homo sapiens Mitogen-activated protein kinase 13 Proteins 0.000 description 1
- 101000593405 Homo sapiens Myb-related protein B Proteins 0.000 description 1
- 101000585555 Homo sapiens PCNA-associated factor Proteins 0.000 description 1
- 101001067833 Homo sapiens Peptidyl-prolyl cis-trans isomerase A Proteins 0.000 description 1
- 101000878253 Homo sapiens Peptidyl-prolyl cis-trans isomerase FKBP5 Proteins 0.000 description 1
- 101000741790 Homo sapiens Peroxisome proliferator-activated receptor gamma Proteins 0.000 description 1
- 101000609532 Homo sapiens Phosphoinositide-3-kinase-interacting protein 1 Proteins 0.000 description 1
- 101000983161 Homo sapiens Phospholipase A2, membrane associated Proteins 0.000 description 1
- 101000615965 Homo sapiens Phosphoserine phosphatase Proteins 0.000 description 1
- 101001091365 Homo sapiens Plasma kallikrein Proteins 0.000 description 1
- 101001135471 Homo sapiens Potassium voltage-gated channel subfamily D member 3 Proteins 0.000 description 1
- 101000614345 Homo sapiens Prolyl 4-hydroxylase subunit alpha-1 Proteins 0.000 description 1
- 101001091094 Homo sapiens Prorelaxin H1 Proteins 0.000 description 1
- 101001136592 Homo sapiens Prostate stem cell antigen Proteins 0.000 description 1
- 101000605534 Homo sapiens Prostate-specific antigen Proteins 0.000 description 1
- 101000804792 Homo sapiens Protein Wnt-5a Proteins 0.000 description 1
- 101001091538 Homo sapiens Pyruvate kinase PKM Proteins 0.000 description 1
- 101000620593 Homo sapiens Ras-related protein Rab-37 Proteins 0.000 description 1
- 101001074727 Homo sapiens Ribonucleoside-diphosphate reductase large subunit Proteins 0.000 description 1
- 101000688579 Homo sapiens SH3 domain-binding glutamic acid-rich-like protein Proteins 0.000 description 1
- 101000837007 Homo sapiens SH3 domain-binding glutamic acid-rich-like protein 2 Proteins 0.000 description 1
- 101000867466 Homo sapiens Segment polarity protein dishevelled homolog DVL-2 Proteins 0.000 description 1
- 101000867469 Homo sapiens Segment polarity protein dishevelled homolog DVL-3 Proteins 0.000 description 1
- 101001067604 Homo sapiens Serine hydroxymethyltransferase, mitochondrial Proteins 0.000 description 1
- 101000713288 Homo sapiens Solute carrier family 22 member 5 Proteins 0.000 description 1
- 101001056878 Homo sapiens Squalene monooxygenase Proteins 0.000 description 1
- 101000631826 Homo sapiens Stearoyl-CoA desaturase Proteins 0.000 description 1
- 101000629597 Homo sapiens Sterol regulatory element-binding protein 1 Proteins 0.000 description 1
- 101000852559 Homo sapiens Thioredoxin Proteins 0.000 description 1
- 101000809797 Homo sapiens Thymidylate synthase Proteins 0.000 description 1
- 101000711846 Homo sapiens Transcription factor SOX-9 Proteins 0.000 description 1
- 101000636213 Homo sapiens Transcriptional activator Myb Proteins 0.000 description 1
- 101000617776 Homo sapiens U11/U12 small nuclear ribonucleoprotein 48 kDa protein Proteins 0.000 description 1
- 101000617921 Homo sapiens VPS10 domain-containing receptor SorCS2 Proteins 0.000 description 1
- 101000818517 Homo sapiens Zinc-alpha-2-glycoprotein Proteins 0.000 description 1
- 102100027735 Hyaluronan mediated motility receptor Human genes 0.000 description 1
- 206010020880 Hypertrophy Diseases 0.000 description 1
- 206010021079 Hypopnoea Diseases 0.000 description 1
- 102100034671 L-lactate dehydrogenase A chain Human genes 0.000 description 1
- 101710159002 L-lactate oxidase Proteins 0.000 description 1
- 108010001831 LDL receptors Proteins 0.000 description 1
- 102100024100 Leucine-rich repeat and immunoglobulin-like domain-containing nogo receptor-interacting protein 4 Human genes 0.000 description 1
- 102100024640 Low-density lipoprotein receptor Human genes 0.000 description 1
- 102100026371 MHC class II transactivator Human genes 0.000 description 1
- 102000018697 Membrane Proteins Human genes 0.000 description 1
- 108010052285 Membrane Proteins Proteins 0.000 description 1
- 101001066400 Mesocricetus auratus Homeodomain-interacting protein kinase 2 Proteins 0.000 description 1
- 102100037654 Metalloreductase STEAP4 Human genes 0.000 description 1
- 206010027476 Metastases Diseases 0.000 description 1
- 101710181812 Methionine aminopeptidase Proteins 0.000 description 1
- 102100026931 Mitogen-activated protein kinase 10 Human genes 0.000 description 1
- 102100026930 Mitogen-activated protein kinase 13 Human genes 0.000 description 1
- 206010052904 Musculoskeletal stiffness Diseases 0.000 description 1
- 102100034670 Myb-related protein B Human genes 0.000 description 1
- 206010052399 Neuroendocrine tumour Diseases 0.000 description 1
- 206010030113 Oedema Diseases 0.000 description 1
- 108091036255 PCGEM1 Proteins 0.000 description 1
- 102100029879 PCNA-associated factor Human genes 0.000 description 1
- 241001494479 Pecora Species 0.000 description 1
- 102100034539 Peptidyl-prolyl cis-trans isomerase A Human genes 0.000 description 1
- 102100037026 Peptidyl-prolyl cis-trans isomerase FKBP5 Human genes 0.000 description 1
- 102100038825 Peroxisome proliferator-activated receptor gamma Human genes 0.000 description 1
- 241000009328 Perro Species 0.000 description 1
- 102100039472 Phosphoinositide-3-kinase-interacting protein 1 Human genes 0.000 description 1
- 102100026831 Phospholipase A2, membrane associated Human genes 0.000 description 1
- 108090000608 Phosphoric Monoester Hydrolases Proteins 0.000 description 1
- 102000004160 Phosphoric Monoester Hydrolases Human genes 0.000 description 1
- ABLZXFCXXLZCGV-UHFFFAOYSA-N Phosphorous acid Chemical class OP(O)=O ABLZXFCXXLZCGV-UHFFFAOYSA-N 0.000 description 1
- 102100021762 Phosphoserine phosphatase Human genes 0.000 description 1
- 102100033184 Potassium voltage-gated channel subfamily D member 3 Human genes 0.000 description 1
- 241000288906 Primates Species 0.000 description 1
- 102100040477 Prolyl 4-hydroxylase subunit alpha-1 Human genes 0.000 description 1
- 102100034945 Prorelaxin H1 Human genes 0.000 description 1
- 102100036735 Prostate stem cell antigen Human genes 0.000 description 1
- 102100026858 Protein-lysine 6-oxidase Human genes 0.000 description 1
- 102100034911 Pyruvate kinase PKM Human genes 0.000 description 1
- 102100022294 Ras-related protein Rab-37 Human genes 0.000 description 1
- 241000700159 Rattus Species 0.000 description 1
- 208000037656 Respiratory Sounds Diseases 0.000 description 1
- 102100036320 Ribonucleoside-diphosphate reductase large subunit Human genes 0.000 description 1
- 241000283984 Rodentia Species 0.000 description 1
- 102100024243 SH3 domain-binding glutamic acid-rich-like protein Human genes 0.000 description 1
- 102100028663 SH3 domain-binding glutamic acid-rich-like protein 2 Human genes 0.000 description 1
- 102100032753 Segment polarity protein dishevelled homolog DVL-2 Human genes 0.000 description 1
- 102100032754 Segment polarity protein dishevelled homolog DVL-3 Human genes 0.000 description 1
- 102100034606 Serine hydroxymethyltransferase, mitochondrial Human genes 0.000 description 1
- 102100025560 Squalene monooxygenase Human genes 0.000 description 1
- 102100028897 Stearoyl-CoA desaturase Human genes 0.000 description 1
- 102100026839 Sterol regulatory element-binding protein 1 Human genes 0.000 description 1
- 108010002687 Survivin Proteins 0.000 description 1
- 210000001744 T-lymphocyte Anatomy 0.000 description 1
- 229940123237 Taxane Drugs 0.000 description 1
- 102100024547 Tensin-1 Human genes 0.000 description 1
- 108010088950 Tensins Proteins 0.000 description 1
- 102100036407 Thioredoxin Human genes 0.000 description 1
- 102100038618 Thymidylate synthase Human genes 0.000 description 1
- 102100034204 Transcription factor SOX-9 Human genes 0.000 description 1
- 102100030780 Transcriptional activator Myb Human genes 0.000 description 1
- 108010035075 Tyrosine decarboxylase Proteins 0.000 description 1
- 102100022009 U11/U12 small nuclear ribonucleoprotein 48 kDa protein Human genes 0.000 description 1
- 102100021938 VPS10 domain-containing receptor SorCS2 Human genes 0.000 description 1
- 206010047924 Wheezing Diseases 0.000 description 1
- 102000043366 Wnt-5a Human genes 0.000 description 1
- 238000002441 X-ray diffraction Methods 0.000 description 1
- 101100323865 Xenopus laevis arg1 gene Proteins 0.000 description 1
- 102100021144 Zinc-alpha-2-glycoprotein Human genes 0.000 description 1
- REAYFGLASQTHKB-UHFFFAOYSA-N [2-[3-(1H-pyrazol-4-yl)phenoxy]-6-(trifluoromethyl)pyridin-4-yl]methanamine Chemical compound N1N=CC(=C1)C=1C=C(OC2=NC(=CC(=C2)CN)C(F)(F)F)C=CC=1 REAYFGLASQTHKB-UHFFFAOYSA-N 0.000 description 1
- YKKPYMXANSSQCA-UHFFFAOYSA-N [3-[4-(aminomethyl)-6-(trifluoromethyl)pyridin-2-yl]oxyphenyl]-(3-pyrazol-1-ylazetidin-1-yl)methanone Chemical compound N1(N=CC=C1)C1CN(C1)C(=O)C1=CC(=CC=C1)OC1=NC(=CC(=C1)CN)C(F)(F)F YKKPYMXANSSQCA-UHFFFAOYSA-N 0.000 description 1
- 238000002679 ablation Methods 0.000 description 1
- 230000037236 achy joints Effects 0.000 description 1
- 230000002378 acidificating effect Effects 0.000 description 1
- 239000013543 active substance Substances 0.000 description 1
- 125000002252 acyl group Chemical group 0.000 description 1
- 208000009956 adenocarcinoma Diseases 0.000 description 1
- 210000001789 adipocyte Anatomy 0.000 description 1
- 230000003919 adipocyte function Effects 0.000 description 1
- 125000003158 alcohol group Chemical group 0.000 description 1
- 125000003172 aldehyde group Chemical group 0.000 description 1
- 125000000217 alkyl group Chemical group 0.000 description 1
- 208000026935 allergic disease Diseases 0.000 description 1
- 230000001668 ameliorated effect Effects 0.000 description 1
- 150000008064 anhydrides Chemical class 0.000 description 1
- 238000010171 animal model Methods 0.000 description 1
- 150000001450 anions Chemical class 0.000 description 1
- 230000000259 anti-tumor effect Effects 0.000 description 1
- 239000000427 antigen Substances 0.000 description 1
- 230000030741 antigen processing and presentation Effects 0.000 description 1
- 210000000612 antigen-presenting cell Anatomy 0.000 description 1
- 238000011914 asymmetric synthesis Methods 0.000 description 1
- QVGXLLKOCUKJST-UHFFFAOYSA-N atomic oxygen Chemical compound [O] QVGXLLKOCUKJST-UHFFFAOYSA-N 0.000 description 1
- 230000002238 attenuated effect Effects 0.000 description 1
- 230000006472 autoimmune response Effects 0.000 description 1
- 108010032967 beta-Arrestin 2 Proteins 0.000 description 1
- 230000004071 biological effect Effects 0.000 description 1
- 239000000090 biomarker Substances 0.000 description 1
- 235000019282 butylated hydroxyanisole Nutrition 0.000 description 1
- CZBZUDVBLSSABA-UHFFFAOYSA-N butylated hydroxyanisole Chemical compound COC1=CC=C(O)C(C(C)(C)C)=C1.COC1=CC=C(O)C=C1C(C)(C)C CZBZUDVBLSSABA-UHFFFAOYSA-N 0.000 description 1
- 229940043253 butylated hydroxyanisole Drugs 0.000 description 1
- 235000010354 butylated hydroxytoluene Nutrition 0.000 description 1
- 229940095259 butylated hydroxytoluene Drugs 0.000 description 1
- 239000002775 capsule Substances 0.000 description 1
- 150000001721 carbon Chemical group 0.000 description 1
- 125000004432 carbon atom Chemical group C* 0.000 description 1
- 125000003178 carboxy group Chemical group [H]OC(*)=O 0.000 description 1
- 150000001735 carboxylic acids Chemical class 0.000 description 1
- 231100000504 carcinogenesis Toxicity 0.000 description 1
- 239000000969 carrier Substances 0.000 description 1
- 230000015556 catabolic process Effects 0.000 description 1
- 150000001768 cations Chemical class 0.000 description 1
- 230000010261 cell growth Effects 0.000 description 1
- 230000008859 change Effects 0.000 description 1
- 238000006243 chemical reaction Methods 0.000 description 1
- 238000004587 chromatography analysis Methods 0.000 description 1
- 210000000349 chromosome Anatomy 0.000 description 1
- 238000011262 co‐therapy Methods 0.000 description 1
- 125000004122 cyclic group Chemical group 0.000 description 1
- 229940104302 cytosine Drugs 0.000 description 1
- 230000034994 death Effects 0.000 description 1
- 238000006731 degradation reaction Methods 0.000 description 1
- 238000009795 derivation Methods 0.000 description 1
- 230000004069 differentiation Effects 0.000 description 1
- 150000004683 dihydrates Chemical class 0.000 description 1
- 230000005750 disease progression Effects 0.000 description 1
- 239000002552 dosage form Substances 0.000 description 1
- 239000003937 drug carrier Substances 0.000 description 1
- 208000029447 dry hacking cough Diseases 0.000 description 1
- 230000004064 dysfunction Effects 0.000 description 1
- 230000003203 everyday effect Effects 0.000 description 1
- 230000007717 exclusion Effects 0.000 description 1
- 238000010195 expression analysis Methods 0.000 description 1
- VLMZMRDOMOGGFA-WDBKCZKBSA-N festuclavine Chemical compound C1=CC([C@H]2C[C@H](CN(C)[C@@H]2C2)C)=C3C2=CNC3=C1 VLMZMRDOMOGGFA-WDBKCZKBSA-N 0.000 description 1
- 230000003176 fibrotic effect Effects 0.000 description 1
- 239000012530 fluid Substances 0.000 description 1
- 238000001640 fractional crystallisation Methods 0.000 description 1
- 230000006870 function Effects 0.000 description 1
- 239000008273 gelatin Substances 0.000 description 1
- 229920000159 gelatin Polymers 0.000 description 1
- 229940014259 gelatin Drugs 0.000 description 1
- 235000019322 gelatine Nutrition 0.000 description 1
- 235000011852 gelatine desserts Nutrition 0.000 description 1
- 230000002068 genetic effect Effects 0.000 description 1
- 108020004445 glyceraldehyde-3-phosphate dehydrogenase Proteins 0.000 description 1
- 235000011187 glycerol Nutrition 0.000 description 1
- 125000000623 heterocyclic group Chemical group 0.000 description 1
- 125000002887 hydroxy group Chemical group [H]O* 0.000 description 1
- 208000018875 hypoxemia Diseases 0.000 description 1
- 230000001506 immunosuppresive effect Effects 0.000 description 1
- 238000000338 in vitro Methods 0.000 description 1
- 238000001727 in vivo Methods 0.000 description 1
- 230000008595 infiltration Effects 0.000 description 1
- 238000001764 infiltration Methods 0.000 description 1
- SZVJSHCCFOBDDC-UHFFFAOYSA-N iron(II,III) oxide Inorganic materials O=[Fe]O[Fe]O[Fe]=O SZVJSHCCFOBDDC-UHFFFAOYSA-N 0.000 description 1
- 230000007794 irritation Effects 0.000 description 1
- 230000036210 malignancy Effects 0.000 description 1
- 230000007246 mechanism Effects 0.000 description 1
- 238000002844 melting Methods 0.000 description 1
- 230000008018 melting Effects 0.000 description 1
- 239000002207 metabolite Substances 0.000 description 1
- 208000010658 metastatic prostate carcinoma Diseases 0.000 description 1
- 125000002496 methyl group Chemical group [H]C([H])([H])* 0.000 description 1
- 230000005012 migration Effects 0.000 description 1
- 238000013508 migration Methods 0.000 description 1
- 150000004682 monohydrates Chemical class 0.000 description 1
- 210000003205 muscle Anatomy 0.000 description 1
- 231100000252 nontoxic Toxicity 0.000 description 1
- 230000003000 nontoxic effect Effects 0.000 description 1
- 210000000056 organ Anatomy 0.000 description 1
- 229910052760 oxygen Inorganic materials 0.000 description 1
- 239000001301 oxygen Substances 0.000 description 1
- 238000012856 packing Methods 0.000 description 1
- 230000002093 peripheral effect Effects 0.000 description 1
- 239000000546 pharmaceutical excipient Substances 0.000 description 1
- 125000001997 phenyl group Chemical group [H]C1=C([H])C([H])=C(*)C([H])=C1[H] 0.000 description 1
- 230000004962 physiological condition Effects 0.000 description 1
- 230000003389 potentiating effect Effects 0.000 description 1
- 238000012545 processing Methods 0.000 description 1
- 239000000651 prodrug Substances 0.000 description 1
- 229940002612 prodrug Drugs 0.000 description 1
- 238000011321 prophylaxis Methods 0.000 description 1
- 125000001436 propyl group Chemical group [H]C([*])([H])C([H])([H])C([H])([H])[H] 0.000 description 1
- 239000008213 purified water Substances 0.000 description 1
- VXGYRCVTBHVXMZ-UHFFFAOYSA-N quinoline-6-carboxylic acid Chemical compound N1=CC=CC2=CC(C(=O)O)=CC=C21 VXGYRCVTBHVXMZ-UHFFFAOYSA-N 0.000 description 1
- 239000002287 radioligand Substances 0.000 description 1
- 102000005962 receptors Human genes 0.000 description 1
- 108020003175 receptors Proteins 0.000 description 1
- 238000011084 recovery Methods 0.000 description 1
- 238000001953 recrystallisation Methods 0.000 description 1
- 230000002829 reductive effect Effects 0.000 description 1
- 230000001105 regulatory effect Effects 0.000 description 1
- 230000008672 reprogramming Effects 0.000 description 1
- 230000004044 response Effects 0.000 description 1
- 238000012216 screening Methods 0.000 description 1
- 230000011664 signaling Effects 0.000 description 1
- 239000000600 sorbitol Substances 0.000 description 1
- 229960002920 sorbitol Drugs 0.000 description 1
- 235000010356 sorbitol Nutrition 0.000 description 1
- 230000003595 spectral effect Effects 0.000 description 1
- 238000001228 spectrum Methods 0.000 description 1
- 230000000638 stimulation Effects 0.000 description 1
- 150000003871 sulfonates Chemical class 0.000 description 1
- 230000002195 synergetic effect Effects 0.000 description 1
- 230000009885 systemic effect Effects 0.000 description 1
- DKPFODGZWDEEBT-QFIAKTPHSA-N taxane Chemical class C([C@]1(C)CCC[C@@H](C)[C@H]1C1)C[C@H]2[C@H](C)CC[C@@H]1C2(C)C DKPFODGZWDEEBT-QFIAKTPHSA-N 0.000 description 1
- 238000012360 testing method Methods 0.000 description 1
- 150000003536 tetrazoles Chemical class 0.000 description 1
- 229940113082 thymine Drugs 0.000 description 1
- 230000003867 tiredness Effects 0.000 description 1
- 208000016255 tiredness Diseases 0.000 description 1
- 239000004408 titanium dioxide Substances 0.000 description 1
- 230000001988 toxicity Effects 0.000 description 1
- 231100000419 toxicity Toxicity 0.000 description 1
- 230000007704 transition Effects 0.000 description 1
- 230000005748 tumor development Effects 0.000 description 1
- 230000003442 weekly effect Effects 0.000 description 1
- 230000004584 weight gain Effects 0.000 description 1
- 235000019786 weight gain Nutrition 0.000 description 1
- 230000004580 weight loss Effects 0.000 description 1
- 239000013585 weight reducing agent Substances 0.000 description 1
- 229940085728 xtandi Drugs 0.000 description 1
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/335—Heterocyclic compounds having oxygen as the only ring hetero atom, e.g. fungichromin
- A61K31/336—Heterocyclic compounds having oxygen as the only ring hetero atom, e.g. fungichromin having three-membered rings, e.g. oxirane, fumagillin
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/41—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with two or more ring hetero atoms, at least one of which being nitrogen, e.g. tetrazole
- A61K31/4164—1,3-Diazoles
- A61K31/4166—1,3-Diazoles having oxo groups directly attached to the heterocyclic ring, e.g. phenytoin
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents
Definitions
- Prostate cancer is the second-most diagnosed malignancy and is the leading cause of cancer death worldwide among men. More specifically, treatment of advanced prostate cancer with androgen deprivation therapy and androgen receptor antagonists (e.g. enzalutamide) has only provided incremental improvements in survival, as patients inevitably develop resistance. Moreover, continuous androgen deprivation or receptor inhibition therapy has been shown to drive systemic metabolic dysfunction, including weight gain, increased insulin resistance, hyperleptinaemia and reduced circulating adiponectin. Such dysfunctions have been shown to lead to molecular reprogramming in tumours that may be in at least in part responsible for the development of treatment resistance. Finally, elevated expression of the enzyme methionine aminopeptidase type 2 (MetAP2) has recently been shown to be associated with higher grade tumours, including neuroendocrine tumours, and worse clinical outcomes.
- MetAP2 methionine aminopeptidase type 2
- AR androgen receptor pathway inhibitors for the treatment of metastatic castrateresistant prostate cancer
- mCRPC metastatic castrateresistant prostate cancer
- AR inhibition causes major molecular reprograming in tumors, which has resulted in the emergence of highly aggressive and difficult-to-treat molecular subtypes of prostate cancer, termed aggressive variant prostate cancer (AVPC).
- AVPC is a general term for tumors representing the transition from an adenocarcinoma phenotype, toward less differentiated anaplastic phenotypes, which are driven by alternate non-AR mechanisms to promote tumor growth and survival.
- compositions and methods directed to the treatment of prostate cancer including treatments that target MetAP2 and/or that mitigate treatment- induced metabolic dysfunctions.
- the present disclosure provides MetAP2 inhibitors and combinations comprising MetAP2 inhibitors for the treatment of prostate cancer.
- the present disclosure provides methods of treating prostate cancer in a subject, the methods comprising administering at least one amount of at least one MetAP2 inhibitor to the subject, wherein the MetAP2 inhibitor is: salt thereof, wherein x is in the range of 1 to about 450, y is in the range of 1 to about 30 and n is in the range of 1 to about 100, preferably wherein the ratio of x to y is in the range of about 30: 1 to about 3: 1, preferably wherein the ratio of x to y is about 11 : 1, wherein the subject has been previously administered at least one prostate cancer treatment, wherein the prostate cancer treatment comprises androgen deprivation therapy (ADT) and/or at least one androgen receptor antagonist, wherein the prostate cancer has become resistant to treatment with the androgen deprivation therapy (ADT) and/or at least one androgen receptor antagonist, wherein administration of the MetAP2 inhibitor results in reduction in size of the prostate cancer.
- the MetAP2 inhibitor is: salt thereof, wherein x is in the range of 1
- the methods further comprise administering to the subject at least one amount of enzalutamide.
- the prostate cancer is castration-resistant prostate cancer.
- the prostate cancer is castration-sensitive prostate cancer.
- the prostate cancer is androgen receptor-inhibition resistant prostate cancer.
- the prostate cancer is castration-resistant and androgen receptor inhibition-resistant prostate cancer.
- the prostate cancer is PTEN-deficient prostate cancer or partially PTEN-deficient prostate cancer.
- the prostate cancer is PTEN-altered prostate cancer or partially PTEN- altered prostate cancer.
- the prostate cancer is aggressive variant prostate cancer (AVPC).
- AVPC aggressive variant prostate cancer
- the prostate cancer is neuroendocrine prostate cancer (NEPC).
- NEPC neuroendocrine prostate cancer
- the androgen deprivation therapy comprises performing an orchiectomy, administering at least one luteinizing hormone-releasing hormone (LHRH) agonist, administering at least one LHRH antagonist, administering at least one estrogen, or any combination thereof.
- the orchiectomy is a subcapsular orchiectomy.
- the at least one LHRH agonist is selected from leuprolide, goserelin, triptorelin and histrelin.
- the at least one LHRH antagonist is selected from degarelix and relugolix.
- the at least one androgen receptor antagonist is selected from flutamide, bicalutamide, nilutamide, enzalutamide, apalutamide, and darolutamide, preferably wherein the at least one androgen receptor antagonist is enzalutamide.
- the MetAP2 inhibitor is administered within one day, two days, three days, four days, five days, six days, one week or two weeks of the subject exhibiting PSA nadir. [0018] In some aspects, the MetAP2 inhibitor is administered about two weeks, or about three weeks, or about four weeks, about five weeks, or about six weeks, or about seven weeks, or about eight weeks after the subject has exhibited PSA nadir, and wherein the PSA level in the subject has increased from PSA nadir.
- the subject has at least one metabolic dysfunction, wherein the metabolic dysfunction is selected from visceral adiposity, dyslipidemia, obesity (BMI >30), elevated leptin levels, depressed adiponectin levels, high leptin-to-adiponectin ratio, elevated fasting insulin levels, elevated fasting insulin levels accompanied by chronic inflammation, insulin resistance, hyperleptinaemia, high fasting glucose, elevated HbAlc, or any combination thereof.
- the metabolic dysfunction is a prostate cancer treatment-induced metabolic dysfunction.
- the MetAP2 inhibitor is administered to the subject in an amount of: i) about 27 mg/m 2 ; ii) about 36 mg/m 2 ; iii) about 49 mg/m 2 ; or iv) about 65 mg/m 2 .
- MetAP2 inhibitor is administered: i) once every 7 days (Q7D); ii) once every 14 days (Q14D); or iii) once every 21 days (Q21D).
- the enzalutamide is administered to the subject in an amount of: i) about 40 mg; ii) about 80 mg; iii) about 120 mg; or iv) about 160 mg.
- the enzalutamide is administered daily. In some aspects, the enzalutamide is administered weekly.
- FIG. 1 shows the tumor volume in individual mice (left panel) and the average tumor volume across all mice (right panel) in experimental treatment groups described in Example 1.
- FIG. 2 shows the average PSA levels of mice (left panel) and the endpoint tumor mass (right panel) in experimental treatment groups described in Example 1.
- FIG. 3 shows the body weight of individual mice (left panel) and the average body weight across all mice (right panel) in experimental treatment groups described in Example 1.
- FIG. 4 shows the liver, kidney, heart and lung weights at the endpoint of the study in experimental treatment groups described in Example 1.
- FIG. 5 shows the liver, kidney, heart and lung weights as a percentage of body weight at the endpoint of the study in experimental treatment groups described in Example 1.
- FIG. 6 is a graph showing the overall survival of the mice in experimental treatment groups described in Example 1.
- FIG. 7 shows necropsy images of tumors excised from mice in the experimental treatment groups described in Example 1.
- FIG. 8 shows immunohistochemistry analysis of CD34 immunoreactivity from select mice in the experimental treatment groups described in Example 1.
- FIG. 9 shows the average tumor volume across all mice in the experimental treatment groups described in Example 2.
- FIG. 10 shows the tumor mass at the conclusion of the study in the experimental treatment groups described in Example 2.
- FIG. 11 shows the average PSA levels across all mice during the course of the study in the experimental treatment groups described in Example 2.
- FIG. 12 shows the liver, kidney, heart and lung weights at the endpoint of the study in experimental treatment groups described in Example 2.
- FIG. 13 shows the liver, kidney, heart and lung weights as a percentage of body weight at the endpoint of the study in experimental treatment groups described in Example 2.
- FIG. 14 shows the average body weight across all mice in experimental treatment groups described in Example 2.
- FIG. 15 shows immunohistochemistry analysis of CD34 immunoreactivity from select mice in the experimental treatment groups described in Example 2.
- FIG. 16 shows the tumor volume in individual mice (top panel) and the average tumor volume across all mice (bottom panel) in the experimental treatment groups described in Example 3.
- FIG. 17 shows the endpoint tumor mass (left panel) and average PSA levels of mice (right panel) in the experimental treatment groups described in Example 3.
- FIG. 18 shows the body weight of individual mice (top panel) and the average body weight across all mice (bottom panel) in the experimental treatment groups described in Example 3.
- FIG. 19 shows the liver, kidney, heart and lung weights at the endpoint of the study in experimental treatment groups described in Example 3.
- FIG. 20 shows the liver, kidney, heart and lung weights as a percentage of body weight at the endpoint of the study in experimental treatment groups described in Example 3.
- FIG. 21 shows immunohistochemistry analysis of CD34 immunoreactivity from select mice in the experimental treatment groups described in Example 3.
- FIG. 22 the average tumor volume in the experimental treatment groups described in Example 4.
- FIG. 23 the average tumor volume in the experimental treatment groups described in Example 4.
- FIG. 24 shows the endpoint tumor mass in the experimental treatment groups described in Example 4.
- FIG. 25 shows the average PSA levels of mice in the experimental treatment groups described in Example 4.
- FIG. 26 shows the body weight of individual mice (top panel) and the average body weight across all mice (bottom panel) in the experimental treatment groups described in Example 4.
- FIG. 27 shows the liver, kidney, heart and lung weights at the endpoint of the study in experimental treatment groups described in Example 4.
- FIG. 28 shows the liver, kidney, heart and lung weights as a percentage of body weight at the endpoint of the study in experimental treatment groups described in Example 4.
- FIG. 29 shows immunohistochemistry analysis of CD34 immunoreactivity from select mice in the experimental treatment groups described in Example 4.
- FIG. 30 shows the average tumor volume in the experimental treatment groups described in Example 5.
- FIG. 31 shows the endpoint tumor mass in the experimental treatment groups described in Example 5.
- FIG. 32 shows immunohistochemistry analysis of CD34 immunoreactivity from select mice in the experimental treatment groups described in Example 5.
- FIG. 33 A is a graph showing average tumor volume across all mice in the two treatment groups described in Example 7.
- FIG. 33B is a graph showing endpoint tumor volume in mice in the two treatment groups described in Example 7.
- FIG. 33C shows immunohistochemistry analysis of CD34 immunoreactivity from select mice in the experimental treatment groups described in Example 7.
- FIG. 34A is a graph showing tumor volume of all mice in the two treatment groups described in Example 8.
- FIG. 34B is a graph showing average tumor volume across all mice in the two treatment groups described in Example 8.
- FIG. 34C is a graph showing tumor weight reduction across all mice in the two treatment groups described in Example 8.
- FIG. 35 shows a chart of the number of differentially expressed human genes for each pairwise comparison of treatment groups described in Examples 1-5 (left panel) and bubble plots of a selection of significantly enriched (adj. p value ⁇ 0.05) cellular pathways from the MSigDB (Molecular Signatures Database) for each of the comparisons (right panel).
- MSigDB Molecular Signatures Database
- FIGs. 36, 37, 38, 39 and 40 show bubble plots of genes of interest including for pairwise comparisons of treatment groups described in Examples 1-5.
- FIG. 41 shows the expression levels of particular hypoxia induced, extracellular matrix-related genes in tumor samples from the experimental treatment groups described in Example 5.
- FIGs. 42A and 42B show the expression levels of particular glycolysis-related genes in tumor samples from the experimental treatment groups described in Example 5.
- FIG. 43 shows the expression levels of particular serine-glycine one-carbon (SOGC) pathway genes in tumor samples from the experimental treatment groups described in Example 5.
- SOGC serine-glycine one-carbon
- FIG. 44 shows the expression levels of particular cholesterol uptake and synthesis pathway genes in tumor samples from the experimental treatment groups described in Example 5.
- FIG. 45 shows the expression levels of particular fatty acid synthesis pathway genes in tumor samples from the experimental treatment groups described in Example 5.
- FIG. 46 shows the expression levels of particular cell cycle genes in tumor samples from the experimental treatment groups described in Example 5.
- FIG. 47 shows the expression levels of particular hormone/cytokine receptor genes in tumor samples from the experimental treatment groups described in Example 5.
- FIG. 48 shows the expression levels of particular kinase genes in tumor samples from the experimental treatment groups described in Example 5.
- FIG. 49 shows the expression levels of particular transcription factor genes in tumor samples from the experimental treatment groups described in Example 5.
- FIG. 50 shows the expression levels of particular tumor-inhibiting genes in tumor samples from the experimental treatment groups described in Example 5.
- FIGs. 51 A and 5 IB show the expression levels of particular tumor-growth promoting/survival genes in tumor samples from the experimental treatment groups described in Example 5.
- FIG. 52 shows the expression levels of particular nucleotide synthesis genes in tumor samples from the experimental treatment groups described in Example 5.
- FIG. 53 shows the expression levels of particular lipid metabolism genes in tumor samples from the experimental treatment groups described in Example 5.
- FIG. 54 shows the expression levels of particular immune recognition genes in tumor samples from the experimental treatment groups described in Example 5.
- FIG. 55 shows the expression levels of particular immune recognition genes, specifically CD74 ligands and binding partners, in tumor samples from the experimental treatment groups described in Example 5.
- FIG. 56 shows the expression levels of particular genes encoding regulators of MHC II, in tumor samples from the experimental treatment groups described in Example 5. DETAILED DESCRIPTION
- the present disclosure provides, inter alia, a method of treating prostate cancer comprising administering to a subject in need thereof at least one amount of at least one MetAP2 inhibitor of the present disclosure, or a pharmaceutically acceptable salt thereof, or comprising administering to a subject in need thereof at least one amount of at least one MetAP2 inhibitor of the present disclosure, or a pharmaceutically acceptable salt thereof, in combination with at least one additional therapeutic agent.
- the present disclosure provides methods of treating prostate cancer in a subject in need thereof, the method comprising administering to the subject in need thereof at least one amount of at least one MetAP2 inhibitor of the present disclosure, or a pharmaceutically acceptable salt thereof.
- the present disclosure provides at least one MetAP2 inhibitor of the present disclosure, or a pharmaceutically acceptable salt thereof, for use in treating prostate cancer in a subject in need thereof.
- the present disclosure provides the use of at least one MetAP2 inhibitor of the present disclosure, or a pharmaceutically acceptable salt thereof, for the manufacture of a medicament for the treatment of prostate cancer in a subject in need thereof.
- the present disclosure provides a method of preventing prostate cancer in a subject in need thereof, the method comprising administering to the subject in need thereof at least one amount of at least one MetAP2 inhibitor of the present disclosure, or a pharmaceutically acceptable salt thereof.
- the present disclosure provides at least one MetAP2 inhibitor of the present disclosure, or a pharmaceutically acceptable salt thereof, for use in preventing prostate cancer in a subject in need thereof.
- the present disclosure provides the use of at least one MetAP2 inhibitor of the present disclosure, or a pharmaceutically acceptable salt thereof, for the manufacture of a medicament for the prevention of prostate cancer in a subject in need thereof.
- the present disclosure provides a method of preventing prostate cancer growth or recurrence in a subject in need thereof, the method comprising administering to the subject in need thereof at least one amount of at least one MetAP2 inhibitor of the present disclosure, or a pharmaceutically acceptable salt thereof.
- the present disclosure provides at least one MetAP2 inhibitor of the present disclosure, or a pharmaceutically acceptable salt thereof, for use in preventing prostate cancer growth or recurrence in a subject in need thereof.
- the present disclosure provides the use of at least one MetAP2 inhibitor of the present disclosure, or a pharmaceutically acceptable salt thereof, for the manufacture of a medicament for the prevention of prostate cancer growth or recurrence in a subject in need thereof.
- the present disclosure provides a combination therapy comprising at least one amount of at least one MetAP2 inhibitor of the present disclosure, or a pharmaceutically acceptable salt thereof, and at least one amount of enzalutamide, or a pharmaceutically acceptable salt thereof.
- the present disclosure provides a method of treating prostate cancer in a subject in need thereof, the method comprising administering to the subject in need thereof at least one amount of the preceding combination therapy.
- the present disclosure provides a method of preventing prostate cancer in a subject in need thereof, the method comprising administering to the subject in need thereof at least one amount of the preceding combination therapy.
- the present disclosure provides a method of preventing prostate cancer growth or recurrence in a subject in need thereof, the method comprising administering to the subject in need thereof at least one amount of the preceding combination therapy.
- the present disclosure provides a pharmaceutical composition comprising at least one amount of at least one MetAP2 inhibitor of the present disclosure, or a pharmaceutically acceptable salt thereof, and at least one amount of enzalutamide, or a pharmaceutically acceptable salt thereof.
- the present disclosure provides a method of treating prostate cancer in a subject in need thereof, the method comprising administering to the subject in need thereof at least one amount of the preceding pharmaceutical compositions.
- the present disclosure provides a method of preventing prostate cancer in a subject in need thereof, the method comprising administering to the subject in need thereof at least one amount of the preceding pharmaceutical compositions.
- the present disclosure provides a method of preventing prostate cancer growth or recurrence in a subject in need thereof, the method comprising administering to the subject in need thereof at least one amount of the preceding pharmaceutical compositions.
- the present disclosure provides a kit comprising at least one amount of at least one MetAP2 inhibitor of the present disclosure, or a pharmaceutically acceptable salt thereof, and at least one amount of enzalutamide, or a pharmaceutically acceptable salt thereof.
- the present disclosure provides a method of treating prostate cancer in a subject in need thereof, the method comprising administering to the subject in need thereof at least one amount of the preceding kit.
- the present disclosure provides a method of preventing prostate cancer in a subject in need thereof, the method comprising administering to the subject in need thereof at least one amount of the preceding kit.
- the present disclosure provides a method of preventing prostate cancer growth or recurrence in a subject in need thereof, the method comprising administering to the subject in need thereof at least one amount of the preceding kit.
- the present disclosure provides a method of treating prostate cancer in a subject in need thereof, the method comprising administering to the subject at least one amount of at least one MetAP2 inhibitor of the present disclosure, or a pharmaceutically acceptable salt thereof, and at least one amount of enzalutamide, or a pharmaceutically acceptable salt thereof.
- the present disclosure provides a method of preventing prostate cancer in a subject in need thereof, the method comprising administering to the subject at least one amount of at least one MetAP2 inhibitor of the present disclosure, or a pharmaceutically acceptable salt thereof, and at least one amount of enzalutamide, or a pharmaceutically acceptable salt thereof.
- the present disclosure provides a method of preventing prostate cancer growth or recurrence in a subject in need thereof, the method comprising administering to the subject at least one amount of at least one MetAP2 inhibitor of the present disclosure, or a pharmaceutically acceptable salt thereof, and at least one amount of enzalutamide, or a pharmaceutically acceptable salt thereof.
- the present disclosure provides a use of at least one MetAP2 inhibitor of the present disclosure, or a pharmaceutically acceptable salt thereof, in combination with enzalutamide, or a pharmaceutically acceptable salt thereof, in the manufacture of a medicament for the treatment of prostate cancer.
- the present disclosure provides a use of at least one MetAP2 inhibitor of the present disclosure, or a pharmaceutically acceptable salt thereof, in combination with enzalutamide, or a pharmaceutically acceptable salt thereof, in the manufacture of a medicament for the prevention of prostate cancer.
- the present disclosure provides a use of at least one MetAP2 inhibitor of the present disclosure, or a pharmaceutically acceptable salt thereof, in combination with enzalutamide, or a pharmaceutically acceptable salt thereof, in the manufacture of a medicament for the prevention of prostate cancer growth or recurrence.
- the present disclosure provides a use of enzalutamide, or a pharmaceutically acceptable salt thereof, in combination with at least one MetAP2 inhibitor of the present disclosure, or a pharmaceutically acceptable salt thereof, in the manufacture of a medicament for the treatment of prostate cancer.
- the present disclosure provides a use of enzalutamide, or a pharmaceutically acceptable salt thereof, in combination with at least one MetAP2 inhibitor of the present disclosure, or a pharmaceutically acceptable salt thereof, in the manufacture of a medicament for the prevention of prostate cancer.
- the present disclosure provides a use of enzalutamide, or a pharmaceutically acceptable salt thereof, in combination with at least one MetAP2 inhibitor of the present disclosure, or a pharmaceutically acceptable salt thereof, in the manufacture of a medicament for the prevention of prostate cancer growth or recurrence.
- the present disclosure provides a combination of at least one MetAP2 inhibitor of the present disclosure, or a pharmaceutically acceptable salt thereof, and enzalutamide, or a pharmaceutically acceptable salt thereof, for use in the manufacture of a medicament for the treatment of prostate cancer.
- the present disclosure provides a combination of at least one MetAP2 inhibitor of the present disclosure, or a pharmaceutically acceptable salt thereof, and enzalutamide, or a pharmaceutically acceptable salt thereof, for use in the manufacture of a medicament for the prevention of prostate cancer.
- the present disclosure provides a combination of at least one MetAP2 inhibitor of the present disclosure, or a pharmaceutically acceptable salt thereof, and enzalutamide, or a pharmaceutically acceptable salt thereof, for use in the manufacture of a medicament for the prevention of prostate cancer growth or recurrence.
- the present disclosure provides at least one MetAP2 inhibitor of the present disclosure, or a pharmaceutically acceptable salt thereof, for use in combination with enzalutamide, or a pharmaceutically acceptable salt thereof, in treating prostate cancer.
- the present disclosure provides at least one MetAP2 inhibitor of the present disclosure, or a pharmaceutically acceptable salt thereof, for use in combination with enzalutamide, or a pharmaceutically acceptable salt thereof, in preventing prostate cancer.
- the present disclosure provides at least one MetAP2 inhibitor of the present disclosure, or a pharmaceutically acceptable salt thereof, for use in combination with enzalutamide, or a pharmaceutically acceptable salt thereof, in preventing prostate cancer growth or recurrence.
- the present disclosure provides enzalutamide, or a pharmaceutically acceptable salt thereof, for use in combination with at least one MetAP2 inhibitor of the present disclosure, or a pharmaceutically acceptable salt thereof, in treating prostate cancer.
- the present disclosure provides enzalutamide, or a pharmaceutically acceptable salt thereof, for use in combination with at least one MetAP2 inhibitor of the present disclosure, or a pharmaceutically acceptable salt thereof, in preventing prostate cancer.
- the present disclosure provides enzalutamide, or a pharmaceutically acceptable salt thereof, for use in combination with at least one MetAP2 inhibitor of the present disclosure, or a pharmaceutically acceptable salt thereof, in preventing prostate cancer growth or recurrence.
- the present disclosure provides a combination of at least one MetAP2 inhibitor of the present disclosure, or a pharmaceutically acceptable salt thereof, and enzalutamide, or a pharmaceutically acceptable salt thereof, for use in treating prostate cancer.
- the present disclosure provides a combination of at least one MetAP2 inhibitor of the present disclosure, or a pharmaceutically acceptable salt thereof, and enzalutamide, or a pharmaceutically acceptable salt thereof, for use in preventing prostate cancer.
- the present disclosure provides a combination of at least one MetAP2 inhibitor of the present disclosure, or a pharmaceutically acceptable salt thereof, and enzalutamide, or a pharmaceutically acceptable salt thereof, for use in preventing prostate cancer growth or recurrence.
- the present disclosure provides a combination comprising at least one MetAP2 inhibitor of the present disclosure, or a pharmaceutically acceptable salt thereof, for use in treating prostate cancer, wherein the combination further comprises enzalutamide, or a pharmaceutically acceptable salt thereof.
- the present disclosure provides a combination comprising enzalutamide, or a pharmaceutically acceptable salt thereof, for use in treating prostate cancer, wherein the combination further comprises at least one MetAP2 inhibitor of the present disclosure, or a pharmaceutically acceptable salt thereof.
- the present disclosure provides a combination comprising at least one MetAP2 inhibitor of the present disclosure, or a pharmaceutically acceptable salt thereof, for use in preventing prostate cancer, wherein the combination further comprises enzalutamide, or a pharmaceutically acceptable salt thereof.
- the present disclosure provides a combination comprising at least one MetAP2 inhibitor of the present disclosure, or a pharmaceutically acceptable salt thereof, for use in preventing prostate cancer growth or recurrence, wherein the combination further comprises enzalutamide, or a pharmaceutically acceptable salt thereof.
- the present disclosure provides a combination comprising enzalutamide, or a pharmaceutically acceptable salt thereof, for use in preventing prostate cancer, wherein the combination further comprises at least one MetAP2 inhibitor of the present disclosure, or a pharmaceutically acceptable salt thereof.
- the present disclosure provides a combination comprising enzalutamide, or a pharmaceutically acceptable salt thereof, for use in preventing prostate cancer growth or recurrence, wherein the combination further comprises at least one MetAP2 inhibitor of the present disclosure, or a pharmaceutically acceptable salt thereof.
- the present disclosure provides a MetAP2 inhibitor, or a pharmaceutically acceptable salt thereof, for use in a method of treating prostate cancer, wherein the method further comprises administration of enzalutamide, or a pharmaceutically acceptable salt thereof [00135]
- the present disclosure provides enzalutamide, or a pharmaceutically acceptable salt thereof, for use in a method of treating prostate cancer, wherein the method further comprises administration of at least one MetAP2 inhibitor, or a pharmaceutically acceptable salt thereof.
- the present disclosure provides a MetAP2 inhibitor, or a pharmaceutically acceptable salt thereof, for use in a method of preventing prostate cancer, wherein the method further comprises administration of enzalutamide, or a pharmaceutically acceptable salt thereof.
- the present disclosure provides enzalutamide, or a pharmaceutically acceptable salt thereof, for use in a method of preventing prostate cancer, wherein the method further comprises administration of at least one MetAP2 inhibitor, or a pharmaceutically acceptable salt thereof.
- the present disclosure provides a MetAP2 inhibitor, or a pharmaceutically acceptable salt thereof, for use in a method of preventing prostate cancer growth or recurrence, wherein the method further comprises administration of enzalutamide, or a pharmaceutically acceptable salt thereof.
- the present disclosure provides enzalutamide, or a pharmaceutically acceptable salt thereof, for use in a method of preventing prostate cancer growth or recurrence, wherein the method further comprises administration of at least one MetAP2 inhibitor, or a pharmaceutically acceptable salt thereof.
- a MetAP2 inhibitor, or pharmaceutically acceptable salt thereof, and enzalutamide, or pharmaceutically acceptable salt thereof can be administered by the same administration route.
- a MetAP2 inhibitor, or pharmaceutically acceptable salt thereof, and enzalutamide, or pharmaceutically acceptable salt thereof can be administered by different administration routes.
- a MetAP2 inhibitor, or pharmaceutically acceptable salt thereof, and enzalutamide, or pharmaceutically acceptable salt thereof can be administered concurrently.
- a MetAP2 inhibitor, or pharmaceutically acceptable salt thereof, and enzalutamide, or pharmaceutically acceptable salt thereof can be administered in temporal proximity.
- a MetAP2 inhibitor, or pharmaceutically acceptable salt thereof, and enzalutamide, or pharmaceutically acceptable salt thereof can be administered in any order.
- the administration of a MetAP2 inhibitor and/or the administration of a MetAP2 inhibitor in combination with enzalutamide results in a decrease in angiogenesis in at least one tumor in the subject.
- the decrease is at least a 10%, at least a 20%, at least a 30%, at least a 40%, at least a 50%, at least a 60%, at least a 70%, at least an 80%, at least a 90%, at least a 95%, or at least a 99% decrease in angiogenesis.
- the administration of a MetAP2 inhibitor and/or the administration of a MetAP2 inhibitor in combination with enzalutamide results in a decrease in the expression level of at least one gene selected from P4HA1, LOX, GLUT1/SLC2A1, HK2, PDK1FKFB3, FKFB4, PKM, ENO1, LDHA, GLS, PHGDH, SHMT2, TYMS, PSPH, LDL receptor, SQLE, HMGCR, ACACA, ACLY, SCD, CCNB1, CXCR4, FZD8, FZD3, IGFlr, MAP2K6, MAPK13, AURKA, AURKB, EZH2, F0XM1, MYB, SREBF1, MYBL2, BIRC5, ANTRX1, DPYLS3, HMMR, BAG1, Ki67, CCNB1, PCLAF, TK1, RRM2, TK1, RRM1, RRM2, PLA2G2A, M
- the decrease is at least a 10%, at least a 20%, at least a 30%, at least a 40%, at least a 50%, at least a 60%, at least a 70%, at least an 80%, at least a 90%, at least a 95%, or at least a 99% decrease in expression.
- the administration of a MetAP2 inhibitor and/or the administration of a MetAP2 inhibitor in combination with enzalutamide results in an increase in the expression level of at least one gene selected from CDKN2B, PIK3IP1, SH3BGRL2, CD 177, HLA-DRA, HLA-E, HLA-DMA, HLA-DMB, CD74, CIITA, IFI30.
- the increase is at least a 10%, at least a 20%, at least a 30%, at least a 40%, at least a 50%, at least a 60%, at least a 70%, at least an 80%, at least a 90%, at least a 95%, or at least a 99% increase in expression.
- MetAP2 inhibitors described herein can be used in the kits, pharmaceutical compositions, uses and methods described herein.
- a MetAP2 inhibitor can be Compound 1, or a pharmaceutically acceptable salt, analog, derivative, salt or ester thereof, wherein Compound 1 is represented by:
- y is in the range of 1 to about 30 and n is in the range of 1 to about 100.
- n is in the range of about 1 to about 90; about 1 to about 80; about 1 to about 70; about 1 to about 60; about 1 to about 55; or about 1 to about 50.
- the ratio of x to y can be in the range of about 30: 1 to about 3: 1.
- a MetAP2 inhibitor can be Compound 2, or a pharmaceutically acceptable salt, analog, derivative, salt or ester thereof, wherein Compound 2 is represented by:
- n is in the range of about 1 to about 90; about 1 to about 80; about 1 to about 70; about 1 to about 60; about 1 to about 55; or about 1 to about 50.
- the ratio of x to y can be in the range of about 30:1 to about 3: 1.
- a MetAP2 inhibitor can be Compound 3, or a pharmaceutically acceptable salt, analog, derivative, salt or ester thereof, wherein Compound 3 is represented
- n is in the range of about 1 to about 90; about 1 to about 80; about 1 to about 70; about 1 to about 60; about 1 to about 55; or about 1 to about 50.
- the ratio of x to y can be in the range of about 30:1 to about 3: 1.
- a MetAP2 inhibitor can be Compound 4, or a pharmaceutically acceptable salt, analog, derivative, salt or ester thereof, wherein Compound 4 is represented by:
- Compound 4 wherein x is in the range of 1 to about 450, y is in the range of 1 to about 30 and n is in the range of 1 to about 100. In some aspects, n is in the range of about 1 to about 90; about 1 to about 80; about 1 to about 70; about 1 to about 60; about 1 to about 55; or about 1 to about 50. In some aspects, the ratio of x to y can be in the range of about 30:1 to about 3: 1.
- the MetAP2 inhibitor can be: derivative, salt or ester thereof.
- the MetAP2 inhibitor can be: pharmaceutically acceptable salt, analog, derivative, salt or ester thereof.
- the MetAP2 inhibitor can be: salt, analog, derivative, salt or ester thereof.
- the MetAP2 inhibitor can be:
- the MetAP2 inhibitor can be: pharmaceutically acceptable salt, analog, derivative, salt or ester thereof.
- the MetAP2 inhibitor can be selected from cis-(3aRS,9bRS)-7-
- a MetAP2 inhibitor can be selected from:
- a MetAP2 inhibitor can be: pharmaceutically acceptable salt, analog, derivative, salt or ester thereof.
- a MetAP2 inhibitor can be administered by subcutaneous injection (SC). In some aspects, a MetAP2 inhibitor can be administered by subcutaneous injection to the mid-abdominal (per-umbilical area). In some aspects, a subcutaneous injection of a MetAP2 inhibitor can be administered over an about 30 to about 45 second timeframe at a constant injection rate. In some aspects, the maximum injection volume of a MetAP2 inhibitor is less than about 1.7 ml.
- a MetAP2 inhibitor can be administered about every four days (Q4D).
- a MetAP2 inhibitor can be administered about once every day (QD), about once every two days (Q2D), about once every three days (Q3D), about once every four days (Q4D), about once every 5 days (Q5D), about once every 6 days (Q6D), about once every 7 days (Q7D), about once every 8 days (Q8D), about once every 9 days (Q9D), about once every 10 days (Q10D), about once every 11 days (QI ID), about once every 12 days (QI 2D), about once every 13 days (QI 3D), about once every 14 days (Q14D), or about once every 15 days (Q15D).
- a MetAP2 inhibitor can be administered about once every 7 days (Q7D).
- a MetAP2 inhibitor can be administered about once every 14 days (Q14D).
- an amount of a MetAP2 inhibitor can be a therapeutically effective amount of a MetAP2 inhibitor.
- a MetAP2 inhibitor can be administered in an amount of about 1 mg/m 2 , or about 2 mg/m 2 , or about 3 mg/m 2 , or about 4 mg/m 2 , or about 5 mg/m 2 , or about 6 mg/m 2 , or about 7 mg/m 2 , or about 8 mg/m 2 , or about 9 mg/m 2 , or about 10 mg/m 2 , or about 11 mg/m 2 , or about 12 mg/m 2 , or about 13 mg/m 2 , or about 14 mg/m 2 , or about 15 mg/m 2 , or about 16 mg/m 2 , or about 17 mg/m 2 , or about 18 mg/m 2 , or about 19 mg/m 2 , or about 20 mg/m 2 , or about 21 mg/m 2 , or about 22 mg/m 2 , or about 23 mg/m 2 , or about 24 mg/m 2 , or about 25 mg/m 2 , or about 26 mg/m 2 , or
- a MetAP2 inhibitor can be administered in an amount of about 49 mg/m 2 . In some aspects, a MetAP2 inhibitor can be administered in an amount of about 36 mg/m 2 . In some aspects, a MetAP2 inhibitor can be administered in an amount of about 65 mg/m 2 . In some aspects, a MetAP2 inhibitor can be administered in an amount of about 27 mg/m 2 .
- a MetAP2 inhibitor can be administered in an amount of about 49 mg/m 2 . In some aspects, a MetAP2 inhibitor can be administered in an amount of about 39 mg/m 2 to about 59 mg/m 2 . In some aspects, a MetAP2 inhibitor can be administered in an amount of about 44 mg/m 2 to about 54 mg/m 2 .
- a MetAP2 inhibitor can be administered in an amount of about 36 mg/m 2 . In some aspects, a MetAP2 inhibitor can be administered in an amount of about 26 mg/m 2 to about 49 mg/m 2 . In some aspects, a MetAP2 inhibitor can be administered in an amount of about 31 mg/m 2 to about 65 mg/m 2 .
- a MetAP2 inhibitor can be administered in an amount of about 65 mg/m 2 . In some aspects, a MetAP2 inhibitor can be administered in an amount of about 55 mg/m 2 to about 75 mg/m 2 . In some aspects, a MetAP2 inhibitor can be administered in an amount of about 60 mg/m 2 to about 70 mg/m 2 .
- a therapeutically effective amount of a MetAP2 inhibitor can be about 1 mg/m 2 , or about 2 mg/m 2 , or about 3 mg/m 2 , or about 4 mg/m 2 , or about 5 mg/m 2 , or about 6 mg/m 2 , or about 7 mg/m 2 , or about 8 mg/m 2 , or about 9 mg/m 2 , or about 10 mg/m 2 , or about 11 mg/m 2 , or about 12 mg/m 2 , or about 13 mg/m 2 , or about 14 mg/m 2 , or about 15 mg/m 2 , or about 16 mg/m 2 , or about 17 mg/m 2 , or about 18 mg/m 2 , or about 19 mg/m 2 , or about 20 mg/m 2 , or about 21 mg/m 2 , or about 22 mg/m 2 , or about 23 mg/m 2 , or about 24 mg/m 2 , or about 25 mg/m 2 , or about 26 mg/m 2 , or about 20 mg/m
- a therapeutically effective amount of a MetAP2 inhibitor can be about 49 mg/m 2 . In some aspects, a therapeutically effective amount of a MetAP2 inhibitor can be about 39 mg/m 2 to about 59 mg/m 2 . In some aspects, a therapeutically effective amount of a MetAP2 inhibitor can be about 44 mg/m 2 to about 54 mg/m 2 .
- a therapeutically effective amount of a MetAP2 inhibitor can be about 36 mg/m 2 . In some aspects, a therapeutically effective amount of a MetAP2 inhibitor can be about 26 mg/m 2 to about 49 mg/m 2 . In some aspects, a therapeutically effective amount of a MetAP2 inhibitor can be about 31 mg/m 2 to about 49 mg/m 2 .
- a therapeutically effective amount of a MetAP2 inhibitor can be about 65 mg/m 2 . In some aspects, a therapeutically effective amount of a MetAP2 inhibitor can be about 55 mg/m 2 to about 75 mg/m 2 . In some aspects, a therapeutically effective amount of a MetAP2 inhibitor can be about 60 mg/m 2 to about 70 mg/m 2 .
- a MetAP2 inhibitor can be administered in an amount of about 10 mg, or about 20 mg, or about 30 mg, or about 40 mg, or about 50 mg, or about 60 mg, or about 70 mg, or about 80 mg, or about 90 mg, or about 100 mg or about 110 mg, or about 120 mg, or about 130 mg, or about 140 mg, or about 150 mg, or about 160 mg, or about 170 mg, or about 180 mg, or about 190 mg, or about 200 mg.
- a MetAP2 inhibitor can be administered in an amount of about 80 mg.
- a MetAP2 inhibitor can be administered in an amount of about of about 70 mg to about 90 mg.
- a MetAP2 inhibitor can be administered in an amount of about 75 mg to about 85 mg.
- a therapeutically effective amount of a MetAP2 inhibitor can be about 10 mg, or about 20 mg, or about 30 mg, or about 40 mg, or about 50 mg, or about 60 mg, or about 70 mg, or about 80 mg, or about 90 mg, or about 100 mg.
- a therapeutically effective amount of a MetAP2 inhibitor can be about 80 mg.
- a therapeutically effective amount of a MetAP2 inhibitor can be about of about 70 mg to about 90 mg.
- a therapeutically effective amount of a MetAP2 inhibitor can be about 75 mg to about 85 mg.
- enzalutamide has the following chemical structure:
- enzalutamide may be identified by any of the following names: 4-[3-[4-Cyano-3-(trifluoromethyl)phenyl]-5,5- dimethyl-4-oxo-2-thioxo-l-imidazolidinyl]-2-fluoro-7V-methylbenzamide, MDV 3100, Xtandi, and S -Enzalutamide.
- enzalutamide may be identified as CAS No. 915087-33-1. In the figures accompanying the present disclosure, enzalutamide may be abbreviated “ENZ” or “Enz”.
- enzalutamide can be administered orally.
- an amount of enzalutamide can be a therapeutically effective amount of enzalutamide.
- an amount of enzalutamide can be any of the amounts listed below.
- enzalutamide can be administered in an amount of about 20 mg, or about 40 mg, or about 60 mg, or about 80 mg, or about 100 mg, or about 120 mg, or about 140 mg, or about 160 mg, or about 180 mg, or about 200 mg, or about 220 mg, or about 240 mg, or about 260 mg, or about 280 mg, or about 300 mg, or about 320 mg, or about 340 mg, or about 360 mg, or about 380 mg, or about 400 mg, or about 420 mg, or about 440 mg, or about 460 mg, or about 480 mg, or about 500 mg.
- enzalutamide can be administered in an amount of about 160 mg. In aspects wherein enzalutamide is administered in an amount of about 160 mg, the amount can be administered by orally administering four capsules of 160 mg.
- a therapeutically effective amount of enzalutamide can be any of the enzalutamide amounts described herein.
- enzalutamide can be administered as a pharmaceutical composition, wherein the pharmaceutical composition comprises capryl ocaproyl polyoxylglycerides.
- the pharmaceutical composition can comprise at least one of caprylocaproyl polyoxylglycerides, butylated hydroxy anisole, butylated hydroxytoluene, gelatin, sorbitol sorbitan solution, glycerin, purified water, titanium dioxide, and black iron oxide [00187]
- enzalutamide can be administered about once a day.
- cancer and ’’cancerous refer to or describe the physiological condition in mammals that is typically characterized by unregulated cell growth.
- the prostate cancer can be androgen receptor-positive (AR+) prostate cancer.
- AR+ androgen receptor-positive
- the prostate cancer is androgen sensitive prostate cancer.
- the prostate cancer is a prostate cancer that has reverted to an androgen sensitive state from an androgen-insensitive state.
- the prostate cancer can be castration-resistant prostate cancer.
- the prostate cancer is castration-sensitive prostate cancer.
- the prostate cancer is metastatic.
- the prostate cancer can be phosphatase and tensin homologue deleted on chromosome 10 (PTEN)-deficient prostate cancer. In some aspects, the prostate cancer can be partially PTEN-deficient prostate cancer.
- PTEN tensin homologue deleted on chromosome 10
- the prostate cancer can be PTEN-altered prostate cancer. In some aspects, the prostate cancer can be partially PTEN-altered prostate cancer.
- the prostate cancer is metastatic prostate cancer. [00198] In some aspects, the prostate cancer is advanced prostate cancer.
- the prostate cancer is aggressive variant prostate cancer (AVPC).
- the prostate cancer is neuroendocrine prostate cancer (NEPC).
- the prostate cancer is resistant to treatment using androgen deprivation therapy (ADT).
- ADT can include, but is not limited to, performing an orchiectomy, administering at least one luteinizing hormone-releasing hormone (LHRH) agonist, administering at least one LHRH antagonist, administering at least one estrogen, or any combination thereof.
- LHRH luteinizing hormone-releasing hormone
- an orchiectomy can comprise the removal or one or two testicles from a subject.
- an orchiectomy can be a subcapsular orchiectomy, wherein only the tissues in the testicles that produce androgen are removed, rather than the entire testicle.
- LHRH agonists include, but are not limited to, leuprolide, goserelin, triptorelin and histrelin.
- LHRH antagonists include, but are not limited to, degarelix and relugolix.
- the prostate cancer is resistant to treatment using an androgen receptor antagonist or inhibitor.
- the prostate cancer has progressed while the subject has been on a treatment regimen comprising the administration of at least one androgen receptor antagonist or inhibitor.
- androgen receptor antagonists or inhibitors include, but are not limited to flutamide, bicalutamide, nilutamide, enzalutamide, apalutamide, and darolutamide.
- the prostate cancer is resistant to treatment using enzalutamide.
- the prostate cancer has progressed while the subject has been on a treatment regimen comprising the administration of enzalutamide.
- the prostate cancer can be PTEN-deficient, castration resistant prostate cancer.
- the subject in need thereof is an animal.
- the animal can be a mammal.
- the subject in need thereof is a human.
- the subject in need thereof is a human of 18 years or older, or of 25 years or older, or of 50 years or older, or of 60 years or older, or of 65 years or older, or of 70 years or older, or of 75 years or older, or of 80 years or older, or of 85 years or older.
- the subject has been previously administered at least one androgen deprivation therapy (ADT).
- ADT androgen deprivation therapy
- the subject has been previously administered at least one androgen receptor antagonist and at least one androgen deprivation therapy.
- a subject in need thereof has at least one metabolic dysfunction.
- the at least one metabolic dysfunction can be excessive visceral adiposity, dyslipidemia, obesity (BMI >30), elevated leptin levels, depressed adiponectin levels, high leptin-to-adiponectin ratio, elevated fasting insulin levels, elevated fasting insulin levels accompanied by chronic inflammation, insulin resistance, hyperleptinaemia, high fasting glucose, elevated HbAlc, or any combination thereof.
- the at least one metabolic dysfunction is a treatment-induced metabolic dysfunction.
- the metabolic dysfunction is a treatment- induced metabolic dysfunction that is induced by the treatment with at least one androgen deprivation therapy and/or at least one androgen receptor antagonist.
- Certain compounds of the present disclosure may exist in particular geometric or stereoisomeric forms.
- the present disclosure contemplates all such compounds, including cis- and trans-i somers, R- and 5-enantiomers, diastereomers, (D)-isomers, (L)-isomers, the racemic mixtures thereof, and other mixtures thereof, as falling within the scope of the disclosure.
- Additional asymmetric carbon atoms may be present in a substituent such as an alkyl group. All such isomers, as well as mixtures thereof, are intended to be included in this disclosure. Any representation of a particular isomer is merely exemplary (e.g., the exemplification of a trans-isomer, also encompasses a cis-isomer).
- a particular enantiomer of a compound of the present disclosure may be prepared by asymmetric synthesis or by derivation with a chiral auxiliary, where the resulting diastereomeric mixture is separated and the auxiliary group cleaved to provide the pure desired enantiomer.
- the molecule contains a basic functional group, such as amino, or an acidic functional group, such as carboxyl, diastereomeric salts are formed with an appropriate optically-active acid or base, followed by resolution of the diastereomers thus formed by fractional crystallization or chromatographic means well known in the art, and subsequent recovery of the pure enantiomer.
- the structural formula of the compound represents a certain isomer for convenience in some cases, but the present disclosure includes all isomers, such as geometrical isomers, optical isomers based on an asymmetrical carbon, stereoisomers, tautomers, and the like.
- a crystal polymorphism may be present for the compounds represented by the formula. It is noted that any crystal form, crystal form mixture, or anhydride or hydrate thereof is included in the scope of the present disclosure. Furthermore, so-called metabolite which is produced by degradation of the present compound in vivo is included in the scope of the present disclosure.
- “Isomerism” means compounds that have identical molecular formulae but differ in the sequence of bonding of their atoms or in the arrangement of their atoms in space. Isomers that differ in the arrangement of their atoms in space are termed “stereoisomers”. Stereoisomers that are not mirror images of one another are termed “diastereoisomers”, and stereoisomers that are non-superimposable mirror images of each other are termed “enantiomers” or sometimes optical isomers. A mixture containing equal amounts of individual enantiomeric forms of opposite chirality is termed a “racemic mixture”.
- atropic isomers are a type of stereoisomer in which the atoms of two isomers are arranged differently in space. Atropic isomers owe their existence to a restricted rotation caused by hindrance of rotation of large groups about a central bond. Such atropic isomers typically exist as a mixture, however as a result of recent advances in chromatography techniques; it has been possible to separate mixtures of two atropic isomers in select cases.
- Tautomer is one of two or more structural isomers that exist in equilibrium and is readily converted from one isomeric form to another. This conversion results in the formal migration of a hydrogen atom accompanied by a switch of adjacent conjugated double bonds. Tautomers exist as a mixture of a tautomeric set in solution. In solid form, usually one tautomer predominates. In solutions where tautomerization is possible, a chemical equilibrium of the tautomers will be reached. The exact ratio of the tautomers depends on several factors, including temperature, solvent and pH. The concept of tautomers that are interconvertable by tautomerizations is called tautomerism.
- Common tautomeric pairs are: ketone-enol, amide-nitrile, lactam-lactim, amide- imidic acid tautomerism in heterocyclic rings (e.g., in nucleobases such as guanine, thymine and cytosine), amine-enamine and enamine-enamine.
- the compounds of the present disclosure can exist in either hydrated or unhydrated (the anhydrous) form or as solvates with other solvent molecules.
- hydrates include monohydrates, dihydrates, etc.
- solvates include ethanol solvates, acetone solvates, etc.
- Solvate means solvent addition forms that contain either stoichiometric or non stoichiometric amounts of solvent. Some compounds have a tendency to trap a fixed molar ratio of solvent molecules in the crystalline solid state, thus forming a solvate. If the solvent is water the solvate formed is a hydrate; and if the solvent is alcohol, the solvate formed is an alcoholate. Hydrates are formed by the combination of one or more molecules of water with one molecule of the substance in which the water retains its molecular state as H2O.
- analog refers to a chemical compound that is structurally similar to another but differs slightly in composition (as in the replacement of one atom by an atom of a different element or in the presence of a particular functional group, or the replacement of one functional group by another functional group).
- an analog is a compound that is similar or comparable in function and appearance, but not in structure or origin to the reference compound.
- derivative refers to compounds that have a common core structure, and are substituted with various groups as described herein.
- bioisostere refers to a compound resulting from the exchange of an atom or of a group of atoms with another, broadly similar, atom or group of atoms.
- the objective of a bioisosteric replacement is to create a new compound with similar biological properties to the parent compound.
- the bioisosteric replacement may be physicochemically or topologically based.
- Examples of carboxylic acid bioisosteres include, but are not limited to, acyl sulfonimides, tetrazoles, sulfonates and phosphonates. See, e.g., Patani and LaVoie, (Rem. Rev. 96, 3147-3176, 1996.
- Temporal proximity may vary according to various factors, including but not limited to, the age, gender, weight, genetic background, medical condition, disease history, and treatment history of the subject to which the therapeutic agents are to be administered; the disease or condition to be treated or ameliorated; the therapeutic outcome to be achieved; the dosage, dosing frequency, and dosing duration of the therapeutic agents; the pharmacokinetics and pharmacodynamics of the therapeutic agents; and the route(s) through which the therapeutic agents are administered.
- Clinical benefit can be measured by assessing various endpoints, e.g., inhibition, to some extent, of disease progression, including slowing down and/or complete arrest; reduction in the number of disease episodes and/or symptoms; reduction in lesion size; inhibition (i.e., reduction, slowing down or complete stopping) of disease cell infiltration into adjacent peripheral organs and/or tissues; inhibition (i.e.
- autoimmune response which may, but does not have to, result in the regression or ablation of the disease lesion
- relief, to some extent, of one or more symptoms associated with the disorder increase in the length of disease-free presentation following treatment, e.g., progression-free survival; increased overall survival; higher response rate; decreased mortality at a given point of time following treatment; and/or improvement in one of the following symptoms: congestion, fluid/edema, wheezing, coughing, hypoxemia, low oxygen saturation, lung stiffness, shortness of breath, shortness of breath during exercise, dry hacking cough, fast shallow breathing, weight loss, tiredness, aching joints, aching muscles and clubbing.
- the term “pharmaceutically acceptable” refers to those compounds, anions, cations, materials, compositions, carriers, and/or dosage forms which are, within the scope of sound medical judgment, suitable for use in contact with the tissues of human beings and animals without excessive toxicity, irritation, allergic response, or other problem or complication, commensurate with a reasonable benefit/risk ratio.
- the term “combination therapy” or “co-therapy” includes the administration of a compound of the present disclosure, or a pharmaceutically acceptable salt, polymorph or solvate thereof, and at least a second agent as part of a specific treatment regimen intended to provide the beneficial effect from the co-action of these therapeutic agents.
- the beneficial effect of the combination includes, but is not limited to, pharmacokinetic or pharmacodynamic co-action resulting from the combination of therapeutic agents.
- compositions comprising any compound described herein in combination with at least one pharmaceutically acceptable excipient or carrier.
- any description of a method of treatment includes use of the compounds to provide such treatment or prophylaxis as is described herein, as well as use of the compounds to prepare a medicament to treat or prevent such condition.
- the treatment includes treatment of human or non-human animals including rodents and other disease models.
- the term “subject” is interchangeable with the term “subject in need thereof’, both of which refer to a subject having a disease or having an increased risk of developing the disease.
- a “subject” includes a mammal.
- the mammal can be e.g., a human or appropriate non-human mammal, such as primate, mouse, rat, dog, cat, cow, horse, goat, camel, sheep or a pig.
- the subject can also be a bird or fowl.
- the mammal is a human.
- the term “treating” or “treat” describes the management and care of a patient for the purpose of combating a disease, condition, or disorder and includes the administration of a compound of the present disclosure, or a pharmaceutically acceptable salt, polymorph or solvate thereof, to alleviate the symptoms or complications of a disease, condition or disorder, or to eliminate the disease, condition or disorder.
- the term “treat” can also include treatment of a cell in vitro or an animal model.
- a compound of the present disclosure, or a pharmaceutically acceptable salt, polymorph or solvate thereof can or may also be used to prevent a relevant disease, condition or disorder, or used to identify suitable candidates for such purposes.
- preventing describes reducing or eliminating the onset of the symptoms or complications of such disease, condition or disorder.
- Embodiment la A method of treating prostate cancer in a subject, the method comprising administering at least one amount of at least one MetAP2 inhibitor to the subject.
- Embodiment lb A method of preventing prostate cancer in a subject, the method comprising administering at least one amount of at least one MetAP2 inhibitor to the subject.
- Embodiment 1c A method of preventing prostate cancer growth or recurrence in a subject, the method comprising administering at least one amount of at least one MetAP2 inhibitor to the subject.
- Embodiment 2a A MetAP2 inhibitor, or pharmaceutically acceptable salt thereof, for use in treating prostate cancer in a subject.
- Embodiment 2b A MetAP2 inhibitor, or pharmaceutically acceptable salt thereof, for use in preventing prostate cancer in a subject.
- Embodiment 2c A MetAP2 inhibitor, or pharmaceutically acceptable salt thereof, for use in preventing prostate cancer growth or recurrence in a subject.
- Embodiment 3a A combination comprising at least one MetAP2 inhibitor, or a pharmaceutically acceptable salt thereof, and enzalutamide, or a pharmaceutically acceptable salt thereof, for use in treating prostate cancer in a subject.
- Embodiment 3b A combination comprising at least one MetAP2 inhibitor, or a pharmaceutically acceptable salt thereof, and enzalutamide, or a pharmaceutically acceptable salt thereof, for use in preventing prostate cancer in a subject.
- Embodiment 3c A combination comprising at least one MetAP2 inhibitor, or a pharmaceutically acceptable salt thereof, and enzalutamide, or a pharmaceutically acceptable salt thereof, for use in preventing prostate cancer growth or recurrence in a subject.
- Embodiment 4a A method of treating prostate cancer in a subject, the method comprising administering to the subject at least one amount of at least one MetAP2 inhibitor, or a pharmaceutically acceptable salt thereof, and at least one therapeutically effective amount of enzalutamide, or a pharmaceutically acceptable salt thereof.
- Embodiment 4b A method of preventing prostate cancer in a subject, the method comprising administering to the subject at least one amount of at least one MetAP2 inhibitor, or a pharmaceutically acceptable salt thereof, and at least one therapeutically effective amount of enzalutamide, or a pharmaceutically acceptable salt thereof.
- Embodiment 4c A method of preventing prostate cancer growth or recurrence in a subject, the method comprising administering to the subject at least one amount of at least one MetAP2 inhibitor, or a pharmaceutically acceptable salt thereof, and at least one therapeutically effective amount of enzalutamide, or a pharmaceutically acceptable salt thereof.
- Embodiment 5a A MetAP2 inhibitor, or a pharmaceutically acceptable salt thereof, for use in a method of treating prostate cancer in a subject, wherein the method further comprises administration of enzalutamide, or a pharmaceutically acceptable salt thereof.
- Embodiment 5b A MetAP2 inhibitor, or a pharmaceutically acceptable salt thereof, for use in a method of preventing prostate cancer in a subject, wherein the method further comprises administration of enzalutamide, or a pharmaceutically acceptable salt thereof.
- Embodiment 5c A MetAP2 inhibitor, or a pharmaceutically acceptable salt thereof, for use in a method of preventing prostate cancer growth or recurrence in a subject, wherein the method further comprises administration of enzalutamide, or a pharmaceutically acceptable salt thereof.
- Embodiment 6a Enzalutamide, or a pharmaceutically acceptable salt thereof, for use in a method of treating prostate cancer in a subject, wherein the method further comprises administration of at least one MetAP2 inhibitor or a pharmaceutically acceptable salt thereof.
- Embodiment 6b Enzalutamide, or a pharmaceutically acceptable salt thereof, for use in a method of preventing prostate cancer in a subject, wherein the method further comprises administration of at least one MetAP2 inhibitor or a pharmaceutically acceptable salt thereof.
- Embodiment 6c Enzalutamide, or a pharmaceutically acceptable salt thereof, for use in a method of preventing prostate cancer growth or recurrence in a subject, wherein the method further comprises administration of at least one MetAP2 inhibitor or a pharmaceutically acceptable salt thereof.
- Embodiment 7 The method, MetAP2 inhibitor, combination, or enzalutamide of any one of the preceding embodiments, wherein the prostate cancer is castration-resistant prostate cancer.
- Embodiment 8 The method, MetAP2 inhibitor, combination, or enzalutamide of any one of the preceding embodiments, wherein the prostate cancer is castration-sensitive prostate cancer.
- Embodiment 9a The method, MetAP2 inhibitor, combination, or enzalutamide of any one of the preceding embodiments, wherein the prostate cancer is PTEN-deficient prostate cancer or partially PTEN-deficient prostate cancer.
- Embodiment 9b The method, MetAP2 inhibitor, combination, or enzalutamide of any one of the preceding embodiments, wherein the prostate cancer is PTEN-altered prostate cancer or partially PTEN-altered prostate cancer.
- Embodiment 10 The method, MetAP2 inhibitor, combination, or enzalutamide of any one of the preceding embodiments, wherein the prostate cancer is aggressive variant prostate cancer (AVPC).
- AVPC aggressive variant prostate cancer
- Embodiment 11 The method, MetAP2 inhibitor, combination, or enzalutamide of any one of the preceding embodiments, wherein the prostate cancer is neuroendocrine prostate cancer (NEPC).
- NEPC neuroendocrine prostate cancer
- Embodiment 12 The method, MetAP2 inhibitor, combination, or enzalutamide of any one of the preceding embodiments, wherein the at least one MetAP2 inhibitor, or pharmaceutically acceptable salt thereof, and the enzalutamide, or pharmaceutically acceptable salt thereof, are administered concurrently or in temporal proximity.
- Embodiment 13 The method, MetAP2 inhibitor, combination, or enzalutamide of any one of the preceding embodiments, wherein the subject has been previously administered at least one androgen deprivation therapy.
- Embodiment 14 The method, MetAP2 inhibitor, combination, or enzalutamide of any one of the preceding embodiments, wherein the subject has undergone an orchiectomy.
- Embodiment 15 The method, MetAP2 inhibitor, combination, or enzalutamide of embodiment 14, wherein the orchiectomy is a subcapsular orchiectomy.
- Embodiment 16 The method, MetAP2 inhibitor, combination, or enzalutamide of any one of the preceding embodiments, wherein the subject has been previously administered at least one luteinizing hormone-releasing hormone (LHRH) agonist.
- LHRH luteinizing hormone-releasing hormone
- Embodiment 17 The method, MetAP2 inhibitor, combination, or enzalutamide of embodiment 16, wherein the at least one luteinizing hormone-releasing hormone (LHRH) agonist is selected from leuprolide, goserelin, triptorelin and histrelin.
- LHRH luteinizing hormone-releasing hormone
- Embodiment 18 The method, MetAP2 inhibitor, combination, or enzalutamide of any one of the preceding embodiments, wherein the subject has been previously administered at least one LHRH antagonist.
- Embodiment 19 The method, MetAP2 inhibitor, combination, or enzalutamide of embodiment 18, wherein the at least one LHRH antagonist is selected from degarelix and relugolix.
- Embodiment 20 The method, MetAP2 inhibitor, combination, or enzalutamide of any one of the preceding embodiments, wherein the subject has been previously administered at least one androgen receptor antagonist.
- Embodiment 21 The method, MetAP2 inhibitor, combination, or enzalutamide of embodiment 20, wherein the androgen receptor antagonist is selected from flutamide, bicalutamide, nilutamide, enzalutamide, apalutamide, and darolutamide.
- Embodiment 22 The method, MetAP2 inhibitor, combination, or enzalutamide of embodiment 21, wherein the androgen receptor antagonist is enzalutamide.
- Embodiment 23 The method, MetAP2 inhibitor, combination, or enzalutamide of any one of the preceding embodiments, wherein the prostate cancer is resistant to treatment with androgen deprivation therapy.
- Embodiment 24 The method, MetAP2 inhibitor, combination, or enzalutamide of embodiment 23, wherein the androgen deprivation therapy comprises performing an orchiectomy, administering at least one luteinizing hormone-releasing hormone (LHRH) agonist, administering at least one LHRH antagonist, administering at least one estrogen, or any combination thereof.
- LHRH luteinizing hormone-releasing hormone
- Embodiment 25 The method, MetAP2 inhibitor, combination, or enzalutamide of embodiment 24, wherein the orchiectomy is a subcapsular orchiectomy.
- Embodiment 26 The method, MetAP2 inhibitor, combination, or enzalutamide of embodiment 24, wherein the at least one luteinizing hormone-releasing hormone (LHRH) agonist is selected from leuprolide, goserelin, triptorelin and histrelin.
- LHRH luteinizing hormone-releasing hormone
- Embodiment 27 The method, MetAP2 inhibitor, combination, or enzalutamide of embodiment 24, wherein the at least one LHRH antagonist is selected from degarelix and relugolix.
- Embodiment 28 The method, MetAP2 inhibitor, combination, or enzalutamide of any one of the preceding embodiments, wherein the prostate cancer is resistant to treatment with an androgen receptor antagonist.
- Embodiment 29 The method, MetAP2 inhibitor, combination, or enzalutamide of embodiment 28, wherein the androgen receptor antagonist is selected from flutamide, bicalutamide, nilutamide, enzalutamide, apalutamide, and darolutamide.
- Embodiment 30 The method, MetAP2 inhibitor, combination, or enzalutamide of any one of the preceding embodiments, wherein the MetAP2 inhibitor is administered/for administration within one day, two days, three days, four days, five days, six days or one week of the subject exhibiting PSA nadir.
- Embodiment 31 The method, MetAP2 inhibitor, combination, or enzalutamide of any one of the preceding embodiments, wherein the MetAP2 inhibitor is administered/for administration about two weeks, or about three weeks, or about four weeks, or about five weeks after the subject has exhibited PSA nadir, and wherein the PSA level in the subject has increased from PSA nadir.
- Embodiment 32 The method, MetAP2 inhibitor, combination, or enzalutamide of any one of the preceding embodiments, wherein the subject has at least one metabolic dysfunction, wherein the metabolic dysfunction is selected from visceral adiposity, dyslipidemia, obesity (BMI >30), elevated leptin levels, depressed adiponectin levels, high leptin-to-adiponectin ratio, elevated fasting insulin levels, elevated fasting insulin levels accompanied by chronic inflammation, insulin resistance, hyperleptinaemia, high fasting glucose, elevated 14b Ale, or any combination thereof.
- the metabolic dysfunction is selected from visceral adiposity, dyslipidemia, obesity (BMI >30), elevated leptin levels, depressed adiponectin levels, high leptin-to-adiponectin ratio, elevated fasting insulin levels, elevated fasting insulin levels accompanied by chronic inflammation, insulin resistance, hyperleptinaemia, high fasting glucose, elevated 14b Ale, or any combination thereof.
- Embodiment 33 The method, MetAP2 inhibitor, combination, or enzalutamide of any one of the preceding embodiments, wherein the metabolic dysfunction is a treatment-induced metabolic dysfunction.
- Embodiment 34 The method, MetAP2 inhibitor, combination, or enzalutamide of any one of the preceding embodiments, wherein the MetAP2 inhibitor is selected from:
- MetAP2 inhibitor is: (Compound 1), or a pharmaceutically acceptable salt thereof, wherein x is in the range of 1 to about 450, y is in the range of 1 to about 30 and n is in the range of 1 to about 100, preferably wherein the ratio of x to y is in the range of about 30: 1 to about 3: 1, preferably wherein the ratio of x to y is about 11 : 1.
- Embodiment 35 The method, MetAP2 inhibitor, combination, or enzalutamide of any one of the preceding embodiments, or pharmaceutically acceptable salt thereof, wherein the MetAP2 inhibitor is administered/for administration to the subject in an amount of: i) about 27 mg/m 2 ; ii) about 36 mg/m 2 ; iii) about 49 mg/m 2 ; or iv) about 65 mg/m 2 .
- Embodiment 36 The method, MetAP2 inhibitor, combination, or enzalutamide of any one of the preceding embodiments, wherein the MetAP2 inhibitor is administered/for administration: i) once every 7 days (Q7D); ii) once every 14 days (Q14D); or iii) once every 21 days (Q21D).
- Embodiment 37 The method, MetAP2 inhibitor, combination, or enzalutamide of any one of the preceding embodiments, or pharmaceutically acceptable salt thereof, wherein the enzalutamide is administered/for administration to the subject in an amount of: i) about 40 mg; ii) about 80 mg; iii) about 120 mg; or iv) about 160 mg.
- Embodiment 38 The method, MetAP2 inhibitor, combination, or enzalutamide of any one of the preceding embodiments, wherein the enzalutamide is administered/for administration daily.
- Embodiment 39 The method, MetAP2 inhibitor, combination, or enzalutamide of any one of the preceding embodiments, wherein administration of the at least one MetAP2 inhibitor results in a reduction in the size of the prostate cancer.
- Embodiment 40 The method, MetAP2 inhibitor, combination, or enzalutamide of embodiment 36, wherein the reduction in the size of the prostate cancer is at least about a 10%, or about a 20%, or about a 30%, or about a 40%, or about a 50%, or about a 60%, or about a 70%, or about an 80%, or about a 90%, or about a 99% reduction in tumor volume.
- mice were injected subcutaneously with 2xl0 6 LNCaP cells. When tumors reached approximately 200 mm 3 , the mice were split into two treatment groups of four mice each. The first treatment group received Compound 1 in an amount of 12 mg/kg, administered subcutaneously once every 4 days. The second treatment group received a negative control, vehicle treatment comprising 5% mannitol in water.
- FIG. 1 shows the tumor volume in individual mice (left panel) and the average tumor volume across all mice (right panel) in the Compound 1 and Vehicle control treatment groups.
- the vertical dashed lines denote the start of treatment.
- FIG. 2 shows the average PSA levels of mice (left panel) and the endpoint tumor mass (right panel) in the Compound 1 and Vehicle control treatment groups.
- FIG. 3 shows the body weight of individual mice (left panel) and the average body weight across all mice (right panel) in the Compound 1 and Vehicle control treatment groups. The vertical dashed lines denote the start of treatment.
- FIG. 4 shows the liver, kidney, heart and lung weights at the endpoint of the study in select mice in the Compound 1 and Vehicle control treatment groups.
- FIG. 5 shows the liver, kidney, heart and lung weights as a percentage of body weight at the endpoint of the study in select mice in the Compound 1 and Vehicle control treatment groups.
- FIG. 6 is a graph showing the overall survival of the mice in the Compound 1 and Vehicle control treatment groups. As shown in FIG. 6, treatment with Compound 1 resulted in increased survival of the mice.
- FIG. 7 shows necropsy images of tumors excised from mice in the Compound 1 and Vehicle control treatment groups.
- FIG. 8 shows immunohistochemistry analysis of CD34 immunoreactivity from select mice in the Compound 1 and Vehicle control treatment groups.
- the endothelial marker CD34 can be used to quantify tumor vasculature. Accordingly, as shown in FIG. 8, treatment with Compound 1 results in a decrease in tumor vasculature as compared to treatment with the vehicle control.
- FIG. 9 shows the average tumor volume across all mice in the three treatment groups. The vertical dashed lines denote the start of treatment and the gray box denotes castration.
- FIG. 10 shows the tumor mass at the conclusion of the study. The results shown in FIGs. 9 and 10 demonstrate that the administration of Compound 1 prevented tumor growth and resulted in smaller tumors at the end of the study.
- FIG. 11 shows the average PSA levels across all mice in the three treatment groups during the course of the study. The results shown in FIG. 11 demonstrate that PSA levels were not affected by treatment with Compound 1.
- FIG. 12 shows the liver, kidney, heart and lung weights at the endpoint of the study in select mice in the Compound 1 and Vehicle control treatment groups.
- FIG. 13 shows the liver, kidney, heart and lung weights as a percentage of body weight at the endpoint of the study in select mice in the Compound 1 and Vehicle control treatment groups.
- FIG. 14 shows average body weight across all mice in the Compound 1 and Vehicle control treatment groups. The vertical dashed lines denote the start of treatment.
- the Compound 1 6 mg/kg treatment group is denoted as “Cpdl (6 mpk)” and the Compound 1 12 mg/kg treatment group is denoted as “Cpdl (12 mpk)”.
- FIG. 15 shows immunohistochemistry analysis of CD34 immunoreactivity from select mice in the three treatment groups.
- the endothelial marker CD34 can be used to quantify tumor vasculature. Accordingly, as shown in FIG. 15, treatment with Compound 1 prevented the formation of tumor vasculature as compared to treatment with the vehicle control.
- NSG mice prepared as described in Example 2 were subsequently enrolled in one of two treatment groups 2-4 weeks after castration and the recurrence of high PSA levels and tumor growth (i.e., castration-resistant prostate cancer).
- the first treatment group received Compound 1 in an amount of 12 mg/kg, administered subcutaneously once every 4 days.
- the second treatment group received a negative control, vehicle treatment comprising 5% mannitol in water(denoted in some figures as “Veh”).
- FIG. 16 shows the tumor volume in individual mice (top panel) and the average tumor volume across all mice (bottom panel) in the Compound 1 and Vehicle control treatment groups.
- the vertical dashed lines denote the start of treatment.
- FIG. 17 shows the endpoint tumor mass (left panel) and average PSA levels of mice (right panel) and in the Compound 1 and Vehicle control treatment groups. As shown in FIGs. 16 and 17, treatment with Compound 1 resulted a decrease in tumor volume while PSA levels were not affected.
- FIG. 18 shows the body weight of individual mice (top panel) and the average body weight across all mice (bottom panel) in the Compound 1 and Vehicle control treatment groups.
- the vertical dashed lines denote the start of treatment.
- FIG. 19 shows the liver, kidney, heart and lung weights at the endpoint of the study in select mice in the Compound 1 and Vehicle control treatment groups.
- FIG. 20 shows the liver, kidney, heart and lung weights as a percentage of body weight at the endpoint of the study in select mice in the Compound 1 and Vehicle control treatment groups.
- FIG. 21 shows immunohistochemistry analysis of CD34 immunoreactivity from select mice in the Compound 1 and Vehicle control treatment groups.
- the endothelial marker CD34 can be used to quantify tumor vasculature. Accordingly, as shown in FIG. 21, treatment with Compound 1 results in a decrease in tumor vasculature as compared to treatment with the vehicle control.
- mice prepared as described in Example 2 were subsequently enrolled in one of four treatment groups 2-4 weeks after castration and the recurrence of high PSA levels and tumor growth.
- the first treatment group received enzalutamide in an amount of 10 mg/kg daily by oral gavage in combination with a negative control, vehicle treatment of 5% mannitol in water.
- the second treatment group received enzalutamide in an amount of 10 mg/kg daily by oral gavage in combination with Compound 1 in an amount of 12 mg/kg, administered subcutaneously once every 4 days.
- FIG. 22 shows the average tumor volume across mice in the first treatment group described above.
- the first treatment group was stratified into two groups -those that responded to the treatment with enzalutamide alone (“responders”) and those that did not respond to enzalutamide alone (“non-responders”). Dashed line denotes the start of treatment.
- FIG. 23 shows the average tumor volume across mice in the first and second treatment groups described above. The first treatment group was stratified into two groups - those that responded to the treatment with enzalutamide alone (“responders”) and those that did not respond to enzalutamide alone (“non-responders”). Dashed line denotes the start of treatment (enzalutamide or enzalutamide plus Compound 1).
- FIG. 24 shows the endpoint tumor mass in the first and second treatment groups described above.
- the first treatment group was stratified into two groups -those that responded to the treatment with enzalutamide alone (“responders”) and those that did not respond to enzalutamide alone (“non-responders”).
- FIG. 25 shows the PSA levels in the first and second treatment groups described above.
- the first treatment group was stratified into two groups -those that responded to the treatment with enzalutamide alone (“responders”) and those that did not respond to enzalutamide alone (“non-responders”). Dashed line denotes the start of treatment (enzalutamide or enzalutamide plus Compound 1).
- FIG. 26 shows the body weight of individual mice (top panel) and the average body weight across all mice (bottom panel) in the first and second treatment groups described above.
- the vertical dashed lines denote the start of treatment.
- FIG. 27 shows the liver, kidney, heart and lung weights at the endpoint of the study in select mice in the first and second treatment groups described above.
- FIG. 28 shows the liver, kidney, heart and lung weights as a percentage of body weight at the endpoint of the study in select mice in the first and second treatment groups described above.
- FIG. 29 shows immunohistochemistry analysis of CD34 immunoreactivity from select mice in the first and second treatment groups described above.
- the first treatment group was stratified into two groups -those that responded to the treatment with enzalutamide alone (“responders”) and those that did not respond to enzalutamide alone (“non-responders”).
- the endothelial marker CD34 can be used to quantify tumor vasculature. Accordingly, as shown in FIG. 29, treatment with Compound 1 in combination with enzalutamide results in a decrease in tumor vasculature when compared to enzalutamide alone in the responder group.
- mice Physically-castrated NSG mice were injected subcutaneously with patient derived castration-resistant prostate cancer tumor samples (LUCAP35CR). When tumors reached ⁇ 250mm 3 , mice were enrolled in one of two treatment groups. The first treatment group received Compound 1 in an amount of 8 mg/kg, administered subcutaneously once every 4 days. The second treatment group received a negative control, vehicle treatment comprising 5% mannitol in water.
- LUCAP35CR patient derived castration-resistant prostate cancer tumor samples
- FIG. 30 shows the average tumor volume across all mice in the Compound 1 and Vehicle control treatment groups.
- the vertical dashed lines denote the start of treatment.
- FIG. 31 shows the endpoint tumor mass in the Compound 1 and Vehicle control treatment groups. As shown in FIGs. 30 and 31, treatment with Compound 1 resulted in a decrease in tumor volume.
- FIG. 32 shows immunohistochemistry analysis of CD34 immunoreactivity from select mice in the Compound 1 and Vehicle control treatment groups.
- the endothelial marker CD34 can be used to quantify tumor vasculature. Accordingly, as shown in FIG. 32, treatment with Compound 1 results in a decrease in tumor vasculature as compared to the vehicle control.
- Transcriptomic analysis of tumor samples from the first and second treatment groups was also performed.
- FIG. 41 shows the expression levels of particular hypoxia induced, extracellular matrix-related genes in tumor samples from treatment group 1 (Compound 1) and treatment group 2 (vehicle).
- FIGs. 42A and 42B show the expression levels of particular glycolysis-related genes in tumor samples from treatment group 1 (Compound 1) and treatment group 2 (vehicle).
- FIG. 43 shows the expression levels of particular serine-glycine one-carbon (SOGC) pathway genes in tumor samples from treatment group 1 (Compound 1) and treatment group 2 (vehicle).
- SOGC serine-glycine one-carbon
- FIG. 44 shows the expression levels of particular cholesterol uptake and synthesis pathway genes in tumor samples from treatment group 1 (Compound 1) and treatment group 2 (vehicle).
- FIG. 45 shows the expression levels of particular fatty acid synthesis pathway genes in tumor samples from treatment group 1 (Compound 1) and treatment group 2 (vehicle).
- FIG. 46 shows the expression levels of particular cell cycle genes in tumor samples from treatment group 1 (Compound 1) and treatment group 2 (vehicle).
- FIG. 47 shows the expression levels of particular hormone/cytokine receptor genes in tumor samples from treatment group 1 (Compound 1) and treatment group 2 (vehicle).
- FIG. 48 shows the expression levels of particular kinase genes in tumor samples from treatment group 1 (Compound 1) and treatment group 2 (vehicle).
- FIG. 49 shows the expression levels of particular transcription factor genes in tumor samples from treatment group 1 (Compound 1) and treatment group 2 (vehicle).
- FIG. 50 shows the expression levels of particular tumor-inhibiting genes in tumor samples from treatment group 1 (Compound 1) and treatment group 2 (vehicle).
- FIGs. 51 A and 5 IB show the expression levels of particular tumor-growth promoting/survival genes in tumor samples from treatment group 1 (Compound 1) and treatment group 2 (vehicle).
- FIG. 52 shows the expression levels of particular nucleotide synthesis genes in tumor samples from treatment group 1 (Compound 1) and treatment group 2 (vehicle).
- FIG. 53 shows the expression levels of particular lipid metabolism genes in tumor samples from treatment group 1 (Compound 1) and treatment group 2 (vehicle).
- FIG. 54 shows the expression levels of particular immune recognition genes in tumor samples from treatment group 1 (Compound 1) and treatment group 2 (vehicle).
- FIG. 55 shows the expression levels of particular immune recognition genes, specifically CD74 ligands and binding partners, in tumor samples from treatment group 1 (Compound 1) and treatment group 2 (vehicle).
- FIG. 56 shows the expression levels of particular genes encoding regulators of MHC II, in tumor samples from treatment group 1 (Compound 1) and treatment group 2 (vehicle).
- Compound 1 Compound 1
- treatment group 2 vehicle
- proper stimulation of T cells requires efficient HLA class II antigen presentation by professional or non-professional antigen-presenting cells, including prostate cancer cells.
- the transcription factor CIITA whose expression is decreased in many cancers, positively regulates the expression of MHC II genes.
- the enzyme GILT down-regulated in many cancers including prostate cancer, facilitates processing of MHC II-antigen complexes prior to their display on the cell surface.
- mice treated with Compound 1 was les fibrotic, based on the reduction in multiple collagen genes, and less immunosuppressive, based on the reduction in the expression of Argl.
- the increased expression of multiple genes involved in adipocyte function indicate increased adipocyte differentiation or hypertrophy, with increased adiponectin potentially exhibiting anti-tumor effects.
- the left panel in FIG. 35 shows a chart of the number of differentially expressed human genes for each pairwise comparison of treatment groups (see Table A for details on comparison groups). Differential gene expression (DE) is defined by abs.FC > 1.5 and FDR pvalue ⁇ 0.05.
- the right panel in FIG. 35 shows bubble plots of a selection of significantly enriched (adj .pvalue ⁇ 0.05) cellular pathways from the MSigDB (Molecular Signatures Database) for each of the comparisons presented in Table A and the left panel of FIG. 35.
- FIGs. 36-40 show bubble plots of genes of interest including LINGO4, SORCS2, KCND3, SNRNP48, GLS, BAG1, AR, KLK3, DDC, STEAP4, FKBP5, FOLH1, PPIA, RAB37, TXN, SH3BGRL, GAPDH, METAP2, R0R2, CTHRC1, DVL3, ARRB2, PPARG, WNT5A, MAPK10, PPKCZ, DVL2, AMACR, PCGEM1, PC A3, PSCA, NIKX3-1, AZGP1, H0XB13, SOX9 and RLN1 for pairwise comparisons of treatment groups (see Table B for details on comparison groups).
- the first treatment group received enzalutamide in an amount of 10 mg/kg daily by oral gavage in combination with a negative control, vehicle treatment of 5% mannitol in water.
- the second treatment group received enzalutamide in an amount of 10 mg/kg daily by oral gavage in combination with Compound 1 in an amount of 8 mg/kg, administered subcutaneously once every 4 days.
- FIG. 33 A shows the average tumor volume across all mice in the two treatment groups
- the gray box denotes the time period of enzalutamide treatment and the vertical dashed lines denotes the start of resistance to the enzalutamide treatment and start of treatment with Compound 1.
- FIG. 33B shows the endpoint tumor mass in the first and second treatment groups described above. The results shown in FIGs. 33A and 33B demonstrate that the administration of Compound 1 in combination with enzalutamide prevented tumor growth and resulted in smaller tumors at the end of the study compared to tumors in mice treated with enzalutamide alone.
- FIG. 33C shows immunohistochemistry analysis of CD34 immunoreactivity from select mice in the Compound 1 plus enzalutamide and Vehicle enzalutamide control treatment groups described above.
- the endothelial marker CD34 can be used to quantify tumor vasculature. Accordingly, as shown in FIG. 33C, treatment with Compound 1 results in a decrease in tumor vasculature as compared to the vehicle control.
- AVPC aggressive variant prostate cancer
- NEPC neuroendocrine prostate cancer
- LTL545 PDX patient-derived AVPC tumor xenografts (specifically NEPC tumor xenografts) were transplanted into NSG mice. When tumors reached approximately 200 mm 3 , the mice were enrolled in one of two treatments. The first treatment group received Compound 1 in an amount of 8 mg/kg, administered subcutaneously once every 4 days. The second treatment received a negative control, vehicle treatment comprising 5% mannitol in water.
- FIG. 34A shows the tumor volume of all mice in the two treatment groups and FIG. 34B shows the average tumor volume across all mice in the two treatment groups.
- the vertical dashed lines denotes the onset of treatment with Compound 1.
- FIG. 34C shows the endpoint tumor mass in the first and second treatment groups described above.
- the results shown in FIGs. 34A, 34B and 34C demonstrate that the administration of Compound 1 attenuated AVPC tumor growth and resulted in smaller AVPC tumors at the end of the study.
- the results presented in this example demonstrate that Compound 1 of the present disclosure can be used to treat AVPC, including NEPC.
Landscapes
- Health & Medical Sciences (AREA)
- Veterinary Medicine (AREA)
- Chemical & Material Sciences (AREA)
- Medicinal Chemistry (AREA)
- Pharmacology & Pharmacy (AREA)
- Life Sciences & Earth Sciences (AREA)
- Animal Behavior & Ethology (AREA)
- General Health & Medical Sciences (AREA)
- Public Health (AREA)
- Epidemiology (AREA)
- Chemical Kinetics & Catalysis (AREA)
- General Chemical & Material Sciences (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Organic Chemistry (AREA)
- Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
- Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
Abstract
The present disclosure provides pharmaceutical combinations comprising MetAP2 inhibitors for the treatment of prostate cancer.
Description
METAP2 INHIBITORS FOR THE TREATMENT OF PROSTATE CANCER
RELATED APPLICATIONS
[0001] This application claims priority to, and the benefit of, U.S. Provisional Application No. 63/425,942, filed November 16, 2022, U.S. Provisional Application No. 63/459,077, filed April 13, 2023, and U.S. Provisional Application 63/517,334, filed August 2, 2023. The contents of each of the aforementioned patent applications are incorporated herein by reference in their entireties.
BACKGROUND
[0002] Prostate cancer is the second-most diagnosed malignancy and is the leading cause of cancer death worldwide among men. More specifically, treatment of advanced prostate cancer with androgen deprivation therapy and androgen receptor antagonists (e.g. enzalutamide) has only provided incremental improvements in survival, as patients inevitably develop resistance. Moreover, continuous androgen deprivation or receptor inhibition therapy has been shown to drive systemic metabolic dysfunction, including weight gain, increased insulin resistance, hyperleptinaemia and reduced circulating adiponectin. Such dysfunctions have been shown to lead to molecular reprogramming in tumours that may be in at least in part responsible for the development of treatment resistance. Finally, elevated expression of the enzyme methionine aminopeptidase type 2 (MetAP2) has recently been shown to be associated with higher grade tumours, including neuroendocrine tumours, and worse clinical outcomes.
[0003] Additionally, over the last decade, the clinical approval and increased use of highly potent androgen receptor (AR) pathway inhibitors for the treatment of metastatic castrateresistant prostate cancer (mCRPC) has provided significant improvements in patient survival, but the development of resistance remains a significant clinical issue. In particular, AR inhibition causes major molecular reprograming in tumors, which has resulted in the emergence of highly aggressive and difficult-to-treat molecular subtypes of prostate cancer, termed aggressive variant prostate cancer (AVPC). AVPC is a general term for tumors representing the transition from an adenocarcinoma phenotype, toward less differentiated anaplastic phenotypes, which are driven by alternate non-AR mechanisms to promote tumor growth and survival. Identified in around 30% of mCRPC patients, emerging molecular signatures of AVPC display a spectrum of anaplastic features, including biomarkers of neuroendocrine (NE) disease and lack of AR expression or activity. Few therapeutic options are available for patients at this stage of disease. Patients may receive taxane therapy or, in
the wake of encouraging international trials, 177Lutetium-PSMA-617 (Lu-PSMA), a radioligand-based theranostic targeting the cell-surface protein, prostate-specific membrane antigen (PSMA). Nevertheless, -15-30% of patients will not be eligible for Lu-PSMA (or similar targeting agents), especially patients with AVPC metastases characterized as low expression of PSMA by PSMA-PET screening. Therefore, novel, AR-independent therapies are urgently sought for patients with mCRPC and AVPC.
[0004] Thus, there is a need in the art for compositions and methods directed to the treatment of prostate cancer, including treatments that target MetAP2 and/or that mitigate treatment- induced metabolic dysfunctions. The present disclosure provides MetAP2 inhibitors and combinations comprising MetAP2 inhibitors for the treatment of prostate cancer.
SUMMARY
[0005] The present disclosure provides methods of treating prostate cancer in a subject, the methods comprising administering at least one amount of at least one MetAP2 inhibitor to the subject, wherein the MetAP2 inhibitor is:
salt thereof, wherein x is in the range of 1 to about 450, y is in the range of 1 to about 30 and n is in the range of 1 to about 100, preferably wherein the ratio of x to y is in the range of about 30: 1 to about 3: 1, preferably wherein the ratio of x to y is about 11 : 1, wherein the subject has
been previously administered at least one prostate cancer treatment, wherein the prostate cancer treatment comprises androgen deprivation therapy (ADT) and/or at least one androgen receptor antagonist, wherein the prostate cancer has become resistant to treatment with the androgen deprivation therapy (ADT) and/or at least one androgen receptor antagonist, wherein administration of the MetAP2 inhibitor results in reduction in size of the prostate cancer.
[0006] In some aspects, the methods further comprise administering to the subject at least one amount of enzalutamide.
[0007] In some aspects, the prostate cancer is castration-resistant prostate cancer.
[0008] In some aspects, the prostate cancer is castration-sensitive prostate cancer.
[0009] In some aspects, the prostate cancer is androgen receptor-inhibition resistant prostate cancer.
[0010] In some aspects, the prostate cancer is castration-resistant and androgen receptor inhibition-resistant prostate cancer.
[0011] In some aspects, the prostate cancer is PTEN-deficient prostate cancer or partially PTEN-deficient prostate cancer.
[0012] In some aspects, the prostate cancer is PTEN-altered prostate cancer or partially PTEN- altered prostate cancer.
[0013] In some aspects, the prostate cancer is aggressive variant prostate cancer (AVPC).
[0014] In some aspects, the prostate cancer is neuroendocrine prostate cancer (NEPC).
[0015] In some aspects, the androgen deprivation therapy comprises performing an orchiectomy, administering at least one luteinizing hormone-releasing hormone (LHRH) agonist, administering at least one LHRH antagonist, administering at least one estrogen, or any combination thereof. In some aspects, the orchiectomy is a subcapsular orchiectomy. In some aspects, the at least one LHRH agonist is selected from leuprolide, goserelin, triptorelin and histrelin. In some aspects, the at least one LHRH antagonist is selected from degarelix and relugolix.
[0016] In some aspects, the at least one androgen receptor antagonist is selected from flutamide, bicalutamide, nilutamide, enzalutamide, apalutamide, and darolutamide, preferably wherein the at least one androgen receptor antagonist is enzalutamide.
[0017] In some aspects, the MetAP2 inhibitor is administered within one day, two days, three days, four days, five days, six days, one week or two weeks of the subject exhibiting PSA nadir. [0018] In some aspects, the MetAP2 inhibitor is administered about two weeks, or about three weeks, or about four weeks, about five weeks, or about six weeks, or about seven weeks, or
about eight weeks after the subject has exhibited PSA nadir, and wherein the PSA level in the subject has increased from PSA nadir.
[0019] In some aspects, the subject has at least one metabolic dysfunction, wherein the metabolic dysfunction is selected from visceral adiposity, dyslipidemia, obesity (BMI >30), elevated leptin levels, depressed adiponectin levels, high leptin-to-adiponectin ratio, elevated fasting insulin levels, elevated fasting insulin levels accompanied by chronic inflammation, insulin resistance, hyperleptinaemia, high fasting glucose, elevated HbAlc, or any combination thereof. In some aspects, the metabolic dysfunction is a prostate cancer treatment-induced metabolic dysfunction.
[0020] In some aspects, the MetAP2 inhibitor is administered to the subject in an amount of: i) about 27 mg/m2; ii) about 36 mg/m2; iii) about 49 mg/m2; or iv) about 65 mg/m2.
[0021] In some aspects, MetAP2 inhibitor is administered: i) once every 7 days (Q7D); ii) once every 14 days (Q14D); or iii) once every 21 days (Q21D).
[0022] In some aspects, the enzalutamide is administered to the subject in an amount of: i) about 40 mg; ii) about 80 mg; iii) about 120 mg; or iv) about 160 mg.
[0023] In some aspects, the enzalutamide is administered daily. In some aspects, the enzalutamide is administered weekly.
[0024] Any of the above aspects, or any other aspect described herein, can be combined with any other aspect.
[0025] Unless otherwise defined, all technical and scientific terms used herein have the same meaning as commonly understood by one of ordinary skill in the art to which this disclosure belongs. In the Specification, the singular forms also include the plural unless the context clearly dictates otherwise; as examples, the terms “a,” “an,” and “the” are understood to be singular or plural and the term “or” is understood to be inclusive. By way of example, “an element” means one or more element. Throughout the specification the word “comprising,” or variations such as “comprises” or “comprising,” will be understood to imply the inclusion of a stated element, integer or step, or group of elements, integers or steps, but not the exclusion of any other element, integer or step, or group of elements, integers or steps. About can be understood as within 10%, 9%, 8%, 7%, 6%, 5%, 4%, 3%, 2%, 1%, 0.5%, 0.1%, 0.05%, or 0.01% of the stated value. Unless otherwise clear from the context, all numerical values provided herein are modified by the term “about.”
[0026] Although methods and materials similar or equivalent to those described herein can be used in the practice or testing of the present disclosure, suitable methods and materials are described below. All publications, patent applications, patents, and other references
mentioned herein are incorporated by reference in their entirety. The references cited herein are not admitted to be prior art to the claimed invention. In the case of conflict, the present Specification, including definitions, will control. In addition, the materials, methods, and examples are illustrative only and are not intended to be limiting. Other features and advantages of the disclosure will be apparent from the following detailed description and claim.
BRIEF DESCRIPTION OF THE DRAWINGS
[0027] The above and further features will be more clearly appreciated from the following detailed description when taken in conjunction with the accompanying drawings.
[0028] FIG. 1 shows the tumor volume in individual mice (left panel) and the average tumor volume across all mice (right panel) in experimental treatment groups described in Example 1.
[0029] FIG. 2 shows the average PSA levels of mice (left panel) and the endpoint tumor mass (right panel) in experimental treatment groups described in Example 1.
[0030] FIG. 3 shows the body weight of individual mice (left panel) and the average body weight across all mice (right panel) in experimental treatment groups described in Example 1. [0031] FIG. 4 shows the liver, kidney, heart and lung weights at the endpoint of the study in experimental treatment groups described in Example 1.
[0032] FIG. 5 shows the liver, kidney, heart and lung weights as a percentage of body weight at the endpoint of the study in experimental treatment groups described in Example 1.
[0033] FIG. 6 is a graph showing the overall survival of the mice in experimental treatment groups described in Example 1.
[0034] FIG. 7 shows necropsy images of tumors excised from mice in the experimental treatment groups described in Example 1.
[0035] FIG. 8 shows immunohistochemistry analysis of CD34 immunoreactivity from select mice in the experimental treatment groups described in Example 1.
[0036] FIG. 9 shows the average tumor volume across all mice in the experimental treatment groups described in Example 2.
[0037] FIG. 10 shows the tumor mass at the conclusion of the study in the experimental treatment groups described in Example 2.
[0038] FIG. 11 shows the average PSA levels across all mice during the course of the study in the experimental treatment groups described in Example 2.
[0039] FIG. 12 shows the liver, kidney, heart and lung weights at the endpoint of the study in experimental treatment groups described in Example 2.
[0040] FIG. 13 shows the liver, kidney, heart and lung weights as a percentage of body weight at the endpoint of the study in experimental treatment groups described in Example 2. [0041] FIG. 14 shows the average body weight across all mice in experimental treatment groups described in Example 2.
[0042] FIG. 15 shows immunohistochemistry analysis of CD34 immunoreactivity from select mice in the experimental treatment groups described in Example 2.
[0043] FIG. 16 shows the tumor volume in individual mice (top panel) and the average tumor volume across all mice (bottom panel) in the experimental treatment groups described in Example 3.
[0044] FIG. 17 shows the endpoint tumor mass (left panel) and average PSA levels of mice (right panel) in the experimental treatment groups described in Example 3.
[0045] FIG. 18 shows the body weight of individual mice (top panel) and the average body weight across all mice (bottom panel) in the experimental treatment groups described in Example 3.
[0046] FIG. 19 shows the liver, kidney, heart and lung weights at the endpoint of the study in experimental treatment groups described in Example 3.
[0047] FIG. 20 shows the liver, kidney, heart and lung weights as a percentage of body weight at the endpoint of the study in experimental treatment groups described in Example 3. [0048] FIG. 21 shows immunohistochemistry analysis of CD34 immunoreactivity from select mice in the experimental treatment groups described in Example 3.
[0049] FIG. 22 the average tumor volume in the experimental treatment groups described in Example 4.
[0050] FIG. 23 the average tumor volume in the experimental treatment groups described in Example 4.
[0051] FIG. 24 shows the endpoint tumor mass in the experimental treatment groups described in Example 4.
[0052] FIG. 25 shows the average PSA levels of mice in the experimental treatment groups described in Example 4.
[0053] FIG. 26 shows the body weight of individual mice (top panel) and the average body weight across all mice (bottom panel) in the experimental treatment groups described in Example 4.
[0054] FIG. 27 shows the liver, kidney, heart and lung weights at the endpoint of the study in experimental treatment groups described in Example 4.
[0055] FIG. 28 shows the liver, kidney, heart and lung weights as a percentage of body weight at the endpoint of the study in experimental treatment groups described in Example 4. [0056] FIG. 29 shows immunohistochemistry analysis of CD34 immunoreactivity from select mice in the experimental treatment groups described in Example 4.
[0057] FIG. 30 shows the average tumor volume in the experimental treatment groups described in Example 5.
[0058] FIG. 31 shows the endpoint tumor mass in the experimental treatment groups described in Example 5.
[0059] FIG. 32 shows immunohistochemistry analysis of CD34 immunoreactivity from select mice in the experimental treatment groups described in Example 5.
[0060] FIG. 33 A is a graph showing average tumor volume across all mice in the two treatment groups described in Example 7.
[0061] FIG. 33B is a graph showing endpoint tumor volume in mice in the two treatment groups described in Example 7.
[0062] FIG. 33C shows immunohistochemistry analysis of CD34 immunoreactivity from select mice in the experimental treatment groups described in Example 7.
[0063] FIG. 34A is a graph showing tumor volume of all mice in the two treatment groups described in Example 8.
[0064] FIG. 34B is a graph showing average tumor volume across all mice in the two treatment groups described in Example 8.
[0065] FIG. 34C is a graph showing tumor weight reduction across all mice in the two treatment groups described in Example 8.
[0066] FIG. 35 shows a chart of the number of differentially expressed human genes for each pairwise comparison of treatment groups described in Examples 1-5 (left panel) and bubble plots of a selection of significantly enriched (adj. p value < 0.05) cellular pathways from the MSigDB (Molecular Signatures Database) for each of the comparisons (right panel).
[0067] FIGs. 36, 37, 38, 39 and 40 show bubble plots of genes of interest including for pairwise comparisons of treatment groups described in Examples 1-5.
[0068] FIG. 41 shows the expression levels of particular hypoxia induced, extracellular matrix-related genes in tumor samples from the experimental treatment groups described in Example 5.
[0069] FIGs. 42A and 42B show the expression levels of particular glycolysis-related genes in tumor samples from the experimental treatment groups described in Example 5.
[0070] FIG. 43 shows the expression levels of particular serine-glycine one-carbon (SOGC) pathway genes in tumor samples from the experimental treatment groups described in Example 5.
[0071] FIG. 44 shows the expression levels of particular cholesterol uptake and synthesis pathway genes in tumor samples from the experimental treatment groups described in Example 5.
[0072] FIG. 45 shows the expression levels of particular fatty acid synthesis pathway genes in tumor samples from the experimental treatment groups described in Example 5.
[0073] FIG. 46 shows the expression levels of particular cell cycle genes in tumor samples from the experimental treatment groups described in Example 5.
[0074] FIG. 47 shows the expression levels of particular hormone/cytokine receptor genes in tumor samples from the experimental treatment groups described in Example 5.
[0075] FIG. 48 shows the expression levels of particular kinase genes in tumor samples from the experimental treatment groups described in Example 5.
[0076] FIG. 49 shows the expression levels of particular transcription factor genes in tumor samples from the experimental treatment groups described in Example 5.
[0077] FIG. 50 shows the expression levels of particular tumor-inhibiting genes in tumor samples from the experimental treatment groups described in Example 5.
[0078] FIGs. 51 A and 5 IB show the expression levels of particular tumor-growth promoting/survival genes in tumor samples from the experimental treatment groups described in Example 5.
[0079] FIG. 52 shows the expression levels of particular nucleotide synthesis genes in tumor samples from the experimental treatment groups described in Example 5.
[0080] FIG. 53 shows the expression levels of particular lipid metabolism genes in tumor samples from the experimental treatment groups described in Example 5.
[0081] FIG. 54 shows the expression levels of particular immune recognition genes in tumor samples from the experimental treatment groups described in Example 5.
[0082] FIG. 55 shows the expression levels of particular immune recognition genes, specifically CD74 ligands and binding partners, in tumor samples from the experimental treatment groups described in Example 5.
[0083] FIG. 56 shows the expression levels of particular genes encoding regulators of MHC II, in tumor samples from the experimental treatment groups described in Example 5.
DETAILED DESCRIPTION
[0084] The present disclosure provides, inter alia, a method of treating prostate cancer comprising administering to a subject in need thereof at least one amount of at least one MetAP2 inhibitor of the present disclosure, or a pharmaceutically acceptable salt thereof, or comprising administering to a subject in need thereof at least one amount of at least one MetAP2 inhibitor of the present disclosure, or a pharmaceutically acceptable salt thereof, in combination with at least one additional therapeutic agent.
[0085] Methods and Combinations of the Present Disclosure
[0086] The present disclosure provides methods of treating prostate cancer in a subject in need thereof, the method comprising administering to the subject in need thereof at least one amount of at least one MetAP2 inhibitor of the present disclosure, or a pharmaceutically acceptable salt thereof.
[0087] The present disclosure provides at least one MetAP2 inhibitor of the present disclosure, or a pharmaceutically acceptable salt thereof, for use in treating prostate cancer in a subject in need thereof.
[0088] The present disclosure provides the use of at least one MetAP2 inhibitor of the present disclosure, or a pharmaceutically acceptable salt thereof, for the manufacture of a medicament for the treatment of prostate cancer in a subject in need thereof.
[0089] The present disclosure provides a method of preventing prostate cancer in a subject in need thereof, the method comprising administering to the subject in need thereof at least one amount of at least one MetAP2 inhibitor of the present disclosure, or a pharmaceutically acceptable salt thereof.
[0090] The present disclosure provides at least one MetAP2 inhibitor of the present disclosure, or a pharmaceutically acceptable salt thereof, for use in preventing prostate cancer in a subject in need thereof.
[0091] The present disclosure provides the use of at least one MetAP2 inhibitor of the present disclosure, or a pharmaceutically acceptable salt thereof, for the manufacture of a medicament for the prevention of prostate cancer in a subject in need thereof.
[0092] The present disclosure provides a method of preventing prostate cancer growth or recurrence in a subject in need thereof, the method comprising administering to the subject in need thereof at least one amount of at least one MetAP2 inhibitor of the present disclosure, or a pharmaceutically acceptable salt thereof.
[0093] The present disclosure provides at least one MetAP2 inhibitor of the present disclosure, or a pharmaceutically acceptable salt thereof, for use in preventing prostate cancer growth or recurrence in a subject in need thereof.
[0094] The present disclosure provides the use of at least one MetAP2 inhibitor of the present disclosure, or a pharmaceutically acceptable salt thereof, for the manufacture of a medicament for the prevention of prostate cancer growth or recurrence in a subject in need thereof.
[0095] The present disclosure provides a combination therapy comprising at least one amount of at least one MetAP2 inhibitor of the present disclosure, or a pharmaceutically acceptable salt thereof, and at least one amount of enzalutamide, or a pharmaceutically acceptable salt thereof.
[0096] The present disclosure provides a method of treating prostate cancer in a subject in need thereof, the method comprising administering to the subject in need thereof at least one amount of the preceding combination therapy.
[0097] The present disclosure provides a method of preventing prostate cancer in a subject in need thereof, the method comprising administering to the subject in need thereof at least one amount of the preceding combination therapy.
[0098] The present disclosure provides a method of preventing prostate cancer growth or recurrence in a subject in need thereof, the method comprising administering to the subject in need thereof at least one amount of the preceding combination therapy.
[0099] The present disclosure provides a pharmaceutical composition comprising at least one amount of at least one MetAP2 inhibitor of the present disclosure, or a pharmaceutically acceptable salt thereof, and at least one amount of enzalutamide, or a pharmaceutically acceptable salt thereof.
[00100] The present disclosure provides a method of treating prostate cancer in a subject in need thereof, the method comprising administering to the subject in need thereof at least one amount of the preceding pharmaceutical compositions.
[00101] The present disclosure provides a method of preventing prostate cancer in a subject in need thereof, the method comprising administering to the subject in need thereof at least one amount of the preceding pharmaceutical compositions.
[00102] The present disclosure provides a method of preventing prostate cancer growth or recurrence in a subject in need thereof, the method comprising administering to the subject in need thereof at least one amount of the preceding pharmaceutical compositions.
[00103] The present disclosure provides a kit comprising at least one amount of at least one MetAP2 inhibitor of the present disclosure, or a pharmaceutically acceptable salt thereof, and at least one amount of enzalutamide, or a pharmaceutically acceptable salt thereof.
[00104] The present disclosure provides a method of treating prostate cancer in a subject in need thereof, the method comprising administering to the subject in need thereof at least one amount of the preceding kit.
[00105] The present disclosure provides a method of preventing prostate cancer in a subject in need thereof, the method comprising administering to the subject in need thereof at least one amount of the preceding kit.
[00106] The present disclosure provides a method of preventing prostate cancer growth or recurrence in a subject in need thereof, the method comprising administering to the subject in need thereof at least one amount of the preceding kit.
[00107] The present disclosure provides a method of treating prostate cancer in a subject in need thereof, the method comprising administering to the subject at least one amount of at least one MetAP2 inhibitor of the present disclosure, or a pharmaceutically acceptable salt thereof, and at least one amount of enzalutamide, or a pharmaceutically acceptable salt thereof.
[00108] The present disclosure provides a method of preventing prostate cancer in a subject in need thereof, the method comprising administering to the subject at least one amount of at least one MetAP2 inhibitor of the present disclosure, or a pharmaceutically acceptable salt thereof, and at least one amount of enzalutamide, or a pharmaceutically acceptable salt thereof.
[00109] The present disclosure provides a method of preventing prostate cancer growth or recurrence in a subject in need thereof, the method comprising administering to the subject at least one amount of at least one MetAP2 inhibitor of the present disclosure, or a pharmaceutically acceptable salt thereof, and at least one amount of enzalutamide, or a pharmaceutically acceptable salt thereof.
[00110] The present disclosure provides a use of at least one MetAP2 inhibitor of the present disclosure, or a pharmaceutically acceptable salt thereof, in combination with enzalutamide, or a pharmaceutically acceptable salt thereof, in the manufacture of a medicament for the treatment of prostate cancer.
[00111] The present disclosure provides a use of at least one MetAP2 inhibitor of the present disclosure, or a pharmaceutically acceptable salt thereof, in combination with enzalutamide,
or a pharmaceutically acceptable salt thereof, in the manufacture of a medicament for the prevention of prostate cancer.
[00112] The present disclosure provides a use of at least one MetAP2 inhibitor of the present disclosure, or a pharmaceutically acceptable salt thereof, in combination with enzalutamide, or a pharmaceutically acceptable salt thereof, in the manufacture of a medicament for the prevention of prostate cancer growth or recurrence.
[00113] The present disclosure provides a use of enzalutamide, or a pharmaceutically acceptable salt thereof, in combination with at least one MetAP2 inhibitor of the present disclosure, or a pharmaceutically acceptable salt thereof, in the manufacture of a medicament for the treatment of prostate cancer.
[00114] The present disclosure provides a use of enzalutamide, or a pharmaceutically acceptable salt thereof, in combination with at least one MetAP2 inhibitor of the present disclosure, or a pharmaceutically acceptable salt thereof, in the manufacture of a medicament for the prevention of prostate cancer.
[00115] The present disclosure provides a use of enzalutamide, or a pharmaceutically acceptable salt thereof, in combination with at least one MetAP2 inhibitor of the present disclosure, or a pharmaceutically acceptable salt thereof, in the manufacture of a medicament for the prevention of prostate cancer growth or recurrence.
[00116] The present disclosure provides a combination of at least one MetAP2 inhibitor of the present disclosure, or a pharmaceutically acceptable salt thereof, and enzalutamide, or a pharmaceutically acceptable salt thereof, for use in the manufacture of a medicament for the treatment of prostate cancer.
[00117] The present disclosure provides a combination of at least one MetAP2 inhibitor of the present disclosure, or a pharmaceutically acceptable salt thereof, and enzalutamide, or a pharmaceutically acceptable salt thereof, for use in the manufacture of a medicament for the prevention of prostate cancer.
[00118] The present disclosure provides a combination of at least one MetAP2 inhibitor of the present disclosure, or a pharmaceutically acceptable salt thereof, and enzalutamide, or a pharmaceutically acceptable salt thereof, for use in the manufacture of a medicament for the prevention of prostate cancer growth or recurrence.
[00119] The present disclosure provides at least one MetAP2 inhibitor of the present disclosure, or a pharmaceutically acceptable salt thereof, for use in combination with enzalutamide, or a pharmaceutically acceptable salt thereof, in treating prostate cancer.
[00120] The present disclosure provides at least one MetAP2 inhibitor of the present disclosure, or a pharmaceutically acceptable salt thereof, for use in combination with enzalutamide, or a pharmaceutically acceptable salt thereof, in preventing prostate cancer. [00121] The present disclosure provides at least one MetAP2 inhibitor of the present disclosure, or a pharmaceutically acceptable salt thereof, for use in combination with enzalutamide, or a pharmaceutically acceptable salt thereof, in preventing prostate cancer growth or recurrence.
[00122] The present disclosure provides enzalutamide, or a pharmaceutically acceptable salt thereof, for use in combination with at least one MetAP2 inhibitor of the present disclosure, or a pharmaceutically acceptable salt thereof, in treating prostate cancer.
[00123] The present disclosure provides enzalutamide, or a pharmaceutically acceptable salt thereof, for use in combination with at least one MetAP2 inhibitor of the present disclosure, or a pharmaceutically acceptable salt thereof, in preventing prostate cancer.
[00124] The present disclosure provides enzalutamide, or a pharmaceutically acceptable salt thereof, for use in combination with at least one MetAP2 inhibitor of the present disclosure, or a pharmaceutically acceptable salt thereof, in preventing prostate cancer growth or recurrence.
[00125] The present disclosure provides a combination of at least one MetAP2 inhibitor of the present disclosure, or a pharmaceutically acceptable salt thereof, and enzalutamide, or a pharmaceutically acceptable salt thereof, for use in treating prostate cancer.
[00126] The present disclosure provides a combination of at least one MetAP2 inhibitor of the present disclosure, or a pharmaceutically acceptable salt thereof, and enzalutamide, or a pharmaceutically acceptable salt thereof, for use in preventing prostate cancer.
[00127] The present disclosure provides a combination of at least one MetAP2 inhibitor of the present disclosure, or a pharmaceutically acceptable salt thereof, and enzalutamide, or a pharmaceutically acceptable salt thereof, for use in preventing prostate cancer growth or recurrence.
[00128] The present disclosure provides a combination comprising at least one MetAP2 inhibitor of the present disclosure, or a pharmaceutically acceptable salt thereof, for use in treating prostate cancer, wherein the combination further comprises enzalutamide, or a pharmaceutically acceptable salt thereof.
[00129] The present disclosure provides a combination comprising enzalutamide, or a pharmaceutically acceptable salt thereof, for use in treating prostate cancer, wherein the
combination further comprises at least one MetAP2 inhibitor of the present disclosure, or a pharmaceutically acceptable salt thereof.
[00130] The present disclosure provides a combination comprising at least one MetAP2 inhibitor of the present disclosure, or a pharmaceutically acceptable salt thereof, for use in preventing prostate cancer, wherein the combination further comprises enzalutamide, or a pharmaceutically acceptable salt thereof.
[00131] The present disclosure provides a combination comprising at least one MetAP2 inhibitor of the present disclosure, or a pharmaceutically acceptable salt thereof, for use in preventing prostate cancer growth or recurrence, wherein the combination further comprises enzalutamide, or a pharmaceutically acceptable salt thereof.
[00132] The present disclosure provides a combination comprising enzalutamide, or a pharmaceutically acceptable salt thereof, for use in preventing prostate cancer, wherein the combination further comprises at least one MetAP2 inhibitor of the present disclosure, or a pharmaceutically acceptable salt thereof.
[00133] The present disclosure provides a combination comprising enzalutamide, or a pharmaceutically acceptable salt thereof, for use in preventing prostate cancer growth or recurrence, wherein the combination further comprises at least one MetAP2 inhibitor of the present disclosure, or a pharmaceutically acceptable salt thereof.
[00134] The present disclosure provides a MetAP2 inhibitor, or a pharmaceutically acceptable salt thereof, for use in a method of treating prostate cancer, wherein the method further comprises administration of enzalutamide, or a pharmaceutically acceptable salt thereof [00135] The present disclosure provides enzalutamide, or a pharmaceutically acceptable salt thereof, for use in a method of treating prostate cancer, wherein the method further comprises administration of at least one MetAP2 inhibitor, or a pharmaceutically acceptable salt thereof.
[00136] The present disclosure provides a MetAP2 inhibitor, or a pharmaceutically acceptable salt thereof, for use in a method of preventing prostate cancer, wherein the method further comprises administration of enzalutamide, or a pharmaceutically acceptable salt thereof. [00137] The present disclosure provides enzalutamide, or a pharmaceutically acceptable salt thereof, for use in a method of preventing prostate cancer, wherein the method further comprises administration of at least one MetAP2 inhibitor, or a pharmaceutically acceptable salt thereof.
[00138] The present disclosure provides a MetAP2 inhibitor, or a pharmaceutically acceptable salt thereof, for use in a method of preventing prostate cancer growth or recurrence, wherein the method further comprises administration of enzalutamide, or a pharmaceutically acceptable salt thereof.
[00139] The present disclosure provides enzalutamide, or a pharmaceutically acceptable salt thereof, for use in a method of preventing prostate cancer growth or recurrence, wherein the method further comprises administration of at least one MetAP2 inhibitor, or a pharmaceutically acceptable salt thereof.
[00140] In some aspects, a MetAP2 inhibitor, or pharmaceutically acceptable salt thereof, and enzalutamide, or pharmaceutically acceptable salt thereof, can be administered by the same administration route.
[00141] In some aspects, a MetAP2 inhibitor, or pharmaceutically acceptable salt thereof, and enzalutamide, or pharmaceutically acceptable salt thereof, can be administered by different administration routes.
[00142] In some aspects, a MetAP2 inhibitor, or pharmaceutically acceptable salt thereof, and enzalutamide, or pharmaceutically acceptable salt thereof, can be administered concurrently. [00143] In some aspects, a MetAP2 inhibitor, or pharmaceutically acceptable salt thereof, and enzalutamide, or pharmaceutically acceptable salt thereof, can be administered in temporal proximity.
[00144] In some aspects, a MetAP2 inhibitor, or pharmaceutically acceptable salt thereof, and enzalutamide, or pharmaceutically acceptable salt thereof, can be administered in any order.
[00145] In some aspects of the methods and uses presented herein, the administration of a MetAP2 inhibitor and/or the administration of a MetAP2 inhibitor in combination with enzalutamide, results in a decrease in angiogenesis in at least one tumor in the subject. In some aspects, the decrease is at least a 10%, at least a 20%, at least a 30%, at least a 40%, at least a 50%, at least a 60%, at least a 70%, at least an 80%, at least a 90%, at least a 95%, or at least a 99% decrease in angiogenesis.
[00146] In some aspects of the methods and uses presented herein, the administration of a MetAP2 inhibitor and/or the administration of a MetAP2 inhibitor in combination with enzalutamide, results in a decrease in the expression level of at least one gene selected from P4HA1, LOX, GLUT1/SLC2A1, HK2, PDK1FKFB3, FKFB4, PKM, ENO1, LDHA, GLS, PHGDH, SHMT2, TYMS, PSPH, LDL receptor, SQLE, HMGCR, ACACA, ACLY, SCD, CCNB1, CXCR4, FZD8, FZD3, IGFlr, MAP2K6, MAPK13, AURKA, AURKB, EZH2, F0XM1, MYB, SREBF1, MYBL2, BIRC5, ANTRX1, DPYLS3, HMMR, BAG1, Ki67,
CCNB1, PCLAF, TK1, RRM2, TK1, RRM1, RRM2, PLA2G2A, MIF, CXCR4 and CD44. In some aspects, the decrease is at least a 10%, at least a 20%, at least a 30%, at least a 40%, at least a 50%, at least a 60%, at least a 70%, at least an 80%, at least a 90%, at least a 95%, or at least a 99% decrease in expression.
[00147] In some aspects of the methods and uses presented herein, the administration of a MetAP2 inhibitor and/or the administration of a MetAP2 inhibitor in combination with enzalutamide, results in an increase in the expression level of at least one gene selected from CDKN2B, PIK3IP1, SH3BGRL2, CD 177, HLA-DRA, HLA-E, HLA-DMA, HLA-DMB, CD74, CIITA, IFI30. In some aspects, the increase is at least a 10%, at least a 20%, at least a 30%, at least a 40%, at least a 50%, at least a 60%, at least a 70%, at least an 80%, at least a 90%, at least a 95%, or at least a 99% increase in expression.
[00148] MetAP2 inhibitors
[00149] Any of the MetAP2 inhibitors described herein can be used in the kits, pharmaceutical compositions, uses and methods described herein.
[00150] In some aspects, a MetAP2 inhibitor can be Compound 1, or a pharmaceutically acceptable salt, analog, derivative, salt or ester thereof, wherein Compound 1 is represented by:
about 450, y is in the range of 1 to about 30 and n is in the range of 1 to about 100. In some aspects, n is in the range of about 1 to about 90; about 1 to about 80; about 1 to about 70; about 1 to about 60; about 1 to about 55; or about 1 to about 50. In some aspects, the ratio of x to y can be in the range of about 30: 1 to about 3: 1.
[00151] In some aspects, a MetAP2 inhibitor can be Compound 2, or a pharmaceutically acceptable salt, analog, derivative, salt or ester thereof, wherein Compound 2 is represented by:
is in the range of 1 to about 450, y is in the range of 1 to about 30 and n is in the range of 1 to about 100. In some aspects, n is in the range of about 1 to about 90; about 1 to about 80; about 1 to about 70; about 1 to about 60; about 1 to about 55; or about 1 to about 50. In some aspects, the ratio of x to y can be in the range of about 30:1 to about 3: 1.
[00152] In some aspects, a MetAP2 inhibitor can be Compound 3, or a pharmaceutically acceptable salt, analog, derivative, salt or ester thereof, wherein Compound 3 is represented
about 100. In some aspects, n is in the range of about 1 to about 90; about 1 to about 80; about 1 to about 70; about 1 to about 60; about 1 to about 55; or about 1 to about 50. In some aspects, the ratio of x to y can be in the range of about 30:1 to about 3: 1.
[00153] In some aspects, a MetAP2 inhibitor can be Compound 4, or a pharmaceutically acceptable salt, analog, derivative, salt or ester thereof, wherein Compound 4 is represented by:
(Compound 4) , wherein x is in the range of 1 to about 450, y is in the range of 1 to about 30 and n is in the range of 1 to about 100. In some aspects, n is in the range of about 1 to about 90; about 1 to about 80; about 1 to about 70; about 1 to about 60; about 1 to about 55; or about 1 to about 50. In some aspects, the ratio of x to y can be in the range of about 30:1 to about 3: 1.
[00155] In some aspects, the MetAP2 inhibitor can be:
pharmaceutically acceptable salt, analog, derivative, salt or ester thereof.
[00156] In some aspects, the MetAP2 inhibitor can be:
salt, analog, derivative, salt or ester thereof.
[00158] In some aspects, the MetAP2 inhibitor can be:
pharmaceutically acceptable salt, analog, derivative, salt or ester thereof.
[00159] In some aspects, the MetAP2 inhibitor can be selected from cis-(3aRS,9bRS)-7-
(benzenesulfonylamino)-l,3a,4,9b-tetrahydro-2H-furo[2,3-c]chromene-6-carboxylic acid; cis-(3 aRS,9bRS)-7-[2-(3-diethylaminopropyl)-4-fluorobenzenesulfonyl-amino]-l,3a,4,9b- tetrahydro-2H-furo[2,3-c]chromene-6-carboxylic acid; cis-(3aRS,9bRS)-7-[2-(3-{pyrrolidin- l-yl}propyl)-4-fluorobenzenesulfonylamino]-l,3a,4,9b-tetrahydro-2H-furo[2,3-c]chromene-
6-carboxylic acid; cis-(3aRS,9bRS)-7-[2-((Z)-3-diethylaminoprop-l-enyl)-4- fluorobenzenesulfonylamino]-l,3a,4,9b-tetrahydro-2H-furo[2,3-c]chromene-6-carboxylic
acid; cis-(3aR,9bR)-7-[2-((Z)-3-diethylaminoprop-l-enyl)-4-fluoro-benzenesulfonylamino]- l,3a,4,9b-tetrahydro-2H-furo[2,3-c]chromene-6-carboxylic acid; cis-(3aS,9bS)-7-[2-((Z)-3- diethylaminoprop-l-enyl)-4-fluorobenzenesulfonylamino]-l,3a,4,9b-tetrahydro-2H-furo[2,3- c]chromene-6-carboxylic acid; 7-[2-((Z)-3-diethylaminoprop-l-enyl)-4- fluorobenzenesulfonylamino]-l,2-dihydrofuro[2,3-c]quinoline-6-carboxylic acid formate salt; 7-(benzenesulfonylamino))-l,2-dihydrofuro[2,3-c]quinoline-6-carboxylic acid formate salt; cis-(3aRS,9bRS)-7-[2-((Z)-3-diethylaminoprop-l-enyl)-4-fluorobenzenesulfonylamino]- l,2,3a,4,5,9b-hexahydrofuro[2,3-c]quinoline-6-carboxylic acid; (1 aRS,7bSR)-5-[2-((Z)-3- di ethylaminoprop- 1 -enyl)-4-fluorobenzenesulfonylamino]- 1 , 1 a, 2,7b- tetrahydrocyclopropa[c]chromene-4-carboxylic acid; (laR,7bS)-5-[2-((Z)-3- di ethylaminoprop- 1 -enyl)-4-fluorobenzenesulfonylamino]- 1 , 1 a, 2,7b- tetrahydrocyclopropa[c]chromene-4-carboxylic acid; (1 aS,7bR)-5-[2-((Z)-3- di ethylaminoprop- 1 -enyl)-4-fluorobenzenesulfonylamino]- 1 , 1 a, 2,7b- tetrahydrocyclopropa[c]chromene-4-carboxylic acid; (laRS,7bSR)-5-[2-((Z)-3- diethylaminoprop-l-enyl)-4-fluorobenzenesulfonylamino]-7b-methyl-l, 1 a, 2,7b- tetrahydrocyclopropa[c]chromene-4-carboxylic acid; (laRS,7bSR)-5-[2-((E)-3- di ethylaminoprop- l-enyl)-4-fhiorobenzenesulfonylamino]-7b-methyl- 1,1 a, 2,7b- tetrahydrocyclopropa[c]chromene-4-carboxylic acid; cis-(3aRS,9bRS)-7-[2-(4- dimethylamino-butylamino)-benzenesulfonylamino]-l,3a,4,9b-tetrahydro-2H-furo[2,3- c]chromene-6-carboxylic acid; (1 aR,7bS)-5-[2-(3-diethylaminopropyl)-4- fluorobenzenesulfonyl-amino]-l,la,2,7b-tetrahydrocyclopropa[c]chromene-4-carboxylic acid; (laRS,7bSR)-5-[2-((Z)-3-diethylaminoprop-l-enyl)-4-fluorobenzene-sulfonylamino]- 1 , 1 -difluoro- 1 , 1 a,2,7b-tetrahydrocyclopropa[c]chromene-4-carboxylic acid; ( 1 aR,7b S)-5-[2- ((Z)-3-diethylaminoprop-l-enyl)-4-fluorobenzene-sulfonylamino]-l,l-difluoro-l,la,2,7b- tetrahydrocyclopropa[c]chromene-4-carboxylic acid; (1 aS,7bR)-5-[2-((Z)-3- di ethylaminoprop- 1 -enyl)-4-fluorobenzene-sulfonylamino]- 1 , 1 -difluoro- 1 , 1 a, 2,7b- tetrahydrocyclopropa[c]chromene-4-carboxylic acid; (laRS,7bSR)-5-[2((Z)-3- ethylaminoprop- 1 -enyl)-4-fluoro-benzenesulfonylamino]- 1 , 1 a,2,7b-tetrahydrocyclopropa- [c]chromene-4-carboxylic acid; (laR,7bS)-5-[2((Z)-3-ethylaminoprop-l-enyl)-4- fluorobenzenesulfonylamino]-l,la,2,7b-tetrahydrocyclopropa[c]chromene-4-carboxylic acid; ( 1 aS,7bR)-5-[2((Z)-3 -ethylaminoprop- 1 -enyl)-4-fluorobenzene-sulfonylamino]- 1 , 1 a, 2,7b- tetrahydro-cyclopropa[c]chromene-4-carboxylic acid; (laRS,7bSR)-5-{2[(Z)-3-(pyrrolidin-l- yl)prop- 1 -enyl]-4-fhiorobenzenesulfonylamino}-l , 1 a,2,7b-tetrahydro- cyclopropa[c]chromene-4-carboxylic acid; (laR,7bS)-5-{2[(Z)-3-(pyrrolidin-l-yl)prop-l-
enyl]-4-fluorobenzenesulfonyl-amino}-l,la,2,7b-tetrahydro-cyclopropa[c]chromene-4- carboxylic acid; (1 aS,7bR)-5-{2 [(Z)-3-(pyrrolidin-l-yl)prop-l-enyl]-4- fluorobenzenesulfonylamino}-l,la,2,7b-tetrahydro-cyclopropa[c]chromene-4-carboxylic acid; (laRS,7bSR)-5-[2-(3-dimethylaminopropylamino)-benzenesulfonylamino]-l,la,2,7b- tetrahydrocyclopropa[c]chromene-4-carboxylic acid; (1 aR,7bS)-5-[2-(3- dimethylaminopropylamino)benzene-sulfonylamino]- 1 , 1 a, 2,7b- tetrahydrocyclopropa[c]chromene-4-carboxylic acid; (laS,7bR)-5-[2-(3- dimethylaminopropyl-amino)benzenesulfonylamino]- 1 , 1 a, 2,7b- tetrahydrocyclopropa[c]chromene-4-carboxylic acid; (laRS,7bSR)-5-[2-(4- dimethylaminobutylamino)benzenesulfonylamino]-l,la,2,7b- tetrahydrocyclopropa[c]chromene-4-carboxylic acid; (laR,7bS)-5-[2-(4-dimethylamino- butylamino)benzenesulfonylamino]-l,la,2,7b-tetrahydrocyclopropa[c]chromene-4- carboxylic acid; (laS,7bR)-5-[2-(4-dimethylaminobutylamino]-l,la,2,7b- tetrahydrocyclopropa[c]chromene-4-carboxylic acid; (1 aRS,7bSR)-5-[2-(5-dimethylamino- pentylamino)benzene-sulfonylamino]-l,la,2,7b-tetrahydrocyclopropa[c]chromene-4- carboxylic acid; (laRS,7bSR)-5-{2[(Z)-3-(propan-2-yl)aminoprop-l-enyl]-4- fluorobenzenesulfonyl-amino}-l,la,2,7b-tetrahydrocyclopropa[c]chromene-4-carboxylic acid; (1 aRS,7bSR)-5-{2[(Z)-3-((S)-3-hydroxypyrrolidin-l-yl)aminoprop-l-enyl]-4- fluorobenzenesulfonylamino}-l,la,2,7b-tetrahydrocyclopropa[c]chromene-4-carboxylic acid; (1 aRS,7bSR)-5-{2[(Z)-3-((R)-3-hydroxypyrrolidin-l-yl)aminoprop-l-enyl]-4- fluorobenzene-sulfonylamino}-l,la,2,7b-tetrahydro-cyclopropa[c]chromene-4-carboxylic acid; (laRS,7bSR)-5-[2((Z)-4-diethylaminobut-l-enyl)-4-fluorobenzenesulfonyl-amino]- 1, la,2,7b-tetrahydrocyclopropa[c]chromene-4-carboxylic acid; (laR,7bS)-5-[2((Z)-4- diethylaminobut- 1 -enyl)-4-fluorobenzenesulfonyl-amino]- 1 , 1 a, 2, 7b- tetrahydrocyclopropa[c]chromene-4-carboxylic acid; (1 aS,7bR)-5-[2((Z)-4-diethylaminobut- l-enyl)-4-fluorobenzenesulfonyl-amino]-l,la,2,7b-tetrahydro-cyclopropa[c]chromene-4- carboxylic acid; (1 aRS,7bSR)-5-{2-[2-(4-ethylpiperazin-l-yl)-ethyl]-4- fluorobenzenesulfonylamino}-l,la,2,7b-tetrahydrocyclopropa[c]chromene-4-carboxylic acid; (laRS,7bSR)-5-{2[(Z)-3-(azetidin-l-yl)prop-l-enyl]-4-fluorobenzene-sulfonylamino}- l,la,2,7b-tetrahydro-cyclopropa[c]chromene-4-carboxylic acid; (laRS,7bSR)-5-{2[(Z)-3-(3- hydroxy-azetidin- 1 -yl)prop- 1 -enyl]-4-fluorobenzene-sulfonylamino} - 1 , 1 a, 2,7b- tetrahydrocyclopropa-[c]chromene-4-carboxylic acid; (laRS,7bSR)-5-{2[(Z)-3-(azetidin-l- yl)propyl]-4-fluorobenzenesulfonylamino}-l,la,2,7b-tetrahydrocyclopropa[c]chromene-4- carboxylic acid; (1 aRS,7bSR)-5-[2((Z)-4-diethylaminobutyl)-4-
fluorobenzenesulfonylamino]-l,la,2,7b-tetrahydrocyclopropa[c]chromene-4-carboxylic acid; (1 aRS,7bSR)-5-{2-[N-(4-dimethylaminobutyl)-N-methylamino]-benzenesulfonyl-amino}- l,la,2,7b-tetrahydrocyclopropa-[c]chromene-4-carboxylic acid; (laRS,7bSR)-5-{2-[((S)-l- ethylpyrrolidin-3-ylcarbamoyl)-methyl]-4-fluoro-benzenesulfonyl-amino}-l,la,2,7b- tetrahydrocyclopropa-[c]chromene-4-carboxylic acid; (laRS,7bSR)-5-[2-(l-ethylazetidin-3- yl)-4-fluorobenzenesulfonylamino]-l,la,2,7b-tetrahydro-cyclopropa[c]chromene-4- carboxylic acid; (1 aRS,7bSR)-5-{2-[((R)-l-ethylpyrrolidin-3-ylcarbamoyl)methyl]-4- fluorobenzenesulfonyl-amino}-l,la,2,7b-tetrahydro-cyclopropa[c]chromene-4-carboxylic acid; (1 aRS,7bSR)-5-{2-[2-(pyrrolidin-l-yl)-ethyl]-4-fluorobenzenesulfonylamino}- 1, la,2,7b-tetrahydrocyclopropa[c]chromene-4-carboxylic acid; (laRS,7bSR)-5-[2-((R)-l- ethylpyrrolidin-3-ylmethyl)-4-fluorobenzenesulfonyl-amino]-l,la,2,7b-tetrahydro- cyclopropa[c]chromene-4-carboxylic acid; (laS,7bR)-5-[2-((R)-l-ethylpyrrolidin-3- ylmethyl)-4-fluorobenzenesulfonyl-amino]-l,la,2,7b-tetrahydro-cyclopropa[c]chromene-4- carboxylic acid; (1 aR,7bS)-5-[2-((R)-l-ethylpyrrolidin-3-ylmethyl)-4- fluorobenzenesulfonyl-amino]-l,la,2,7b-tetrahydro-cyclopropa[c]chromene-4-carboxylic acid; (laRS,7bSR)-5-{2-[((S)-l-ethylpyrrolidin-2-yl)carbonyl-aminomethyl]-4- fluorobenzene-sulfonylamino}-l,la,2,7b-tetrahydrocyclopropa[c]chromene-4-carboxylic acid; (1 aRS,7bSR)-5-[2-(4-dimethylaminobutyrylamino)-4-fluorobenzenesulfonyl-amino]- l,la,2,7b-tetrahydrocyclopropa-[c]chromene-4-carboxylic acid; (laRS,7bSR)-5-[2-((S)-l- ethyl-pyrrolidin-3-ylmethyl)-4-fluorobenzenesulfonyl-amino]-l,la,2,7b- tetrahydrocyclopropa[c]chromene-4-carboxylic acid; (laRS,7bSR)-5-[2-(3- dimethylaminopropylcarbamoyl)benzene-sulfonylamino]- 1 , 1 a, 2,7b- tetrahydrocyclopropa[c]chromene-4-carboxylic acid; (1 aRS,7bSR)-5-(2-{[N-((S)-l-ethyl- pyrrolidin-3-yl)-N-methylcarbamoyl]methyl}-4-fluoro-benzenesulfonylamino)-l,la,2,7b- tetrahydrocyclopropa-[c]chromene-4-carboxylic acid; (1 aRS,7bSR)-5-(2-{[N-((R)-l-ethyl- pyrrolidin-3-yl)-N-methylcarbamoyl]methyl}-4-fluoro-benzenesulfonylamino)-l,la,2,7b- tetrahydrocyclopropa-[c]chromene-4-carboxylic acid; (1 aRS,7bSR)-5-{2-[2-((S)-l- ethylpyrrolidin-2-yl)ethylamino]-benzenesulfonyl-amino}-l,la,2,7b-tetrahydrocyclopropa- [c]chromene-4-carboxylic acid; (laRS,7bSR)-5-{2-[2-((R)-l-ethylpyrrolidin-2- yl)ethylamino]-benzenesulfonyl-amino}-l,la,2,7b-tetrahydrocyclopropa-[c]chromene-4- carboxylic acid; (laRS,7bSR)-5-[2-(3-N,N,-diethylaminopropylamino)benzene- sulfonylamino]-l, la,2,7b-tetrahydrocyclopropa[c]chromene-4-carboxylic acid; (laRS,7bSR)- 5-(2-{[((R)-l-ethylpyrrolidine-2-yl)carbonyl-amino]methyl}-4- fluorobenzenesulfonylamino)-l,la,2,7b-tetrahydrocyclopropa[c]chromene-4-carboxylic acid;
(laRS,7bSR)-5-{2-[(l-ethylazetidin-3-ylmethyl)amino]benzene-sulfonylamino}-l,la,2,7b- tetrahydrocyclopropa[c]chromene-4-carboxylic acid; (1 aS,7bR)-5-[2-((Z)-3- di ethylaminoprop- 1 -enyl)benzenesulfonylamino]- 1 , 1 a, 2,7b- tetrahydrocyclopropa[c]chromene-4-carboxylic acid; (1 aR,7bS)-5-[2-((Z)-3- di ethylaminoprop- 1 -enyl)benzenesulfonylamino]- 1 , 1 a, 2,7b- tetrahydrocyclopropa[c]chromene-4-carboxylic acid; (1 aRS,7bSR)-5-(2-{N-[((R)-l- ethylpyrrolidine-2-yl)carbonyl]-N-methyl-aminomethyl}-4-fluorobenzenesulfonylamino)- l,la,2,7b-tetrahydrocyclopropa[c]chromene-4-carboxylic acid; (1 aRS,7bSR)-5-(2-{N-[((S)- l-ethylpyrrolidine-2-yl)carbonyl]-N-methylamino-methyl}-4-fluorobenzenesulfonylamino)- l,la,2,7b-tetrahydrocyclopropa[c]chromene-4-carboxylic acid; (1 aRS,7bSR)-5-[2-(4- dimethylaminobutylamino)-4-fluorobenzenesulfonyl-amino]-l,la,2,7b- tetrahydrocyclopropa[c]chromene-4-carboxylic acid; (laRS,7bSR)-5-{2-[((R)-l- ethylpyrrolidin-3-ylmethyl)amino]-benzenesulfonylamino}-l,la,2,7b-tetrahydrocyclopropa- [c]chromene-4-carboxylic acid; (laRS,7bSR)-5-{2-[((S)-l-ethylpyrrolidin-3- ylmethyl)amino]-benzenesulfonylamino}-l,la,2,7b-tetrahydrocyclopropa-[c]chromene-4- carboxylic acid; (laRS,7bSR)-5-[2-(4-ethyl-2-oxopiperazin-l-ylmethyl)-4-fluorobenzene- sulfonylamino]-l, la,2,7b-tetrahydrocyclopropa[c]chromene-4-carboxylic acid; (laRS,7bSR)- 5-[2-(l-ethylpiperidin-4-ylmethyl)-4-fluoro-benzenesulfonylamino]-l,la,2,7b- tetrahydrocyclopropa-[c]chromene-4-carboxylic acid; (1 aRS,7bSR)-5-{2-[2-(l- ethylazetidin-3-yl)ethyl]-4-fluoro-benzenesulfonyl-amino}-l,la,2,7b- tetrahydrocyclopropa[c]chromene-4-carboxylic acid; (1 aRS,7bSR)-5-{2-[((S)-l- azabicyclo[2.2.2]oct-3-yl)amino]benzenesulfonyl-amino}-l,la,2,7b- tetrahydrocyclopropa[c]chromene-4-carboxylic acid; (1 aRS,7bSR)-5-{2-[((R)-l-azabicyclo- [2.2.2]oct-3-yl)amino]benzenesulfonyl-amino}-l,la,2,7b-tetrahydrocyclopropa[c]chromene- 4-carboxylic acid; (1 aRS,7bSR)-5-(2-{[((S)-l-ethylpyrrolidine-3-carbonyl)amino]methyl}- 4-fluoro-benzenesulfonylamino)-l,la,2,7b-tetrahydrocyclopropa[c]chromene-4-carboxylic acid; (1 aRS,7bSR)-5-{2-[2-((R)-l-ethylpyrrolidin-3-ylamino)ethyl]-4-fluoro- benzenesulfonylamino}-l, la,2,7b-tetrahydrocyclopropa-[c]chromene-4-carboxylic acid; (1 aRS,7bSR)-5-{2-[((R)-l-ethylpyrrolidin-3-yl)amino]-benzenesulfonylamino}-l,la,2,7b- tetrahydrocyclopropa-[c]chromene-4-carboxylic acid; (laRS,7bSR)-5-{2-[((S)-l- ethylpyrrolidin-3-yl)amino]-benzenesulfonylamino}-l,la,2,7b-tetrahydrocyclopropa- [c]chromene-4-carboxylic acid; (1 aRS,7bSR)-5-(2-{[((R)-l-ethylpyrrolidine-3- carbonyl)amino]-methyl)}-4-fluoro-benzenesulfonylamino)-l,la,2,7b-tetrahydro- cyclopropa[c]chromene-4-carboxylic acid; (laRS,7bSR)-5-[2-((Z)-3-diethylamino-2-
methylprop- 1 -enyl)-4-fluorobenzene-sulfonylamino]- 1 , 1 a, 2,7b- tetrahydrocyclopropa[c]chromene-4-carboxylic acid; (1 aRS,7bSR)-5-{2-[2-((R)-l- ethylpyrrolidin-3-yl)ethylamino]-benzenesulfonylamino}-l,la,2,7b-tetrahydrocyclopropa- [c]chromene-4-carboxylic acid; (laRS,7bSR)-5-{2-[2-((S)-l-ethylpyrrolidin-3- yl)ethylamino]-benzenesulfonyl-amino}-l,la,2,7b-tetrahydrocyclopropa-[c]chromene-4- carboxylic acid; (laR,7bS)-5-[2-((S)-l-ethylpyrrolidin-3-yloxymethyl)-4-fluoro- benzenesulfonylamino]-l, la,2,7b-tetrahydrocyclopropa-[c]chromene-4-carboxylic acid; (1 aR,7bS)-5-[2-((R)-l-ethylpyrrolidin-3-yloxymethyl)-4-fluoro-benzenesulfonylamino]- l,la,2,7b-tetrahydrocyclopropa-[c]chromene-4-carboxylic acid; (laR,7bS)-5-[2-(l- ethylpiperi din-3 -ylmethyl)-4-fluorobenzene-sulfonylamino]- 1 , 1 a, 2,7b- tetrahydrocyclopropa[c]chromene-4-carboxylic acid; (laR,7bS)-5-{2-[2-((R)-l- ethylpyrrolidin-2-yl)ethyl]-4-fluorobenzenesulfonyl-amino}-l,la,2,7b-tetrahydrocyclopropa- [c]chromene-4-carboxylic acid; and pharmaceutically acceptable salts, stereoisomers, esters and prodrugs thereof.
pharmaceutically acceptable salt, analog, derivative, salt or ester thereof. [00161] In some aspects, a MetAP2 inhibitor can be:
pharmaceutically acceptable salt, analog, derivative, salt or ester thereof.
[00162] In some aspects, a MetAP2 inhibitor can be administered by subcutaneous injection (SC). In some aspects, a MetAP2 inhibitor can be administered by subcutaneous injection to the mid-abdominal (per-umbilical area). In some aspects, a subcutaneous injection of a MetAP2 inhibitor can be administered over an about 30 to about 45 second timeframe at a constant injection rate. In some aspects, the maximum injection volume of a MetAP2 inhibitor is less than about 1.7 ml.
[00163] In some aspects, a MetAP2 inhibitor can be administered about every four days (Q4D).
[00164] In some aspects, a MetAP2 inhibitor can be administered about once every day (QD), about once every two days (Q2D), about once every three days (Q3D), about once every four days (Q4D), about once every 5 days (Q5D), about once every 6 days (Q6D), about once every 7 days (Q7D), about once every 8 days (Q8D), about once every 9 days (Q9D), about once every 10 days (Q10D), about once every 11 days (QI ID), about once every 12 days (QI 2D), about once every 13 days (QI 3D), about once every 14 days (Q14D), or about once every 15 days (Q15D). In some aspects, a MetAP2 inhibitor can be administered about once every 7 days (Q7D). In some aspects, a MetAP2 inhibitor can be administered about once every 14 days (Q14D).
[00165] In some aspects, an amount of a MetAP2 inhibitor can be a therapeutically effective amount of a MetAP2 inhibitor.
[00166] In some aspects, a MetAP2 inhibitor can be administered in an amount of about 1 mg/m2, or about 2 mg/m2, or about 3 mg/m2, or about 4 mg/m2, or about 5 mg/m2, or about 6 mg/m2, or about 7 mg/m2, or about 8 mg/m2, or about 9 mg/m2, or about 10 mg/m2, or about 11 mg/m2, or about 12 mg/m2, or about 13 mg/m2, or about 14 mg/m2, or about 15 mg/m2, or about 16 mg/m2, or about 17 mg/m2, or about 18 mg/m2, or about 19 mg/m2, or about 20 mg/m2, or about 21 mg/m2, or about 22 mg/m2, or about 23 mg/m2, or about 24 mg/m2, or about 25 mg/m2, or about 26 mg/m2, or about 27 mg/m2, or about 28 mg/m2, or about 29
mg/m2, or about 30 mg/m2, or about 31 mg/m2, or about 32 mg/m2, or about 33 mg/m2, or about 34 mg/m2, or about 35 mg/m2, or about 36 mg/m2, or about 37 mg/m2, or about 38 mg/m2, or about 39 mg/m2, or about 40 mg/m2, or about 41 mg/m2, or about 42 mg/m2, or about 43 mg/m2, or about 44 mg/m2, or about 45 mg/m2, or about 46 mg/m2, or about 47 mg/m2, or about 48 mg/m2, or about 49 mg/m2, or about 50 mg/m2, or about 51 mg/m2, or about 52 mg/m2, or about 53 mg/m2, or about 54 mg/m2, or about 55 mg/m2, or about 56 mg/m2, or about 57 mg/m2, or about 58 mg/m2, or about 59 mg/m2, or about 60 mg/m2, or about mg/m2, or about 61 mg/m2, or about 62 mg/m2, or about 63 mg/m2, or about 64 mg/m2, or about 65 mg/m2, or about 66 mg/m2, or about 67 mg/m2, or about 68 mg/m2, or about 69 mg/m2, or about 70 mg/m2, or about 81 mg/m2, or about 82 mg/m2, or about 83 mg/m2, or about 84 mg/m2, or about 85 mg/m2, or about 86 mg/m2, or about 87 mg/m2, or about 88 mg/m2, or about 89 mg/m2, or about 90 mg/m2, or about 91 mg/m2, or about 92 mg/m2, or about 93 mg/m2, or about 94 mg/m2, or about 95 mg/m2, or about 96 mg/m2, or about 97 mg/m2, or about 98 mg/m2, or about 99 mg/m2, or about 100 mg/m2.
[00167] In some aspects, a MetAP2 inhibitor can be administered in an amount of about 49 mg/m2. In some aspects, a MetAP2 inhibitor can be administered in an amount of about 36 mg/m2. In some aspects, a MetAP2 inhibitor can be administered in an amount of about 65 mg/m2. In some aspects, a MetAP2 inhibitor can be administered in an amount of about 27 mg/m2.
[00168] In some aspects, a MetAP2 inhibitor can be administered in an amount of about 49 mg/m2. In some aspects, a MetAP2 inhibitor can be administered in an amount of about 39 mg/m2 to about 59 mg/m2. In some aspects, a MetAP2 inhibitor can be administered in an amount of about 44 mg/m2 to about 54 mg/m2.
[00169] In some aspects, a MetAP2 inhibitor can be administered in an amount of about 36 mg/m2. In some aspects, a MetAP2 inhibitor can be administered in an amount of about 26 mg/m2 to about 49 mg/m2. In some aspects, a MetAP2 inhibitor can be administered in an amount of about 31 mg/m2 to about 65 mg/m2.
[00170] In some aspects, a MetAP2 inhibitor can be administered in an amount of about 65 mg/m2. In some aspects, a MetAP2 inhibitor can be administered in an amount of about 55 mg/m2 to about 75 mg/m2. In some aspects, a MetAP2 inhibitor can be administered in an amount of about 60 mg/m2 to about 70 mg/m2.
[00171] In some aspects, a therapeutically effective amount of a MetAP2 inhibitor can be about 1 mg/m2, or about 2 mg/m2, or about 3 mg/m2, or about 4 mg/m2, or about 5 mg/m2, or about 6 mg/m2, or about 7 mg/m2, or about 8 mg/m2, or about 9 mg/m2, or about 10 mg/m2, or
about 11 mg/m2, or about 12 mg/m2, or about 13 mg/m2, or about 14 mg/m2, or about 15 mg/m2, or about 16 mg/m2, or about 17 mg/m2, or about 18 mg/m2, or about 19 mg/m2, or about 20 mg/m2, or about 21 mg/m2, or about 22 mg/m2, or about 23 mg/m2, or about 24 mg/m2, or about 25 mg/m2, or about 26 mg/m2, or about 27 mg/m2, or about 28 mg/m2, or about 29 mg/m2, or about 30 mg/m2, or about 31 mg/m2, or about 32 mg/m2, or about 33 mg/m2, or about 34 mg/m2, or about 35 mg/m2, or about 36 mg/m2, or about 37 mg/m2, or about 38 mg/m2, or about 39 mg/m2, or about 40 mg/m2, or about 41 mg/m2, or about 42 mg/m2, or about 43 mg/m2, or about 44 mg/m2, or about 45 mg/m2, or about 46 mg/m2, or about 47 mg/m2, or about 48 mg/m2, or about 49 mg/m2, or about 50 mg/m2, or about 51 mg/m2, or about 52 mg/m2, or about 53 mg/m2, or about 54 mg/m2, or about 55 mg/m2, or about 56 mg/m2, or about 57 mg/m2, or about 58 mg/m2, or about 59 mg/m2, or about 60 mg/m2, or about mg/m2, or about 61 mg/m2, or about 62 mg/m2, or about 63 mg/m2, or about 64 mg/m2, or about 65 mg/m2, or about 66 mg/m2, or about 67 mg/m2, or about 68 mg/m2, or about 69 mg/m2, or about 70 mg/m2, or about 81 mg/m2, or about 82 mg/m2, or about 83 mg/m2, or about 84 mg/m2, or about 85 mg/m2, or about 86 mg/m2, or about 87 mg/m2, or about 88 mg/m2, or about 89 mg/m2, or about 90 mg/m2, or about 91 mg/m2, or about 92 mg/m2, or about 93 mg/m2, or about 94 mg/m2, or about 95 mg/m2, or about 96 mg/m2, or about 97 mg/m2, or about 98 mg/m2, or about 99 mg/m2, or about 100 mg/m2.
[00172] In some aspects, a therapeutically effective amount of a MetAP2 inhibitor can be about 49 mg/m2. In some aspects, a therapeutically effective amount of a MetAP2 inhibitor can be about 39 mg/m2 to about 59 mg/m2. In some aspects, a therapeutically effective amount of a MetAP2 inhibitor can be about 44 mg/m2 to about 54 mg/m2.
[00173] In some aspects, a therapeutically effective amount of a MetAP2 inhibitor can be about 36 mg/m2. In some aspects, a therapeutically effective amount of a MetAP2 inhibitor can be about 26 mg/m2 to about 49 mg/m2. In some aspects, a therapeutically effective amount of a MetAP2 inhibitor can be about 31 mg/m2 to about 49 mg/m2.
[00174] In some aspects, a therapeutically effective amount of a MetAP2 inhibitor can be about 65 mg/m2. In some aspects, a therapeutically effective amount of a MetAP2 inhibitor can be about 55 mg/m2 to about 75 mg/m2. In some aspects, a therapeutically effective amount of a MetAP2 inhibitor can be about 60 mg/m2 to about 70 mg/m2.
[00175] In some aspects, a MetAP2 inhibitor can be administered in an amount of about 10 mg, or about 20 mg, or about 30 mg, or about 40 mg, or about 50 mg, or about 60 mg, or about 70 mg, or about 80 mg, or about 90 mg, or about 100 mg or about 110 mg, or about 120 mg, or about 130 mg, or about 140 mg, or about 150 mg, or about 160 mg, or about 170
mg, or about 180 mg, or about 190 mg, or about 200 mg. In some aspects a MetAP2 inhibitor can be administered in an amount of about 80 mg. In some aspects, a MetAP2 inhibitor can be administered in an amount of about of about 70 mg to about 90 mg. In some aspects, a MetAP2 inhibitor can be administered in an amount of about 75 mg to about 85 mg. [00176] In some aspects, a therapeutically effective amount of a MetAP2 inhibitor can be about 10 mg, or about 20 mg, or about 30 mg, or about 40 mg, or about 50 mg, or about 60 mg, or about 70 mg, or about 80 mg, or about 90 mg, or about 100 mg. In some aspects a therapeutically effective amount of a MetAP2 inhibitor can be about 80 mg. In some aspects, a therapeutically effective amount of a MetAP2 inhibitor can be about of about 70 mg to about 90 mg. In some aspects, a therapeutically effective amount of a MetAP2 inhibitor can be about 75 mg to about 85 mg.
[00177] Enzalutamide
[00178] As would be appreciated by the skilled artisan, enzalutamide has the following chemical structure:
[00179] As would be appreciated by the skilled artisan, it is understood that enzalutamide may be identified by any of the following names: 4-[3-[4-Cyano-3-(trifluoromethyl)phenyl]-5,5- dimethyl-4-oxo-2-thioxo-l-imidazolidinyl]-2-fluoro-7V-methylbenzamide, MDV 3100, Xtandi, and S -Enzalutamide. As would be appreciated by the skilled artisan, enzalutamide may be identified as CAS No. 915087-33-1. In the figures accompanying the present disclosure, enzalutamide may be abbreviated “ENZ” or “Enz”.
[00180] In some aspects, enzalutamide can be administered orally.
[00181] In some aspects, an amount of enzalutamide can be a therapeutically effective amount of enzalutamide.
[00182] In some aspects, an amount of enzalutamide can be any of the amounts listed below.
[00183] In some aspects, enzalutamide can be administered in an amount of about 20 mg, or about 40 mg, or about 60 mg, or about 80 mg, or about 100 mg, or about 120 mg, or about 140 mg, or about 160 mg, or about 180 mg, or about 200 mg, or about 220 mg, or about 240 mg, or about 260 mg, or about 280 mg, or about 300 mg, or about 320 mg, or about 340 mg, or about 360 mg, or about 380 mg, or about 400 mg, or about 420 mg, or about 440 mg, or about 460 mg, or about 480 mg, or about 500 mg.
[00184] In some aspects, enzalutamide can be administered in an amount of about 160 mg. In aspects wherein enzalutamide is administered in an amount of about 160 mg, the amount can be administered by orally administering four capsules of 160 mg.
[00185] In some aspects, a therapeutically effective amount of enzalutamide can be any of the enzalutamide amounts described herein.
[00186] In some aspects, enzalutamide can be administered as a pharmaceutical composition, wherein the pharmaceutical composition comprises capryl ocaproyl polyoxylglycerides. In some aspects, the pharmaceutical composition can comprise at least one of caprylocaproyl polyoxylglycerides, butylated hydroxy anisole, butylated hydroxytoluene, gelatin, sorbitol sorbitan solution, glycerin, purified water, titanium dioxide, and black iron oxide [00187] In some aspects, enzalutamide can be administered about once a day.
[00188] Prostate Cancer
[00189] The terms "cancer" and ’’cancerous" refer to or describe the physiological condition in mammals that is typically characterized by unregulated cell growth.
[00190] In some aspects, the prostate cancer can be androgen receptor-positive (AR+) prostate cancer.
[00191] In some aspects, the prostate cancer is androgen sensitive prostate cancer. In some aspects, the prostate cancer is a prostate cancer that has reverted to an androgen sensitive state from an androgen-insensitive state.
[00192] In some aspects, the prostate cancer can be castration-resistant prostate cancer.
[00193] In some aspects, the prostate cancer is castration-sensitive prostate cancer.
[00194] In some aspects, the prostate cancer is metastatic.
[00195] In some aspects, the prostate cancer can be phosphatase and tensin homologue deleted on chromosome 10 (PTEN)-deficient prostate cancer. In some aspects, the prostate cancer can be partially PTEN-deficient prostate cancer.
[00196] In some aspects, the prostate cancer can be PTEN-altered prostate cancer. In some aspects, the prostate cancer can be partially PTEN-altered prostate cancer.
[00197] In some aspects, the prostate cancer is metastatic prostate cancer.
[00198] In some aspects, the prostate cancer is advanced prostate cancer.
[00199] In some aspects, the prostate cancer is aggressive variant prostate cancer (AVPC). [00200] In some aspects, the prostate cancer is neuroendocrine prostate cancer (NEPC). [00201] In some aspects, the prostate cancer is resistant to treatment using androgen deprivation therapy (ADT). In some aspects, the prostate cancer has progressed while the subject has been on a treatment regimen comprising the administration of at least one ADT. [00202] As would be appreciated by the skilled artisan, ADT can include, but is not limited to, performing an orchiectomy, administering at least one luteinizing hormone-releasing hormone (LHRH) agonist, administering at least one LHRH antagonist, administering at least one estrogen, or any combination thereof.
[00203] As would be appreciated by the skilled artisan, an orchiectomy can comprise the removal or one or two testicles from a subject. In some aspects, an orchiectomy can be a subcapsular orchiectomy, wherein only the tissues in the testicles that produce androgen are removed, rather than the entire testicle.
[00204] As would be appreciated by the skilled artisan, LHRH agonists include, but are not limited to, leuprolide, goserelin, triptorelin and histrelin.
[00205] As would be appreciated by the skilled artisan, LHRH antagonists include, but are not limited to, degarelix and relugolix.
[00206] In some aspects, the prostate cancer is resistant to treatment using an androgen receptor antagonist or inhibitor. In some aspects, the prostate cancer has progressed while the subject has been on a treatment regimen comprising the administration of at least one androgen receptor antagonist or inhibitor.
[00207] As would be appreciated by the skilled artisan, androgen receptor antagonists or inhibitors include, but are not limited to flutamide, bicalutamide, nilutamide, enzalutamide, apalutamide, and darolutamide.
[00208] In some aspects, the prostate cancer is resistant to treatment using enzalutamide.
[00209] In some aspects, the prostate cancer has progressed while the subject has been on a treatment regimen comprising the administration of enzalutamide.
[00210] Any of the above prostate cancer characteristics can be combined. Thus, in a nonlimiting example, the prostate cancer can be PTEN-deficient, castration resistant prostate cancer.
[00211] Subjects
[00212] In some aspects, the subject in need thereof is an animal. In some aspects, the animal can be a mammal. In some aspects, the subject in need thereof is a human.
[00213] In some aspects, the subject in need thereof is a human of 18 years or older, or of 25 years or older, or of 50 years or older, or of 60 years or older, or of 65 years or older, or of 70 years or older, or of 75 years or older, or of 80 years or older, or of 85 years or older.
[00214] In some aspects, the subject has been previously administered at least one androgen deprivation therapy (ADT).
[00215] In some aspects, the subject has been previously administered at least one androgen receptor antagonist.
[00216] In some aspects, the subject has been previously administered at least one androgen receptor antagonist and at least one androgen deprivation therapy.
[00217] In some aspects, a subject in need thereof has at least one metabolic dysfunction. In some aspects, the at least one metabolic dysfunction can be excessive visceral adiposity, dyslipidemia, obesity (BMI >30), elevated leptin levels, depressed adiponectin levels, high leptin-to-adiponectin ratio, elevated fasting insulin levels, elevated fasting insulin levels accompanied by chronic inflammation, insulin resistance, hyperleptinaemia, high fasting glucose, elevated HbAlc, or any combination thereof.
[00218] In some aspects the at least one metabolic dysfunction is a treatment-induced metabolic dysfunction. In a non-limiting example, the metabolic dysfunction is a treatment- induced metabolic dysfunction that is induced by the treatment with at least one androgen deprivation therapy and/or at least one androgen receptor antagonist.
[00219] General Definitions
[00220] Certain compounds of the present disclosure may exist in particular geometric or stereoisomeric forms. The present disclosure contemplates all such compounds, including cis- and trans-i somers, R- and 5-enantiomers, diastereomers, (D)-isomers, (L)-isomers, the racemic mixtures thereof, and other mixtures thereof, as falling within the scope of the disclosure. Additional asymmetric carbon atoms may be present in a substituent such as an alkyl group. All such isomers, as well as mixtures thereof, are intended to be included in this disclosure. Any representation of a particular isomer is merely exemplary (e.g., the exemplification of a trans-isomer, also encompasses a cis-isomer).
[00221] If, for instance, a particular enantiomer of a compound of the present disclosure is desired, it may be prepared by asymmetric synthesis or by derivation with a chiral auxiliary, where the resulting diastereomeric mixture is separated and the auxiliary group cleaved to provide the pure desired enantiomer. Alternatively, where the molecule contains a basic functional group, such as amino, or an acidic functional group, such as carboxyl, diastereomeric salts are formed with an appropriate optically-active acid or base, followed by
resolution of the diastereomers thus formed by fractional crystallization or chromatographic means well known in the art, and subsequent recovery of the pure enantiomer.
[00222] In the present specification, the structural formula of the compound represents a certain isomer for convenience in some cases, but the present disclosure includes all isomers, such as geometrical isomers, optical isomers based on an asymmetrical carbon, stereoisomers, tautomers, and the like. In addition, a crystal polymorphism may be present for the compounds represented by the formula. It is noted that any crystal form, crystal form mixture, or anhydride or hydrate thereof is included in the scope of the present disclosure. Furthermore, so-called metabolite which is produced by degradation of the present compound in vivo is included in the scope of the present disclosure.
[00223] “Isomerism” means compounds that have identical molecular formulae but differ in the sequence of bonding of their atoms or in the arrangement of their atoms in space. Isomers that differ in the arrangement of their atoms in space are termed “stereoisomers”. Stereoisomers that are not mirror images of one another are termed “diastereoisomers”, and stereoisomers that are non-superimposable mirror images of each other are termed “enantiomers” or sometimes optical isomers. A mixture containing equal amounts of individual enantiomeric forms of opposite chirality is termed a “racemic mixture”.
[00224] A carbon atom bonded to four nonidentical substituents is termed a “chiral center”. [00225] “Chiral isomer” means a compound with at least one chiral center. Compounds with more than one chiral center may exist either as an individual diastereomer or as a mixture of diastereomers, termed “diastereomeric mixture”. When one chiral center is present, a stereoisomer may be characterized by the absolute configuration (R or S) of that chiral center. Absolute configuration refers to the arrangement in space of the substituents attached to the chiral center. The substituents attached to the chiral center under consideration are ranked in accordance with the Sequence Rule of Cahn, Ingold and Prelog. (Cahn et al., Angew. Chem. Inter. Edit. 1966, 5, 385; errata 511; Cahn et al., Angew. Chem. 1966, 78, 413; Cahn and Ingold, J. Chem. Soc. 1951 (London), 612; Cahn et al., Experientia 1956, 12, 81; Cahn, J. Chem. Educ. 1964, 41, 116).
[00226] “Geometric isomer” means the diastereomers that owe their existence to hindered rotation about double bonds. These configurations are differentiated in their names by the prefixes cis and trans, or Z and E, which indicate that the groups are on the same or opposite side of the double bond in the molecule according to the Cahn-Ingold-Prelog rules.
[00227] Furthermore, the structures and other compounds discussed in this disclosure include all atropic isomers thereof. “Atropic isomers” are a type of stereoisomer in which the atoms
of two isomers are arranged differently in space. Atropic isomers owe their existence to a restricted rotation caused by hindrance of rotation of large groups about a central bond. Such atropic isomers typically exist as a mixture, however as a result of recent advances in chromatography techniques; it has been possible to separate mixtures of two atropic isomers in select cases.
[00228] “Tautomer” is one of two or more structural isomers that exist in equilibrium and is readily converted from one isomeric form to another. This conversion results in the formal migration of a hydrogen atom accompanied by a switch of adjacent conjugated double bonds. Tautomers exist as a mixture of a tautomeric set in solution. In solid form, usually one tautomer predominates. In solutions where tautomerization is possible, a chemical equilibrium of the tautomers will be reached. The exact ratio of the tautomers depends on several factors, including temperature, solvent and pH. The concept of tautomers that are interconvertable by tautomerizations is called tautomerism.
[00229] Of the various types of tautomerism that are possible, two are commonly observed. In keto-enol tautomerism a simultaneous shift of electrons and a hydrogen atom occurs. Ringchain tautomerism arises as a result of the aldehyde group (-CHO) in a sugar chain molecule reacting with one of the hydroxy groups (-OH) in the same molecule to give it a cyclic (ringshaped) form as exhibited by glucose.
[00230] Common tautomeric pairs are: ketone-enol, amide-nitrile, lactam-lactim, amide- imidic acid tautomerism in heterocyclic rings (e.g., in nucleobases such as guanine, thymine and cytosine), amine-enamine and enamine-enamine.
[00231] It is to be understood that the compounds of the present disclosure may be depicted as different tautomers. It should also be understood that when compounds have tautomeric forms, all tautomeric forms are intended to be included in the scope of the present disclosure, and the naming of the compounds does not exclude any tautomer form.
[00232] The term “crystal polymorphs”, “polymorphs” or “crystal forms” means crystal structures in which a compound (or a salt or solvate thereof) can crystallize in different crystal packing arrangements, all of which have the same elemental composition. Different crystal forms usually have different X-ray diffraction patterns, infrared spectral, melting points, density hardness, crystal shape, optical and electrical properties, stability and solubility. Recrystallization solvent, rate of crystallization, storage temperature, and other factors may cause one crystal form to dominate. Crystal polymorphs of the compounds can be prepared by crystallization under different conditions.
[00233] Additionally, the compounds of the present disclosure, for example, the salts of the compounds, can exist in either hydrated or unhydrated (the anhydrous) form or as solvates with other solvent molecules. Nonlimiting examples of hydrates include monohydrates, dihydrates, etc. Nonlimiting examples of solvates include ethanol solvates, acetone solvates, etc.
[00234] “Solvate” means solvent addition forms that contain either stoichiometric or non stoichiometric amounts of solvent. Some compounds have a tendency to trap a fixed molar ratio of solvent molecules in the crystalline solid state, thus forming a solvate. If the solvent is water the solvate formed is a hydrate; and if the solvent is alcohol, the solvate formed is an alcoholate. Hydrates are formed by the combination of one or more molecules of water with one molecule of the substance in which the water retains its molecular state as H2O.
[00235] As used herein, the term “analog” refers to a chemical compound that is structurally similar to another but differs slightly in composition (as in the replacement of one atom by an atom of a different element or in the presence of a particular functional group, or the replacement of one functional group by another functional group). Thus, an analog is a compound that is similar or comparable in function and appearance, but not in structure or origin to the reference compound.
[00236] As defined herein, the term “derivative” refers to compounds that have a common core structure, and are substituted with various groups as described herein.
[00237] The term “bioisostere” refers to a compound resulting from the exchange of an atom or of a group of atoms with another, broadly similar, atom or group of atoms. The objective of a bioisosteric replacement is to create a new compound with similar biological properties to the parent compound. The bioisosteric replacement may be physicochemically or topologically based. Examples of carboxylic acid bioisosteres include, but are not limited to, acyl sulfonimides, tetrazoles, sulfonates and phosphonates. See, e.g., Patani and LaVoie, (Rem. Rev. 96, 3147-3176, 1996.
[00238] As used herein, the term “temporal proximity” refers to that administration of one therapeutic agent (e.g., a MetAP2 inhibitor compound disclosed herein) occurs within a time period before or after the administration of another therapeutic agent (e.g., enzalutamide), such that the therapeutic effect of the one therapeutic agent overlaps with the therapeutic effect of the other therapeutic agent. In some embodiments, the therapeutic effect of the one therapeutic agent completely overlaps with the therapeutic effect of the other therapeutic agent. In some embodiments, “temporal proximity” means that administration of one therapeutic agent occurs within a time period before or after the administration of another
therapeutic agent, such that there is a synergistic effect between the one therapeutic agent and the other therapeutic agent. “Temporal proximity” may vary according to various factors, including but not limited to, the age, gender, weight, genetic background, medical condition, disease history, and treatment history of the subject to which the therapeutic agents are to be administered; the disease or condition to be treated or ameliorated; the therapeutic outcome to be achieved; the dosage, dosing frequency, and dosing duration of the therapeutic agents; the pharmacokinetics and pharmacodynamics of the therapeutic agents; and the route(s) through which the therapeutic agents are administered. In some embodiments, “temporal proximity” means within 15 minutes, within 30 minutes, within an hour, within two hours, within four hours, within six hours, within eight hours, within 12 hours, within 18 hours, within 24 hours, within 36 hours, within 2 days, within 3 days, within 4 days, within 5 days, within 6 days, within a week, within 2 weeks, within 3 weeks, within 4 weeks, with 6 weeks, or within 8 weeks. In some embodiments, multiple administration of one therapeutic agent can occur in temporal proximity to a single administration of another therapeutic agent. In some embodiments, temporal proximity may change during a treatment cycle or within a dosing regimen.
[00239] The terms “effective amount” and “therapeutically effective amount” of an agent or compound are used in the broadest sense to refer to a nontoxic but sufficient amount of an active agent or compound to provide the desired effect or benefit.
[00240] The term "benefit" is used in the broadest sense and refers to any desirable effect and specifically includes clinical benefit as defined herein. Clinical benefit can be measured by assessing various endpoints, e.g., inhibition, to some extent, of disease progression, including slowing down and/or complete arrest; reduction in the number of disease episodes and/or symptoms; reduction in lesion size; inhibition (i.e., reduction, slowing down or complete stopping) of disease cell infiltration into adjacent peripheral organs and/or tissues; inhibition (i.e. reduction, slowing down or complete stopping) of disease spread; decrease of autoimmune response, which may, but does not have to, result in the regression or ablation of the disease lesion; relief, to some extent, of one or more symptoms associated with the disorder; increase in the length of disease-free presentation following treatment, e.g., progression-free survival; increased overall survival; higher response rate; decreased mortality at a given point of time following treatment; and/or improvement in one of the following symptoms: congestion, fluid/edema, wheezing, coughing, hypoxemia, low oxygen saturation, lung stiffness, shortness of breath, shortness of breath during exercise, dry hacking cough, fast shallow breathing, weight loss, tiredness, aching joints, aching muscles and clubbing.
[00241] As used herein, the term “pharmaceutically acceptable” refers to those compounds, anions, cations, materials, compositions, carriers, and/or dosage forms which are, within the scope of sound medical judgment, suitable for use in contact with the tissues of human beings and animals without excessive toxicity, irritation, allergic response, or other problem or complication, commensurate with a reasonable benefit/risk ratio.
[00242] As used herein, the term “combination therapy” or “co-therapy” includes the administration of a compound of the present disclosure, or a pharmaceutically acceptable salt, polymorph or solvate thereof, and at least a second agent as part of a specific treatment regimen intended to provide the beneficial effect from the co-action of these therapeutic agents. The beneficial effect of the combination includes, but is not limited to, pharmacokinetic or pharmacodynamic co-action resulting from the combination of therapeutic agents.
[00243] It is to be understood that the present disclosure also provides pharmaceutical compositions comprising any compound described herein in combination with at least one pharmaceutically acceptable excipient or carrier.
[00244] It is to be understood that, unless otherwise stated, any description of a method of treatment includes use of the compounds to provide such treatment or prophylaxis as is described herein, as well as use of the compounds to prepare a medicament to treat or prevent such condition. The treatment includes treatment of human or non-human animals including rodents and other disease models.
[00245] As used herein, the term “subject” is interchangeable with the term “subject in need thereof’, both of which refer to a subject having a disease or having an increased risk of developing the disease. A “subject” includes a mammal. The mammal can be e.g., a human or appropriate non-human mammal, such as primate, mouse, rat, dog, cat, cow, horse, goat, camel, sheep or a pig. The subject can also be a bird or fowl. In one embodiment, the mammal is a human.
[00246] As used herein, the term “treating” or “treat” describes the management and care of a patient for the purpose of combating a disease, condition, or disorder and includes the administration of a compound of the present disclosure, or a pharmaceutically acceptable salt, polymorph or solvate thereof, to alleviate the symptoms or complications of a disease, condition or disorder, or to eliminate the disease, condition or disorder. The term “treat” can also include treatment of a cell in vitro or an animal model.
[00247] It is to be understood that a compound of the present disclosure, or a pharmaceutically acceptable salt, polymorph or solvate thereof, can or may also be used to prevent a relevant disease, condition or disorder, or used to identify suitable candidates for such purposes.
[00248] As used herein, the term “preventing,” “prevent,” or “protecting against” describes reducing or eliminating the onset of the symptoms or complications of such disease, condition or disorder.
[00249] Exemplary Embodiments
[00250] Embodiment la. A method of treating prostate cancer in a subject, the method comprising administering at least one amount of at least one MetAP2 inhibitor to the subject.
[00251] Embodiment lb. A method of preventing prostate cancer in a subject, the method comprising administering at least one amount of at least one MetAP2 inhibitor to the subject.
[00252] Embodiment 1c. A method of preventing prostate cancer growth or recurrence in a subject, the method comprising administering at least one amount of at least one MetAP2 inhibitor to the subject.
[00253] Embodiment 2a. A MetAP2 inhibitor, or pharmaceutically acceptable salt thereof, for use in treating prostate cancer in a subject.
[00254] Embodiment 2b. A MetAP2 inhibitor, or pharmaceutically acceptable salt thereof, for use in preventing prostate cancer in a subject.
[00255] Embodiment 2c. A MetAP2 inhibitor, or pharmaceutically acceptable salt thereof, for use in preventing prostate cancer growth or recurrence in a subject.
[00256] Embodiment 3a. A combination comprising at least one MetAP2 inhibitor, or a pharmaceutically acceptable salt thereof, and enzalutamide, or a pharmaceutically acceptable salt thereof, for use in treating prostate cancer in a subject.
[00257] Embodiment 3b. A combination comprising at least one MetAP2 inhibitor, or a pharmaceutically acceptable salt thereof, and enzalutamide, or a pharmaceutically acceptable salt thereof, for use in preventing prostate cancer in a subject.
[00258] Embodiment 3c. A combination comprising at least one MetAP2 inhibitor, or a pharmaceutically acceptable salt thereof, and enzalutamide, or a pharmaceutically acceptable salt thereof, for use in preventing prostate cancer growth or recurrence in a subject.
[00259] Embodiment 4a. A method of treating prostate cancer in a subject, the method comprising administering to the subject at least one amount of at least one MetAP2 inhibitor, or a pharmaceutically acceptable salt thereof, and at least one therapeutically effective amount of enzalutamide, or a pharmaceutically acceptable salt thereof.
[00260] Embodiment 4b. A method of preventing prostate cancer in a subject, the method comprising administering to the subject at least one amount of at least one MetAP2 inhibitor, or a pharmaceutically acceptable salt thereof, and at least one therapeutically effective amount of enzalutamide, or a pharmaceutically acceptable salt thereof.
[00261] Embodiment 4c. A method of preventing prostate cancer growth or recurrence in a subject, the method comprising administering to the subject at least one amount of at least one MetAP2 inhibitor, or a pharmaceutically acceptable salt thereof, and at least one therapeutically effective amount of enzalutamide, or a pharmaceutically acceptable salt thereof.
[00262] Embodiment 5a. A MetAP2 inhibitor, or a pharmaceutically acceptable salt thereof, for use in a method of treating prostate cancer in a subject, wherein the method further comprises administration of enzalutamide, or a pharmaceutically acceptable salt thereof.
[00263] Embodiment 5b. A MetAP2 inhibitor, or a pharmaceutically acceptable salt thereof, for use in a method of preventing prostate cancer in a subject, wherein the method further comprises administration of enzalutamide, or a pharmaceutically acceptable salt thereof.
[00264] Embodiment 5c. A MetAP2 inhibitor, or a pharmaceutically acceptable salt thereof, for use in a method of preventing prostate cancer growth or recurrence in a subject, wherein the method further comprises administration of enzalutamide, or a pharmaceutically acceptable salt thereof.
[00265] Embodiment 6a. Enzalutamide, or a pharmaceutically acceptable salt thereof, for use in a method of treating prostate cancer in a subject, wherein the method further comprises administration of at least one MetAP2 inhibitor or a pharmaceutically acceptable salt thereof. [00266] Embodiment 6b. Enzalutamide, or a pharmaceutically acceptable salt thereof, for use in a method of preventing prostate cancer in a subject, wherein the method further comprises administration of at least one MetAP2 inhibitor or a pharmaceutically acceptable salt thereof. [00267] Embodiment 6c. Enzalutamide, or a pharmaceutically acceptable salt thereof, for use in a method of preventing prostate cancer growth or recurrence in a subject, wherein the method further comprises administration of at least one MetAP2 inhibitor or a pharmaceutically acceptable salt thereof.
[00268] Embodiment 7. The method, MetAP2 inhibitor, combination, or enzalutamide of any one of the preceding embodiments, wherein the prostate cancer is castration-resistant prostate cancer.
[00269] Embodiment 8. The method, MetAP2 inhibitor, combination, or enzalutamide of any one of the preceding embodiments, wherein the prostate cancer is castration-sensitive prostate cancer.
[00270] Embodiment 9a. The method, MetAP2 inhibitor, combination, or enzalutamide of any one of the preceding embodiments, wherein the prostate cancer is PTEN-deficient prostate cancer or partially PTEN-deficient prostate cancer.
[00271] Embodiment 9b. The method, MetAP2 inhibitor, combination, or enzalutamide of any one of the preceding embodiments, wherein the prostate cancer is PTEN-altered prostate cancer or partially PTEN-altered prostate cancer.
[00272] Embodiment 10. The method, MetAP2 inhibitor, combination, or enzalutamide of any one of the preceding embodiments, wherein the prostate cancer is aggressive variant prostate cancer (AVPC).
[00273] Embodiment 11. The method, MetAP2 inhibitor, combination, or enzalutamide of any one of the preceding embodiments, wherein the prostate cancer is neuroendocrine prostate cancer (NEPC).
[00274] Embodiment 12. The method, MetAP2 inhibitor, combination, or enzalutamide of any one of the preceding embodiments, wherein the at least one MetAP2 inhibitor, or pharmaceutically acceptable salt thereof, and the enzalutamide, or pharmaceutically acceptable salt thereof, are administered concurrently or in temporal proximity.
[00275] Embodiment 13. The method, MetAP2 inhibitor, combination, or enzalutamide of any one of the preceding embodiments, wherein the subject has been previously administered at least one androgen deprivation therapy.
[00276] Embodiment 14. The method, MetAP2 inhibitor, combination, or enzalutamide of any one of the preceding embodiments, wherein the subject has undergone an orchiectomy.
[00277] Embodiment 15. The method, MetAP2 inhibitor, combination, or enzalutamide of embodiment 14, wherein the orchiectomy is a subcapsular orchiectomy.
[00278] Embodiment 16. The method, MetAP2 inhibitor, combination, or enzalutamide of any one of the preceding embodiments, wherein the subject has been previously administered at least one luteinizing hormone-releasing hormone (LHRH) agonist.
[00279] Embodiment 17. The method, MetAP2 inhibitor, combination, or enzalutamide of embodiment 16, wherein the at least one luteinizing hormone-releasing hormone (LHRH) agonist is selected from leuprolide, goserelin, triptorelin and histrelin.
[00280] Embodiment 18. The method, MetAP2 inhibitor, combination, or enzalutamide of any one of the preceding embodiments, wherein the subject has been previously administered at least one LHRH antagonist.
[00281] Embodiment 19. The method, MetAP2 inhibitor, combination, or enzalutamide of embodiment 18, wherein the at least one LHRH antagonist is selected from degarelix and relugolix.
[00282] Embodiment 20. The method, MetAP2 inhibitor, combination, or enzalutamide of any one of the preceding embodiments, wherein the subject has been previously administered at least one androgen receptor antagonist.
[00283] Embodiment 21. The method, MetAP2 inhibitor, combination, or enzalutamide of embodiment 20, wherein the androgen receptor antagonist is selected from flutamide, bicalutamide, nilutamide, enzalutamide, apalutamide, and darolutamide.
[00284] Embodiment 22. The method, MetAP2 inhibitor, combination, or enzalutamide of embodiment 21, wherein the androgen receptor antagonist is enzalutamide.
[00285] Embodiment 23. The method, MetAP2 inhibitor, combination, or enzalutamide of any one of the preceding embodiments, wherein the prostate cancer is resistant to treatment with androgen deprivation therapy.
[00286] Embodiment 24. The method, MetAP2 inhibitor, combination, or enzalutamide of embodiment 23, wherein the androgen deprivation therapy comprises performing an orchiectomy, administering at least one luteinizing hormone-releasing hormone (LHRH) agonist, administering at least one LHRH antagonist, administering at least one estrogen, or any combination thereof.
[00287] Embodiment 25. The method, MetAP2 inhibitor, combination, or enzalutamide of embodiment 24, wherein the orchiectomy is a subcapsular orchiectomy.
[00288] Embodiment 26. The method, MetAP2 inhibitor, combination, or enzalutamide of embodiment 24, wherein the at least one luteinizing hormone-releasing hormone (LHRH) agonist is selected from leuprolide, goserelin, triptorelin and histrelin.
[00289] Embodiment 27. The method, MetAP2 inhibitor, combination, or enzalutamide of embodiment 24, wherein the at least one LHRH antagonist is selected from degarelix and relugolix.
[00290] Embodiment 28. The method, MetAP2 inhibitor, combination, or enzalutamide of any one of the preceding embodiments, wherein the prostate cancer is resistant to treatment with an androgen receptor antagonist.
[00291] Embodiment 29. The method, MetAP2 inhibitor, combination, or enzalutamide of embodiment 28, wherein the androgen receptor antagonist is selected from flutamide, bicalutamide, nilutamide, enzalutamide, apalutamide, and darolutamide.
[00292] Embodiment 30. The method, MetAP2 inhibitor, combination, or enzalutamide of any one of the preceding embodiments, wherein the MetAP2 inhibitor is administered/for administration within one day, two days, three days, four days, five days, six days or one week of the subject exhibiting PSA nadir.
[00293] Embodiment 31. The method, MetAP2 inhibitor, combination, or enzalutamide of any one of the preceding embodiments, wherein the MetAP2 inhibitor is administered/for administration about two weeks, or about three weeks, or about four weeks, or about five weeks after the subject has exhibited PSA nadir, and wherein the PSA level in the subject has increased from PSA nadir.
[00294] Embodiment 32. The method, MetAP2 inhibitor, combination, or enzalutamide of any one of the preceding embodiments, wherein the subject has at least one metabolic dysfunction, wherein the metabolic dysfunction is selected from visceral adiposity, dyslipidemia, obesity (BMI >30), elevated leptin levels, depressed adiponectin levels, high leptin-to-adiponectin ratio, elevated fasting insulin levels, elevated fasting insulin levels accompanied by chronic inflammation, insulin resistance, hyperleptinaemia, high fasting glucose, elevated 14b Ale, or any combination thereof.
[00295] Embodiment 33. The method, MetAP2 inhibitor, combination, or enzalutamide of any one of the preceding embodiments, wherein the metabolic dysfunction is a treatment-induced metabolic dysfunction.
[00296] Embodiment 34. The method, MetAP2 inhibitor, combination, or enzalutamide of any one of the preceding embodiments, wherein the MetAP2 inhibitor is selected from:
pharmaceutically acceptable salt thereof, wherein x is in the range of 1 to about 450, y is in the range of 1 to about 30 and n is in the range of 1 to about 100, preferably wherein the ratio of x to y is in the range of about 30:1 to about 3: 1, preferably wherein the ratio of x to y is about 11 : 1.
[00297] Embodiment 31. The method, MetAP2 inhibitor, combination, or enzalutamide of any one of the preceding embodiments, wherein the MetAP2 inhibitor is:
(Compound 1), or a pharmaceutically acceptable salt thereof, wherein x is in the range of 1 to about 450, y is in the range of 1 to about 30 and n is in the range of 1 to about 100, preferably wherein the ratio of x to y is in the range of about 30: 1 to about 3: 1, preferably wherein the ratio of x to y is about 11 : 1.
[00298] Embodiment 35. The method, MetAP2 inhibitor, combination, or enzalutamide of any one of the preceding embodiments, or pharmaceutically acceptable salt thereof, wherein the MetAP2 inhibitor is administered/for administration to the subject in an amount of: i) about 27 mg/m2; ii) about 36 mg/m2; iii) about 49 mg/m2; or iv) about 65 mg/m2.
[00299] Embodiment 36. The method, MetAP2 inhibitor, combination, or enzalutamide of any one of the preceding embodiments, wherein the MetAP2 inhibitor is administered/for administration: i) once every 7 days (Q7D); ii) once every 14 days (Q14D); or
iii) once every 21 days (Q21D).
[00300] Embodiment 37. The method, MetAP2 inhibitor, combination, or enzalutamide of any one of the preceding embodiments, or pharmaceutically acceptable salt thereof, wherein the enzalutamide is administered/for administration to the subject in an amount of: i) about 40 mg; ii) about 80 mg; iii) about 120 mg; or iv) about 160 mg.
[00301] Embodiment 38. The method, MetAP2 inhibitor, combination, or enzalutamide of any one of the preceding embodiments, wherein the enzalutamide is administered/for administration daily.
[00302] Embodiment 39. The method, MetAP2 inhibitor, combination, or enzalutamide of any one of the preceding embodiments, wherein administration of the at least one MetAP2 inhibitor results in a reduction in the size of the prostate cancer.
[00303] Embodiment 40. The method, MetAP2 inhibitor, combination, or enzalutamide of embodiment 36, wherein the reduction in the size of the prostate cancer is at least about a 10%, or about a 20%, or about a 30%, or about a 40%, or about a 50%, or about a 60%, or about a 70%, or about an 80%, or about a 90%, or about a 99% reduction in tumor volume.
[00304] Example 1
[00305] The following is a non-limiting example of the treatment of castration-sensitive prostate cancer using Compound 1 of the present disclosure.
[00306JNSG mice were injected subcutaneously with 2xl06 LNCaP cells. When tumors reached approximately 200 mm3, the mice were split into two treatment groups of four mice each. The first treatment group received Compound 1 in an amount of 12 mg/kg, administered subcutaneously once every 4 days. The second treatment group received a negative control, vehicle treatment comprising 5% mannitol in water.
[00307] FIG. 1 shows the tumor volume in individual mice (left panel) and the average tumor volume across all mice (right panel) in the Compound 1 and Vehicle control treatment groups. The vertical dashed lines denote the start of treatment.
[00308] FIG. 2 shows the average PSA levels of mice (left panel) and the endpoint tumor mass (right panel) in the Compound 1 and Vehicle control treatment groups.
[00309] As shown in FIGs. 1 and 2, treatment with Compound 1 resulted in both a decrease in tumor volume as well as a decrease in PSA levels.
[00310] FIG. 3 shows the body weight of individual mice (left panel) and the average body weight across all mice (right panel) in the Compound 1 and Vehicle control treatment groups. The vertical dashed lines denote the start of treatment.
[00311] FIG. 4 shows the liver, kidney, heart and lung weights at the endpoint of the study in select mice in the Compound 1 and Vehicle control treatment groups.
[00312] FIG. 5 shows the liver, kidney, heart and lung weights as a percentage of body weight at the endpoint of the study in select mice in the Compound 1 and Vehicle control treatment groups.
[00313] Without wishing to be bound by theory, the results presented in FIGs. 3-5 demonstrate that treatment with Compound 1 was well-tolerated.
[00314] FIG. 6 is a graph showing the overall survival of the mice in the Compound 1 and Vehicle control treatment groups. As shown in FIG. 6, treatment with Compound 1 resulted in increased survival of the mice.
[00315] FIG. 7 shows necropsy images of tumors excised from mice in the Compound 1 and Vehicle control treatment groups.
[00316] FIG. 8 shows immunohistochemistry analysis of CD34 immunoreactivity from select mice in the Compound 1 and Vehicle control treatment groups. As would be appreciated by the skilled artisan, the endothelial marker CD34 can be used to quantify tumor vasculature. Accordingly, as shown in FIG. 8, treatment with Compound 1 results in a decrease in tumor vasculature as compared to treatment with the vehicle control.
[00317] Without wishing to be bound by theory, the results presented in this example demonstrate that Compound 1 of the present disclosure can be used to treat castrationsensitive prostate cancer.
[00318] Example 2
[00319] The following is a non-limiting example of the prevention of castration-resistant prostate cancer development using Compound 1 of the present disclosure.
[00320]NSG mice were injected subcutaneously with 2xl06 LNCaP cells. When tumors reached approximately 200 mm3, the mice were physically castrated and subsequently enrolled in one of three treatment groups within 5 to 8 days. The first treatment group received Compound 1 in an amount of 6 mg/kg, administered subcutaneously once every 4 days. The second treatment group received Compound 1 in an amount of 12 mg/kg administered subcutaneously once every 4 days. The third treatment group received a negative control, vehicle treatment comprising 5% 5% mannitol in water.
[00321] FIG. 9 shows the average tumor volume across all mice in the three treatment groups. The vertical dashed lines denote the start of treatment and the gray box denotes castration. FIG. 10 shows the tumor mass at the conclusion of the study. The results shown in FIGs. 9 and 10 demonstrate that the administration of Compound 1 prevented tumor growth and resulted in smaller tumors at the end of the study.
[00322] FIG. 11 shows the average PSA levels across all mice in the three treatment groups during the course of the study. The results shown in FIG. 11 demonstrate that PSA levels were not affected by treatment with Compound 1.
[00323] FIG. 12 shows the liver, kidney, heart and lung weights at the endpoint of the study in select mice in the Compound 1 and Vehicle control treatment groups. FIG. 13 shows the liver, kidney, heart and lung weights as a percentage of body weight at the endpoint of the study in select mice in the Compound 1 and Vehicle control treatment groups. FIG. 14 shows average body weight across all mice in the Compound 1 and Vehicle control treatment groups. The vertical dashed lines denote the start of treatment. In FIGs. 12-14, the Compound 1 6 mg/kg treatment group is denoted as “Cpdl (6 mpk)” and the Compound 1 12 mg/kg treatment group is denoted as “Cpdl (12 mpk)”.
[00324] Without wishing to be bound by theory, the results presented in FIGs. 12-14 demonstrate that treatment with Compound 1 was well-tolerated.
[00325] FIG. 15 shows immunohistochemistry analysis of CD34 immunoreactivity from select mice in the three treatment groups. As would be appreciated by the skilled artisan, the endothelial marker CD34 can be used to quantify tumor vasculature. Accordingly, as shown in FIG. 15, treatment with Compound 1 prevented the formation of tumor vasculature as compared to treatment with the vehicle control.
[00326] Without wishing to be bound by theory, the results presented in this example demonstrate that Compound 1 of the present disclosure can be used to prevent castrationresistant prostate cancer.
[00327] Example 3
[00328] The following is a non-limiting example of the treatment of castration-resistant prostate cancer using Compound 1 of the present disclosure.
[00329] NSG mice prepared as described in Example 2 were subsequently enrolled in one of two treatment groups 2-4 weeks after castration and the recurrence of high PSA levels and tumor growth (i.e., castration-resistant prostate cancer). The first treatment group received Compound 1 in an amount of 12 mg/kg, administered subcutaneously once every 4 days. The
second treatment group received a negative control, vehicle treatment comprising 5% mannitol in water(denoted in some figures as “Veh”).
[00330] FIG. 16 shows the tumor volume in individual mice (top panel) and the average tumor volume across all mice (bottom panel) in the Compound 1 and Vehicle control treatment groups. The vertical dashed lines denote the start of treatment. FIG. 17 shows the endpoint tumor mass (left panel) and average PSA levels of mice (right panel) and in the Compound 1 and Vehicle control treatment groups. As shown in FIGs. 16 and 17, treatment with Compound 1 resulted a decrease in tumor volume while PSA levels were not affected.
[00331] FIG. 18 shows the body weight of individual mice (top panel) and the average body weight across all mice (bottom panel) in the Compound 1 and Vehicle control treatment groups. The vertical dashed lines denote the start of treatment.
[00332] FIG. 19 shows the liver, kidney, heart and lung weights at the endpoint of the study in select mice in the Compound 1 and Vehicle control treatment groups.
[00333] FIG. 20 shows the liver, kidney, heart and lung weights as a percentage of body weight at the endpoint of the study in select mice in the Compound 1 and Vehicle control treatment groups.
[00334] Without wishing to be bound by theory, the results presented in FIGs. 18-20 demonstrate that treatment with Compound 1 was well-tolerated.
[00335] FIG. 21 shows immunohistochemistry analysis of CD34 immunoreactivity from select mice in the Compound 1 and Vehicle control treatment groups. As would be appreciated by the skilled artisan, the endothelial marker CD34 can be used to quantify tumor vasculature. Accordingly, as shown in FIG. 21, treatment with Compound 1 results in a decrease in tumor vasculature as compared to treatment with the vehicle control.
[00336] Without wishing to be bound by theory, the results presented in this example demonstrate that Compound 1 of the present disclosure can be used to treat castrationresistant prostate cancer.
[00337] Example 4
[00338] The following is a non-limiting example of the treatment of established castrationresistant prostate cancer using Compound 1 of the present disclosure in combination with enzalutamide.
[00339] NSG mice prepared as described in Example 2, were subsequently enrolled in one of four treatment groups 2-4 weeks after castration and the recurrence of high PSA levels and tumor growth. The first treatment group received enzalutamide in an amount of 10 mg/kg daily by oral gavage in combination with a negative control, vehicle treatment of 5%
mannitol in water. The second treatment group received enzalutamide in an amount of 10 mg/kg daily by oral gavage in combination with Compound 1 in an amount of 12 mg/kg, administered subcutaneously once every 4 days.
[00340] FIG. 22 shows the average tumor volume across mice in the first treatment group described above. The first treatment group was stratified into two groups -those that responded to the treatment with enzalutamide alone (“responders”) and those that did not respond to enzalutamide alone (“non-responders”). Dashed line denotes the start of treatment. [00341] FIG. 23 shows the average tumor volume across mice in the first and second treatment groups described above. The first treatment group was stratified into two groups - those that responded to the treatment with enzalutamide alone (“responders”) and those that did not respond to enzalutamide alone (“non-responders”). Dashed line denotes the start of treatment (enzalutamide or enzalutamide plus Compound 1).
[00342] FIG. 24 shows the endpoint tumor mass in the first and second treatment groups described above. The first treatment group was stratified into two groups -those that responded to the treatment with enzalutamide alone (“responders”) and those that did not respond to enzalutamide alone (“non-responders”).
[00343] FIG. 25 shows the PSA levels in the first and second treatment groups described above. The first treatment group was stratified into two groups -those that responded to the treatment with enzalutamide alone (“responders”) and those that did not respond to enzalutamide alone (“non-responders”). Dashed line denotes the start of treatment (enzalutamide or enzalutamide plus Compound 1).
[00344] As shown in FIGs. 22-25, treatment with Compound 1 in combination with enzalutamide resulted a decrease in tumor volume while PSA levels were not significantly affected.
[00345] FIG. 26 shows the body weight of individual mice (top panel) and the average body weight across all mice (bottom panel) in the first and second treatment groups described above. The vertical dashed lines denote the start of treatment.
[00346] FIG. 27 shows the liver, kidney, heart and lung weights at the endpoint of the study in select mice in the first and second treatment groups described above.
[00347] FIG. 28 shows the liver, kidney, heart and lung weights as a percentage of body weight at the endpoint of the study in select mice in the first and second treatment groups described above.
[00348] Without wishing to be bound by theory, the results presented in FIGs. 26-28 demonstrate that treatment with Compound 1 in combination with enzalutamide is well- tolerated.
[00349] FIG. 29 shows immunohistochemistry analysis of CD34 immunoreactivity from select mice in the first and second treatment groups described above. The first treatment group was stratified into two groups -those that responded to the treatment with enzalutamide alone (“responders”) and those that did not respond to enzalutamide alone (“non-responders”). As would be appreciated by the skilled artisan, the endothelial marker CD34 can be used to quantify tumor vasculature. Accordingly, as shown in FIG. 29, treatment with Compound 1 in combination with enzalutamide results in a decrease in tumor vasculature when compared to enzalutamide alone in the responder group.
[00350] Without wishing to be bound by theory, the results presented in this example demonstrate that Compound 1 of the present disclosure in combination with enzalutamide can be used to treat castration-resistant prostate cancer.
[00351] Example 5
[00352] The following is a non-limiting example of the treatment of castration-resistant prostate cancer using Compound 1 of the present disclosure.
[00353] Physically-castrated NSG mice were injected subcutaneously with patient derived castration-resistant prostate cancer tumor samples (LUCAP35CR). When tumors reached ~250mm3, mice were enrolled in one of two treatment groups. The first treatment group received Compound 1 in an amount of 8 mg/kg, administered subcutaneously once every 4 days. The second treatment group received a negative control, vehicle treatment comprising 5% mannitol in water.
[00354] FIG. 30 shows the average tumor volume across all mice in the Compound 1 and Vehicle control treatment groups. The vertical dashed lines denote the start of treatment. FIG. 31 shows the endpoint tumor mass in the Compound 1 and Vehicle control treatment groups. As shown in FIGs. 30 and 31, treatment with Compound 1 resulted in a decrease in tumor volume.
[00355] FIG. 32 shows immunohistochemistry analysis of CD34 immunoreactivity from select mice in the Compound 1 and Vehicle control treatment groups. As would be appreciated by the skilled artisan, the endothelial marker CD34 can be used to quantify tumor vasculature. Accordingly, as shown in FIG. 32, treatment with Compound 1 results in a decrease in tumor vasculature as compared to the vehicle control.
[00356] Transcriptomic analysis of tumor samples from the first and second treatment groups was also performed.
[00357] FIG. 41 shows the expression levels of particular hypoxia induced, extracellular matrix-related genes in tumor samples from treatment group 1 (Compound 1) and treatment group 2 (vehicle).
[00358] FIGs. 42A and 42B show the expression levels of particular glycolysis-related genes in tumor samples from treatment group 1 (Compound 1) and treatment group 2 (vehicle).
[00359] FIG. 43 shows the expression levels of particular serine-glycine one-carbon (SOGC) pathway genes in tumor samples from treatment group 1 (Compound 1) and treatment group 2 (vehicle).
[00360] FIG. 44 shows the expression levels of particular cholesterol uptake and synthesis pathway genes in tumor samples from treatment group 1 (Compound 1) and treatment group 2 (vehicle).
[00361] FIG. 45 shows the expression levels of particular fatty acid synthesis pathway genes in tumor samples from treatment group 1 (Compound 1) and treatment group 2 (vehicle). [00362] FIG. 46 shows the expression levels of particular cell cycle genes in tumor samples from treatment group 1 (Compound 1) and treatment group 2 (vehicle).
[00363] FIG. 47 shows the expression levels of particular hormone/cytokine receptor genes in tumor samples from treatment group 1 (Compound 1) and treatment group 2 (vehicle).
[00364] FIG. 48 shows the expression levels of particular kinase genes in tumor samples from treatment group 1 (Compound 1) and treatment group 2 (vehicle).
[00365] FIG. 49 shows the expression levels of particular transcription factor genes in tumor samples from treatment group 1 (Compound 1) and treatment group 2 (vehicle).
[00366] FIG. 50 shows the expression levels of particular tumor-inhibiting genes in tumor samples from treatment group 1 (Compound 1) and treatment group 2 (vehicle).
[00367] FIGs. 51 A and 5 IB show the expression levels of particular tumor-growth promoting/survival genes in tumor samples from treatment group 1 (Compound 1) and treatment group 2 (vehicle).
[00368] FIG. 52 shows the expression levels of particular nucleotide synthesis genes in tumor samples from treatment group 1 (Compound 1) and treatment group 2 (vehicle).
[00369] FIG. 53 shows the expression levels of particular lipid metabolism genes in tumor samples from treatment group 1 (Compound 1) and treatment group 2 (vehicle).
[00370] FIG. 54 shows the expression levels of particular immune recognition genes in tumor samples from treatment group 1 (Compound 1) and treatment group 2 (vehicle).
[00371] FIG. 55 shows the expression levels of particular immune recognition genes, specifically CD74 ligands and binding partners, in tumor samples from treatment group 1 (Compound 1) and treatment group 2 (vehicle). As would be appreciated by the skilled artisan, studies have implicated MIF in tumor development and cancer progression and that MIF signaling via CD74 requires an additional co-receptor such as CXCR4 or CD44.
[00372] FIG. 56 shows the expression levels of particular genes encoding regulators of MHC II, in tumor samples from treatment group 1 (Compound 1) and treatment group 2 (vehicle). AS would be appreciated by the skilled artisan, proper stimulation of T cells requires efficient HLA class II antigen presentation by professional or non-professional antigen-presenting cells, including prostate cancer cells. Moreover, the transcription factor CIITA, whose expression is decreased in many cancers, positively regulates the expression of MHC II genes. Finally, the enzyme GILT, down-regulated in many cancers including prostate cancer, facilitates processing of MHC II-antigen complexes prior to their display on the cell surface. [00373] In addition to the transcriptomic analysis shown in FIGs. 41-56, the bulk RNASeq data obtained from tumor samples from the first and second treatment groups was analyzed for changes in mouse genes, removing signals from human genes. As would be appreciated by the skilled artisan, such an analysis allows for interrogation of the tumor microenvironment (TME). Results from this analysis are shown in Table C.
[00375] As shown in Table C, the TME in mice treated with Compound 1 was les fibrotic, based on the reduction in multiple collagen genes, and less immunosuppressive, based on the reduction in the expression of Argl. Moreover, without wishing to be bound by theory, the
increased expression of multiple genes involved in adipocyte function indicate increased adipocyte differentiation or hypertrophy, with increased adiponectin potentially exhibiting anti-tumor effects.
[00376] Without wishing to be bound by theory, the results presented in this example demonstrate that Compound 1 of the present disclosure can be used to treat castrationresistant prostate cancer.
[00377] Example 6
[00378] Gene expression analysis was performed for various treatment groups presented in Examples 1-5 above.
[00379] The left panel in FIG. 35 shows a chart of the number of differentially expressed human genes for each pairwise comparison of treatment groups (see Table A for details on comparison groups). Differential gene expression (DE) is defined by abs.FC > 1.5 and FDR pvalue < 0.05. The right panel in FIG. 35 shows bubble plots of a selection of significantly enriched (adj .pvalue < 0.05) cellular pathways from the MSigDB (Molecular Signatures Database) for each of the comparisons presented in Table A and the left panel of FIG. 35.
[00381] FIGs. 36-40 show bubble plots of genes of interest including LINGO4, SORCS2, KCND3, SNRNP48, GLS, BAG1, AR, KLK3, DDC, STEAP4, FKBP5, FOLH1, PPIA, RAB37, TXN, SH3BGRL, GAPDH, METAP2, R0R2, CTHRC1, DVL3, ARRB2, PPARG, WNT5A, MAPK10, PPKCZ, DVL2, AMACR, PCGEM1, PC A3, PSCA, NIKX3-1, AZGP1, H0XB13, SOX9 and RLN1 for pairwise comparisons of treatment groups (see Table B for details on comparison groups). The shading indicates the direction of differential expression (e.g. up or down) and the size indicates the significance at FDR.p<=0.05.
[00383] Example 7
[00384] The following is a non-limiting example of the treatment of enzalutamide-resistant, castration-resistant prostate cancer using Compound 1 of the present disclosure.
[00385]LUCaP.35CR PDX patient-derived castrate resistant prostate cancer tumors were transplanted into castrated NSG mice. When tumors reached approximately 100-200 mm3 and PSA was approximately 30-50ng/ml, the mice were treated with enzalutamide in an amount of 10 mg/kg daily by oral gavage. Treatment continued for approximately 2-3 weeks until tumor size increased to 400-500 mm3 demonstrating that treatment of the tumors with enzalutamide was ineffective (i.e. the tumors were enzalutamide-resistant). The mice were then enrolled in two treatment groups. The first treatment group received enzalutamide in an amount of 10 mg/kg daily by oral gavage in combination with a negative control, vehicle treatment of 5% mannitol in water. The second treatment group received enzalutamide in an amount of 10 mg/kg daily by oral gavage in combination with Compound 1 in an amount of 8 mg/kg, administered subcutaneously once every 4 days.
[00386] FIG. 33 A shows the average tumor volume across all mice in the two treatment groups The gray box denotes the time period of enzalutamide treatment and the vertical dashed lines denotes the start of resistance to the enzalutamide treatment and start of treatment with Compound 1. FIG. 33B shows the endpoint tumor mass in the first and second treatment groups described above. The results shown in FIGs. 33A and 33B demonstrate that the administration of Compound 1 in combination with enzalutamide prevented tumor growth and resulted in smaller tumors at the end of the study compared to tumors in mice treated with enzalutamide alone.
[00387] FIG. 33C shows immunohistochemistry analysis of CD34 immunoreactivity from select mice in the Compound 1 plus enzalutamide and Vehicle enzalutamide control treatment groups described above. As would be appreciated by the skilled artisan, the
endothelial marker CD34 can be used to quantify tumor vasculature. Accordingly, as shown in FIG. 33C, treatment with Compound 1 results in a decrease in tumor vasculature as compared to the vehicle control.
[00388] Without wishing to be bound by theory, the results presented in this example demonstrate that Compound 1 of the present disclosure can be used to treat enzalutamide- resistant, castration-resistant prostate cancer.
[00389] Example 8
[00390] The following is a non-limiting example of the treatment of aggressive variant prostate cancer (AVPC), including neuroendocrine prostate cancer (NEPC) using Compound 1 of the present disclosure.
[00391] LTL545 PDX patient-derived AVPC tumor xenografts (specifically NEPC tumor xenografts) were transplanted into NSG mice. When tumors reached approximately 200 mm3, the mice were enrolled in one of two treatments. The first treatment group received Compound 1 in an amount of 8 mg/kg, administered subcutaneously once every 4 days. The second treatment received a negative control, vehicle treatment comprising 5% mannitol in water.
[00392] FIG. 34A shows the tumor volume of all mice in the two treatment groups and FIG. 34B shows the average tumor volume across all mice in the two treatment groups. The vertical dashed lines denotes the onset of treatment with Compound 1. FIG. 34C shows the endpoint tumor mass in the first and second treatment groups described above. The results shown in FIGs. 34A, 34B and 34C demonstrate that the administration of Compound 1 attenuated AVPC tumor growth and resulted in smaller AVPC tumors at the end of the study. [00393] Without wishing to be bound by theory, the results presented in this example demonstrate that Compound 1 of the present disclosure can be used to treat AVPC, including NEPC.
Claims
1. A method of treating prostate cancer in a subject, the method comprising administering at least one amount of at least one MetAP2 inhibitor to the subject, wherein the MetAP2 inhibitor is:
(Compound 1), or a pharmaceutically acceptable salt thereof, wherein x is in the range of 1 to about 450, y is in the range of 1 to about 30 and n is in the range of 1 to about 100, preferably wherein the ratio of x to y is in the range of about 30:1 to about 3: 1, preferably wherein the ratio of x to y is about 11 : 1, wherein the subject has been previously administered at least one prostate cancer treatment, wherein the prostate cancer treatment comprises androgen deprivation therapy (ADT) and/or at least one androgen receptor antagonist, wherein the prostate cancer has become resistant to treatment with the androgen deprivation therapy (ADT) and/or at least one androgen receptor antagonist, wherein administration of the MetAP2 inhibitor results in reduction in size of the prostate cancer.
2. The method of claim 1, wherein the method further comprises administering to the subject at least one amount of enzalutamide.
3. The method of claim 1 or claim 2, wherein the prostate cancer is castration-resistant prostate cancer.
4. The method of claim 1 or claim 2, wherein the prostate cancer is castration-sensitive prostate cancer.
5. The method of any one of the preceding claims, wherein the prostate cancer is PTEN- deficient prostate cancer or partially PTEN-deficient prostate cancer.
6. The method of any one of the preceding claims, wherein the prostate cancer is aggressive variant prostate cancer (AVPC).
7. The method of any one of the preceding claims, wherein the prostate cancer is neuroendocrine prostate cancer.
8. The method of any one of the preceding claims, wherein the androgen deprivation therapy comprises performing an orchiectomy, administering at least one luteinizing hormone-releasing hormone (LHRH) agonist, administering at least one LHRH antagonist, administering at least one estrogen, or any combination thereof.
9. The method of claim 8, wherein the orchiectomy is a subcapsular orchiectomy.
10. The method of claim 8, wherein the at least one LHRH agonist is selected from leuprolide, goserelin, triptorelin and histrelin.
11. The method of claim 8, wherein the at least one LHRH antagonist is selected from degarelix and relugolix.
12. The method of any one of the preceding claims, wherein the at least one androgen receptor antagonist is selected from flutamide, bicalutamide, nilutamide, enzalutamide, apalutamide, and darolutamide, preferably wherein the at least one androgen receptor antagonist is enzalutamide.
13. The method of any one of the preceding claims, wherein the MetAP2 inhibitor is administered within one day, two days, three days, four days, five days, six days or one week of the subject exhibiting PSA nadir.
14. The method of any one of the preceding claims, wherein the MetAP2 inhibitor is administered about two weeks, or about three weeks, or about four weeks, or about five weeks after the subject has exhibited PSA nadir, and wherein the PSA level in the subject has increased from PSA nadir.
15. The method of any one of the preceding claims, wherein the subject has at least one metabolic dysfunction, wherein the metabolic dysfunction is selected from visceral adiposity, dyslipidemia, obesity (BMI >30), elevated leptin levels, depressed adiponectin levels, high leptin-to-adiponectin ratio, elevated fasting insulin levels, elevated fasting insulin levels accompanied by chronic inflammation, insulin resistance, hyperleptinaemia, high fasting glucose, elevated HbAlc, or any combination thereof.
16. The method of any one of the preceding claims, wherein the metabolic dysfunction is a treatment-induced metabolic dysfunction.
17. The method of any one of the preceding claims, wherein the MetAP2 inhibitor is administered to the subject in an amount of: i) about 27 mg/m2; ii) about 36 mg/m2; iii) about 49 mg/m2; or iv) about 65 mg/m2.
18. The method of any one of the preceding claims, wherein the MetAP2 inhibitor is administered: i) once every 7 days (Q7D); ii) once every 14 days (Q14D); or iii) once every 21 days (Q21D).
19. The method of any one of the preceding claims, wherein the enzalutamide is administered/for administration to the subject in an amount of:
i) about 40 mg; ii) about 80 mg; iii) about 120 mg; or iv) about 160 mg.
20. The method of any one of the preceding claims, wherein the enzalutamide is administered daily.
Applications Claiming Priority (6)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
US202263425942P | 2022-11-16 | 2022-11-16 | |
US63/425,942 | 2022-11-16 | ||
US202363459077P | 2023-04-13 | 2023-04-13 | |
US63/459,077 | 2023-04-13 | ||
US202363517334P | 2023-08-02 | 2023-08-02 | |
US63/517,334 | 2023-08-02 |
Publications (1)
Publication Number | Publication Date |
---|---|
WO2024107996A1 true WO2024107996A1 (en) | 2024-05-23 |
Family
ID=89223979
Family Applications (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
PCT/US2023/080080 WO2024107996A1 (en) | 2022-11-16 | 2023-11-16 | Metap2 inhibitors for the treatment of prostate cancer |
Country Status (1)
Country | Link |
---|---|
WO (1) | WO2024107996A1 (en) |
Citations (2)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
US20170196830A1 (en) * | 2016-01-11 | 2017-07-13 | Syndevrx, Inc. | Treatment for tumors driven by metabolic dysfunction |
US20200129457A1 (en) * | 2018-10-26 | 2020-04-30 | Syndevrx, Inc. | Biomarkers of metap2 inhibitors and applications thereof |
-
2023
- 2023-11-16 WO PCT/US2023/080080 patent/WO2024107996A1/en unknown
Patent Citations (2)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
US20170196830A1 (en) * | 2016-01-11 | 2017-07-13 | Syndevrx, Inc. | Treatment for tumors driven by metabolic dysfunction |
US20200129457A1 (en) * | 2018-10-26 | 2020-04-30 | Syndevrx, Inc. | Biomarkers of metap2 inhibitors and applications thereof |
Non-Patent Citations (8)
Title |
---|
"CAS", Database accession no. 915087-33-1 |
CAHN ET AL., ANGEW. CHEM. INTER. EDIT., vol. 5, no. 385, 1966, pages 511 |
CAHN ET AL., ANGEW. CHEM., vol. 78, 1966, pages 413 |
CAHN ET AL., EXPERIENTIA, vol. 12, 1956, pages 81 |
CAHN, J. CHEM. EDUC., vol. 41, 1964, pages 116 |
CAHNINGOLD, J. CHEM. SOC., 1951, pages 612 |
MAITLAND NORMAN: "Resistance to Antiandrogens in Prostate Cancer: Is It Inevitable, Intrinsic or Induced?", CANCERS, vol. 13, no. 2, 17 January 2021 (2021-01-17), CH, pages 327, XP093132738, ISSN: 2072-6694, DOI: 10.3390/cancers13020327 * |
PATANILAVOIE, CHEM. REV., vol. 96, 1996, pages 3147 - 3176 |
Similar Documents
Publication | Publication Date | Title |
---|---|---|
US11787804B2 (en) | Compositions and methods for modulating hair growth | |
US7638543B2 (en) | Cystic fibrosis transmembrane conductance regulator protein inhibitors and uses thereof | |
AU2009279756B2 (en) | PDE10 inhibitors and related compositions and methods | |
US5948771A (en) | Method for treating heart failure using tetrapyrroles and metallotetrapyrroles | |
US20070299042A1 (en) | Use of etodolac to treat hyperplasia | |
WO2021068952A1 (en) | Benzodihydropyran compound targeting aldo-keto reductase 1c3 | |
EP3458448B1 (en) | Fasn inhibitors for use in treating non-alcoholic steatohepatitis | |
TW201501711A (en) | Pyrazole-amide compounds and medical use thereof | |
JP2010511632A (en) | Compositions and methods of treatment comprising 5-lipoxygenase activated protein inhibitors and nitric oxide modulators | |
US20230044606A1 (en) | Spiro compound serving as erk inhibitor, and application thereof | |
US20210130312A1 (en) | Inhibitors of eya3-protein tyrosine phosphatase in dna damage repair signaling of pulmonary arterial hypertension | |
US20230404963A1 (en) | Combinations of metap2 inhibitors and cd4/6 inhibitors for the treatment of cancer | |
EA011484B1 (en) | Tetrazole derivatives and methods of treatment of metabolic-related disorders thereof | |
US20230073512A1 (en) | Modulators of cullin 3 adaptor kbtbd4 as anti-cancer compounds | |
WO2024107996A1 (en) | Metap2 inhibitors for the treatment of prostate cancer | |
US11370766B2 (en) | Sulfonyl amidine as indoleamine-2,3-dioxygenase inhibitor, and preparation method therefor and use thereof | |
EP3400210B1 (en) | "multi-target" compounds with inhibitory activity towards histone deacetylases and tubulin polymerisation, for use in the treatment of cancer | |
US11434195B2 (en) | Compositions and methods for treatment of central nervous system tumors | |
TW201818964A (en) | Methods of using tryptophan hydroxylase inhibitors | |
US9457016B2 (en) | Methods for treating polycystic kidney disease | |
US20120316156A1 (en) | [1,2,4]thiadiazine 1,1-dioxide compounds for lowering serum uric acid | |
US11649232B2 (en) | Synthetic dimeric cinchona alkaloids against cancer | |
US20200399224A1 (en) | Cyclopentaimidazolones for the treatment of cancer | |
BR112016016386B1 (en) | COMPOUND OR A SALT OR SOLVATE THEREOF, PHARMACEUTICAL COMPOSITION AND USE OF A COMPOUND IN THE PREPARATION OF A DRUG | |
WO2023178255A1 (en) | Combinations comprising metap2 inhibitors for the treatment of cancer |